

NTP Historical Controls Report

By Route and Vehicle

Harlan Sprague-Dawley RATS

November 2024

This report shows the tumor rates of control group animals from selected studies. The studies used are shown on the Study Summary page.

This report is broken up into sections based on the route and vehicle used to deliver the chemical. The Table of Contents on Page 4 shows the different Route/Vehicle combinations. To see the data from all routes and vehicles combined into one set, please refer to the "All Routes" report.

The individual tumor rates shown on the data pages of the report relate to the Study Summary page as follows: the tumor rates are shown in the same order as the Study Summary page, except that they are grouped horizontally in sets of three, with the males in the first set of three and the females in the second set. For example if the study summary showed the studies like this:

Male M1 M2 M3 M4 M5 Female F1 F2 F3 F4 F5

the data would be shown as:

	Male			Female	
M1	M2	M3	F1	F2	F3
M4	M5		F4	F5	

Directly beneath the individual tumor rates on the data pages are the overall totals for that tumor/site combination. This includes the total tumors/animals, the overall mean (in parentheses), the mean of the study means, and the standard deviation of the study means.

Studies with no control animals of a particular gender are listed on the summary page with the Number of Animals shown as zero and the Start Date and Length of Study shown as "N/A". On the data pages for these studies, there are blank spaces where the tumor rates would normally be found, so that the male and female rates for the remaining studies can be easily compared.

NOMENCLATURE CHANGES

The following changes to tissue or morphology nomenclature are seen in recent historical control reports:

Skin "Malignant Fibrous Histiocytoma" is now labeled as "Pleomorphic Fibrosarcoma" (changed on 2024 report).

The All Organs "Malignant Lymphoma" pool label now includes "Large Granular" (changed on 2024 report).

"Carcinoma" is now labeled as "Adenocarcinoma" for several organs, including harderian gland, intestine, mammary gland, salivary gland, and uterus (changed on 2022 report).

Small Intestine "Site Unspecified" is now labeled as "Any Site" (changed on 2022 report).

Table of Contents

Route	Vehicle	Page Number
INHALATION	AIR	5
ORAL	FEED	41
PERINATAL AND POSTNATAL	FEED	77
PERINATAL AND POSTNATAL	WATER	113
PERINATAL AND POSTNATAL GAVAGE	METHYLCELLULOSE	149
Whole Body Exposure	AIR	185

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC

Toxicology Data Management System Tumor Incidence for Selected Control Animal Groups Route: INHALATION Vehicle: AIR

				Stu	dy Summary		
Laboratory Name	Study Number	Study Start Date	Length of Study in Days	Number of Animals Total and (#/Cage)	Number Surviving and (Mean Life Span)	Maximum Mean Weekly Body Weight	Chemical
					Male		
Battelle Columbus Laboratory Battelle Columbus Laboratory Battelle Northwest	050706203 052030203 051047203	06/13/16 02/23/15 01/17/11	728 730 729	50(1) 50(1) 50(5)	21(681) 22(660) 25(661)	578.9 566.4 609.4	1020 Long Multiwalled Carbon Nanotubes alpha-Pinene p-Chloro-a,a,a-trifluorotoluene
					Female		
Battelle Columbus Laboratory Battelle Columbus Laboratory Battelle Northwest	050706203 052030203 051047203	06/13/16 02/23/15 01/17/11	730 731 731	50(1) 50(1) 50(5)	29(683) 28(668) 22(626)	376.0 350.6 377.3	1020 Long Multiwalled Carbon Nanotubes alpha-Pinene p-Chloro-a,a,a-trifluorotoluene

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC				ogy Data Management nce for Selected Control A Route: INHALATION Vehicle: AIR	Page: 6 Report Date: 11/07/2024					
			Male			Female				
#All Organs: Benign Tumors		33/50 (66%)	24/50 (48%)	30/50 (60%)		43/50 (86%)	39/50 (78%)	39/50 (78%)		
Overall Incidence	Total	87/150 (58%)	Mean 58%	SD 9.17%	Total	121/150 (80.67%)	Mean 80.67%	SD 4.62%		
#All Organs: Malignant Tumors		6/50 (12%)	20/50 (40%)	12/50 (24%)		8/50 (16%)	16/50 (32%)	11/50 (22%)		
Overall Incidence	Total	38/150 (25.33%)	Mean 25.33%	SD 14.05%	Total	35/150 (23.33%)	Mean 23.33%	SD 8.08%		
#All Organs: Malignant and Benign Tumo Overall Incidence	ors Total	35/50 (70%) 108/150 (72%)	36/50 (72%) Mean 72%	37/50 (74%) SD 2%	Total	44/50 (88%) 130/150 (86.67%)	45/50 (90%) Mean 86.67%	41/50 (82%) SD 4.16%		
#All Organs: Hemangioma Overall Incidence	Total	0/50 (0%) 1/150 (0.67%)	0/50 (0%) Mean 0.67%	1/50 (2%) SD 1.15%	Total	0/50 (0%) 0/150 (0%)	0/50 (0%) Mean 0%	0/50 (0%) SD 0%		
#All Organs: Hemangiosarcoma		0/50 (0%)	2/50 (4%)	0/50 (0%)		0/50 (0%)	0/50 (0%)	0/50 (0%)		
Overall Incidence	Total	2/150 (1.33%)	Mean 1.33%	SD 2.31%	Total	0/150 (0%)	Mean 0%	SD 0%		
#All Organs: Hemangiosarcoma or Hema	ingioma	0/50 (0%)	2/50 (4%)	1/50 (2%)		0/50 (0%)	0/50 (0%)	0/50 (0%)		
Overall Incidence	Total	3/150 (2%)	Mean 2%	SD 2%	Total	0/150 (0%)	Mean 0%	SD 0%		

Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC			Tumor Incider	Report Da	te: 11/07/2024			
			Male				Female	
#All Organs: Histiocytic Sarcoma		1/50 (2%)	0/50 (0%)	0/50 (0%)		0/50 (0%)	0/50 (0%)	0/50 (0%)
Overall Incidence	Total	1/150 (0.67%)	Mean 0.67%	SD 1.15%	Total	0/150 (0%)	Mean 0%	SD 0%
#All Organs: Leukemia: Granulocytic		0/50 (0%)	0/50 (0%)	1/50 (2%)		0/50 (0%)	0/50 (0%)	0/50 (0%)
Overall Incidence	Total	1/150 (0.67%)	Mean 0.67%	SD 1.15%	Total	0/150 (0%)	Mean 0%	SD 0%
#All Organs: Leukemia: Lymphocytic, Mo Dverall Incidence #All Organs:	Total	0/50 (0%) 3/150 (2%)	0/50 (0%) Mean 2%	3/50 (6%) SD 3.46%	Total	0/50 (0%) 0/150 (0%)	0/50 (0%) Mean 0%	0/50 (0%) SD 0%
Malignant Lymphoma: Histi Undifferentiated Cell Type	ocytic, Lym		-					
Overall Incidence	Total	1/50 (2%) 3/150 (2%)	2/50 (4%) Mean 2%	0/50 (0%) SD 2%	Total	0/50 (0%) 1/150 (0.67%)	1/50 (2%) Mean 0.67%	0/50 (0%) SD 1.15%
#All Organs:				0/50 (0%)		0/50 (0%)	0/50 (0%)	2/50 (4%)
Malignant Schwannoma		0/50 (0%)	0/50 (0%)	0/00 (0/0)				
C	Total	0/50 (0%) 0/150 (0%)	0/50 (0%) Mean 0%	SD 0%	Total	2/150 (1.33%)	Mean 1.33%	SD 2.31%
Malignant Schwannoma Overall Incidence #All Organs: Mesothelioma: Benign, Mali		0/150 (0%)	()	· · · /	Total	()	()	· · ·

Toxicology Data Management System

Page: 7

*: Denominator is number of animals with tissues examined microscopically

#: Denominator is number of animals necropsied

Version: Nov2024

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC			Toxicol Tumor Incider		Page: 8 Report Date: 11/07/2024					
			Male			Female				
#All Organs: Mesothelioma: Malignant		0/50 (0%)	0/50 (0%)	1/50 (2%)		0/50 (0%)	0/50 (0%)	0/50 (0%)		
Overall Incidence	Total	1/150 (0.67%)	Mean 0.67%	SD 1.15%	Total	0/150 (0%)	Mean 0%	SD 0%		
*Adrenal Cortex: Adenoma				-/ />						
Overall Incidence	Total	0/50 (0%) 4/150 (2.67%)	1/50 (2%) Mean 2.67%	3/50 (6%) SD 3.06%	Total	0/50 (0%) 2/150 (1.33%)	2/50 (4%) Mean 1.33%	0/50 (0%) SD 2.31%		
*Adrenal Cortex: Carcinoma Overall Incidence	Total	0/50 (0%) 0/150 (0%)	0/50 (0%) Mean 0%	0/50 (0%) SD 0%	Total	0/50 (0%) 1/150 (0.67%)	1/50 (2%) Mean 0.67%	0/50 (0%) SD 1.15%		
Adrenal Cortex: Carcinoma or Adenoma Overall Incidence	Total	0/50 (0%) 4/150 (2.67%)	1/50 (2%) Mean 2.67%	3/50 (6%) SD 3.06%	Total	0/50 (0%) 3/150 (2%)	3/50 (6%) Mean 2%	0/50 (0%) SD 3.46%		
*Adrenal Medulla: Ganglioneuroma		0/50 (0%)	0/50 (0%)	0/50 (0%)		0/50 (0%)	0/50 (0%)	0/49 (0%)		
Overall Incidence	Total	0/150 (0%)	Mean 0%	SD 0%	Total	0/149 (0%)	Mean 0%	SD 0%		
*Adrenal Medulla: Pheochromocytoma Benign		9/50 (18%)	6/50 (12%)	12/50 (24%)		2/50 (4%)	3/50 (6%)	0/49 (0%)		
Overall Incidence	Total	27/150 (18%)	Mean 18%	SD 6%	Total	5/149 (3.36%)	Mean 3.33%	SD 3.06%		

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC	b: All Laboratories Tumor Incidence for Selected TS Route: INHA n Sprague-Dawley Vehicle:				-		Page: 9 Report Date: 11/07/2024		
			Male				Female		
*Adrenal Medulla: Pheochromocytoma Compl	ex	0/50 (0%)	0/50 (0%)	0/50 (0%)		0/50 (0%)	0/50 (0%)	0/49 (0%)	
Overall Incidence	Total	0/150 (0%)	Mean 0%	SD 0%	Total	0/149 (0%)	Mean 0%	SD 0%	
*Adrenal Medulla: Pheochromocytoma Malign		0/50 (0%)	6/50 (12%)	2/50 (4%)		0/50 (0%)	2/50 (4%)	0/49 (0%)	
Overall Incidence	Total	8/150 (5.33%)	Mean 5.33%	SD 6.11%	Total	2/149 (1.34%)	Mean 1.33%	SD 2.31%	
*Adrenal Medulla: Pheochromocytoma: Benig Overall Incidence	n, Comple Total	x, Malignant, NOS 9/50 (18%) 35/150 (23.33%)	12/50 (24%) Mean 23.33%	14/50 (28%) SD 5.03%	Total	2/50 (4%) 7/149 (4.7%)	5/50 (10%) Mean 4.67%	0/49 (0%) SD 5.03%	
#Bone: Hemangiosarcoma Overall Incidence	Total	0/50 (0%) 1/150 (0.67%)	1/50 (2%) Mean 0.67%	0/50 (0%) SD 1.15%	Total	0/50 (0%) 0/150 (0%)	0/50 (0%) Mean 0%	0/50 (0%) SD 0%	
#Bone: Osteosarcoma		0/50 (0%)	0/50 (0%)	0/50 (0%)		0/50 (0%)	0/50 (0%)	0/50 (0%)	
Overall Incidence	Total	0/150 (0%)	Mean 0%	SD 0%	Total	0/150 (0%)	Mean 0%	SD 0%	
#Bone: Osteosarcoma or Osteoma		0/50 (0%)	0/50 (0%)	0/50 (0%)		0/50 (0%)	0/50 (0%)	0/50 (0%)	
Overall Incidence	Total	0/150 (0%)	Mean 0%	SD 0%	Total	0/150 (0%)	Mean 0%	SD 0%	

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC

Toxicology Data Management System Tumor Incidence for Selected Control Animal Groups Route: INHALATION

Vehicle: AIR

Page: 10 Report Date: 11/07/2024

			Male		Female				
*Brain: Astrocytoma									
Overall Incidence	Total	0/50 (0%) 1/149 (0.67%)	1/49 (2%) Mean 0.68%	0/50 (0%) SD 1.18%	Total	0/50 (0%) 0/150 (0%)	0/50 (0%) Mean 0%	0/50 (0%) SD 0%	
Brain: Glioma									
Overall Incidence	Total	0/50 (0%) 1/149 (0.67%)	1/49 (2%) Mean 0.68%	0/50 (0%) SD 1.18%	Total	0/50 (0%) 0/150 (0%)	0/50 (0%) Mean 0%	0/50 (0%) SD 0%	
Brain: Glioma Malignant		4/50 (20%)	0/40 (0%)	2/50 (49/)		0/50 (00/)	0/50 (00/.)	4/50 (20())	
Overall Incidence	Total	1/50 (2%) 3/149 (2.01%)	0/49 (0%) Mean 2%	2/50 (4%) SD 2%	Total	0/50 (0%) 1/150 (0.67%)	0/50 (0%) Mean 0.67%	1/50 (2%) SD 1.15%	
Brain: Granular Cell Tumor Be									
Overall Incidence	Total	2/50 (4%) 3/149 (2.01%)	1/49 (2%) Mean 2.01%	0/50 (0%) SD 2%	Total	1/50 (2%) 2/150 (1.33%)	1/50 (2%) Mean 1.33%	0/50 (0%) SD 1.15%	
Brain: Granular Cell Tumor Ma									
Overall Incidence	Total	0/50 (0%) 0/149 (0%)	0/49 (0%) Mean 0%	0/50 (0%) SD 0%	Total	0/50 (0%) 0/150 (0%)	0/50 (0%) Mean 0%	0/50 (0%) SD 0%	
Ɓrain: Meningioma Benign						- /`	- / /`		
Overall Incidence	Total	0/50 (0%) 0/149 (0%)	0/49 (0%) Mean 0%	0/50 (0%) SD 0%	Total	0/50 (0%) 0/150 (0%)	0/50 (0%) Mean 0%	0/50 (0%) SD 0%	

*: Denominator is number of animals with tissues examined microscopically

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC	Dawley Vehicle: AIR					Page: 11 Report Date: 11/07/2024				
			Male				Female			
*Brain: Meningioma Malignant Overall Incidence	Total	0/50 (0%) 0/149 (0%)	0/49 (0%) Mean 0%	0/50 (0%) SD 0%	Total	0/50 (0%) 0/150 (0%)	0/50 (0%) Mean 0%	0/50 (0%) SD 0%		
		0/149 (078)		30 0%		0/130 (078)		30 0%		
*Brain: Meningioma: Benign, Malig	Inant, NOS	0/50 (0%)	0/49 (0%)	0/50 (0%)		0/50 (0%)	0/50 (0%)	0/50 (0%)		
Overall Incidence	Total	0/149 (0%)	Mean 0%	SD 0%	Total	0/150 (0%)	Mean 0%	SD 0%		
*Brain: Oligodendroglioma Malign	ant	0/50 (0%)	0/40 (00/)	0/50 (00/)		0/50 (09/)	0/50 (00/)	0/50 (00/)		
Overall Incidence	Total	0/50 (0%) 0/149 (0%)	0/49 (0%) Mean 0%	0/50 (0%) SD 0%	Total	0/50 (0%) 0/150 (0%)	0/50 (0%) Mean 0%	0/50 (0%) SD 0%		
*Brain: Oligodendroglioma, Glioma										
Overall Incidence	Total	1/50 (2%) 5/149 (3.36%)	2/49 (4%) Mean 3.36%	2/50 (4%) SD 1.18%	Total	0/50 (0%) 1/150 (0.67%)	0/50 (0%) Mean 0.67%	1/50 (2%) SD 1.15%		
*Brain: Schwannoma Malignant										
Overall Incidence	Total	0/50 (0%) 0/149 (0%)	0/49 (0%) Mean 0%	0/50 (0%) SD 0%	Total	0/50 (0%) 1/150 (0.67%)	0/50 (0%) Mean 0.67%	1/50 (2%) SD 1.15%		
*Clitoral/Preputial Gland: Adenocarcinoma										
Overall Incidence	Total	0/50 (0%) 0/150 (0%)	0/50 (0%) Mean 0%	0/50 (0%) SD 0%	Total	0/49 (0%) 0/148 (0%)	0/49 (0%) Mean 0%	0/50 (0%) SD 0%		

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC			Toxicol Tumor Incider	Page: 12 Report Da	te: 11/07/2024				
			Male					Female	
*Clitoral/Preputial Gland: Adenoma									
Overall Incidence	Total	0/50 (0%) 0/150 (0%)	0/50 (0%) Mean 0%	0/50 SD 0%	(0%)	Total	0/49 (0%) 0/148 (0%)	0/49 (0%) Mean 0%	0/50 (0%) SD 0%
*Clitoral/Preputial Gland: Adenoma or Adenocarcinon									
Overall Incidence	Total	0/50 (0%) 0/150 (0%)	0/50 (0%) Mean 0%	0/50 SD 0%	(0%)	Total	0/49 (0%) 0/148 (0%)	0/49 (0%) Mean 0%	0/50 (0%) SD 0%
*Clitoral/Preputial Gland: Squamous Cell Carcinoma				- /					
Overall Incidence	Total	0/50 (0%) 1/150 (0.67%)	1/50 (2%) Mean 0.67%	0/50 SD 1.15%		Total	0/49 (0%) 1/148 (0.68%)	1/49 (2%) Mean 0.68%	0/50 (0%) SD 1.18%
*Clitoral/Preputial Gland: Squamous Cell Papilloma		0/50 (0%)	0/50 (0%)	0/50	(0%)		0/49 (0%)	0/49 (0%)	0/50 (0%)
Overall Incidence	Total	0/150 (0%)	Mean 0%	SD 0%		Total	0/148 (0%)	Mean 0%	SD 0%
*Epididymis: Sarcoma		0/50 (0%)	0/50 (0%)	1/50	(2%)				
Overall Incidence	Total	1/150 (0.67%)	Mean 0.67%	SD 1.15%	· · ·				
#Eye: Leiomyoma		0/50 (0%)	0/50 (0%/)	4/50	(20/)		0/50 (0%)	0/50 (00/.)	0/50 (0%)
Overall Incidence	Total	0/50 (0%) 1/150 (0.67%)	0/50 (0%) Mean 0.67%	1/50 SD 1.15%	(2%) 5	Total	0/50 (0%) 0/150 (0%)	0/50 (0%) Mean 0%	0/50 (0%) SD 0%

*: Denominator is number of animals with tissues examined microscopically #: Denominator is number of animals necropsied

Version: Nov2024 **Toxicology Data Management System** Page: 13 Contract/Lab: All Laboratories Tumor Incidence for Selected Control Animal Groups Report Date: 11/07/2024 Species: RATS Route: INHALATION Strain: Harlan Sprague-Dawley Vehicle: AIR Length of Study: CHRONIC Male Female #Harderian Gland: Schwannoma Malignant 1/50 (2%) 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) SD 0% **Overall Incidence** Total 1/150 (0.67%) Mean 0.67% SD 1.15% Total 0/150 (0%) Mean 0% . *Heart: Schwannoma Malignant 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) **Overall Incidence** Total 0/150 (0%) Mean 0% SD 0% Total 0/150 (0%) Mean 0% SD 0% #Intestine Large: Cecum: Leiomyosarcoma 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) SD 0% **Overall Incidence** Total 0/150 (0%) Mean 0% SD 0% Total 0/150 (0%) Mean 0% #Intesting Large: Cocum:

Overall Incidence	Total	1/150 (0.67%)	Mean 0.67%	SD 1.15%	Total	0/150 (0%)	Mean 0%	SD 0%
		0/50 (0%)	0/50 (0%)	1/50 (2%)		0/50 (0%)	0/50 (0%)	0/50 (0%)
ntestine Large: Colon/R Leiomyoma	Rectum:							
verall Incidence	Total	0/150 (0%)	Mean 0%	SD 0%	Total	0/150 (0%)	Mean 0%	SD 0%
		0/50 (0%)	0/50 (0%)	0/50 (0%)		0/50 (0%)	0/50 (0%)	0/50 (0%)
ntestine Large: Colon/R Granular Cell Tumor Be								
verall Incidence	Total	0/150 (0%)	Mean 0%	SD 0%	Total	0/150 (0%)	Mean 0%	SD 0%
		0/50 (0%)	0/50 (0%)	0/50 (0%)		0/50 (0%)	0/50 (0%)	0/50 (0%)
Liposarcoma								

*: Denominator is number of animals with tissues examined microscopically

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC			Toxicology Data Management System Tumor Incidence for Selected Control Animal Groups Route: INHALATION Vehicle: AIR				Page: 14 Report Date: 11/07/2024				
			Male				Female				
#Intestine Small: Any Site: Adenocarcinoma		0/50 (0%)	1/50 (2%)	0/50 (0%)		0/50 (0%)	0/50 (0%)	0/50 (0%)			
Overall Incidence	Total	1/150 (0.67%)	Mean 0.67%	SD 1.15%	Total	0/150 (0%)	Mean 0%	SD 0%			
#Intestine Small: Any Site: Adenoma or Adenocarcinon		0/50 (0%)	1/50 (2%)	0/50 (0%)		0/50 (0%)	0/50 (0%)	0/50 (0%)			
Overall Incidence	Total	1/150 (0.67%)	Mean 0.67%	SD 1.15%	Total	0/150 (0%)	Mean 0%	SD 0%			
#Intestine Small: Any Site: Leiomyosarcoma		0/50 (0%)	0/50 (0%)	1/50 (2%)		0/50 (0%)	0/50 (0%)	0/50 (0%)			
Overall Incidence	Total	1/150 (0.67%)	Mean 0.67%	SD 1.15%	Total	0/150 (0%)	Mean 0%	SD 0%			
#Intestine Small: Any Site: Leiomyosarcoma or Leiomy		0/50 (0%)	0/50 (0%)	1/50 (2%)		1/50 (2%)	0/50 (0%)	0/50 (0%)			
Overall Incidence	Total	1/150 (0.67%)	Mean 0.67%	SD 1.15%	Total	1/150 (0.67%)	Mean 0.67%	SD 1.15%			
#Intestine Small: Jejunum: Adenocarcinoma		0/50 (0%)	1/50 (2%)	0/50 (0%)		0/50 (0%)	0/50 (0%)	0/50 (0%)			
Overall Incidence	Total	1/150 (0.67%)	Mean 0.67%	SD 1.15%	Total	0/150 (0%)	Mean 0%	SD 0%			
#Intestine Small: Jejunum: Leiomyoma		0/50 (0%)		0/50 (0%)			0/50 (00/.)	0/50 (09()			
Overall Incidence	Total	0/50 (0%) 0/150 (0%)	0/50 (0%) Mean 0%	0/50 (0%) SD 0%	Total	1/50 (2%) 1/150 (0.67%)	0/50 (0%) Mean 0.67%	0/50 (0%) SD 1.15%			

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS **Route: INHALATION** Strain: Harlan Sprague-Dawley Vehicle: AIR Length of Study: CHRONIC Male

#Intestine Small: Jejunum: Leiomyosarcoma (2%) 0/50 (0%) 0/50 (0%) 1/50 0/50 (0%) 0/50 (0%) 0/50 (0%) **Overall Incidence** Total 1/150 (0.67%) Mean 0.67% SD 1.15% Total 0/150 (0%) Mean 0% SD 0% . *Islets, Pancreatic: Adenoma 3/50 (6%) 1/50 (2%) 8/50 (16%) 0/50 (0%) 1/50 (2%) 1/50 (2%) **Overall Incidence** Total 12/150 (8%) Mean 8% SD 7.21% 2/150 (1.33%) Mean 1.33% SD 1.15% Total *Islets, Pancreatic: Carcinoma 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) 1/50 (2%) **Overall Incidence** Total 0/150 (0%) Mean 0% SD 0% Total 1/150 (0.67%) Mean 0.67% SD 1.15% *Islets, Pancreatic: Carcinoma or Adenoma 3/50 (6%) 1/50 (2%) 8/50 (16%) 0/50 (0%) 1/50 (2%) 2/50 (4%) **Overall Incidence** Total 12/150 (8%) Mean 8% SD 7.21% Total 3/150 (2%) Mean 2% SD 2% *Kidney: Pelvis and Urothelium: Papilloma 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) **Overall Incidence** Total 0/150 (0%) Mean 0% SD 0% Total 0/150 (0%) Mean 0% SD 0% *Kidney: Renal Tubule: Adenoma 2/50 (4%) 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) 1/50 (2%) **Overall Incidence** Total 2/150 (1.33%) Mean 1.33% SD 2.31% Mean 0.67% SD 1.15% Total 1/150 (0.67%)

*: Denominator is number of animals with tissues examined microscopically

#: Denominator is number of animals necropsied

Toxicology Data Management System Tumor Incidence for Selected Control Animal Groups Page: 15 Report Date: 11/07/2024

Female

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC			Page: 16 Report Date: 11/07/2024							
			Male			Female				
*Kidney: Renal Tubule: Carcinoma		0/50 (0%)	0/50 (0%)	0/50 (0%)		0/50 (0%)	1/50 (2%)	0/50 (0%)		
Overall Incidence	Total	0/150 (0%)	Mean 0%	SD 0%	Total	1/150 (0.67%)	Mean 0.67%	0/50 (0%) SD 1.15%		
*Kidney: Renal Tubule: Carcinoma or Adenoma		2/50 (4%)	0/50 (0%)	0/50 (0%)		0/50 (0%)	1/50 (2%)	1/50 (2%)		
Overall Incidence	Total	2/150 (1.33%)	Mean 1.33%	SD 2.31%	Total	2/150 (1.33%)	Mean 1.33%	SD 1.15%		
*Kidney: Renal Tubule: Hemangioma		0/50 (0%)	0/50 (0%)	0/50 (0%)		0/50 (0%)	0/50 (0%)	0/50 (0%)		
Overall Incidence	Total	0/150 (0%)	Mean 0%	SD 0%	Total	0/150 (0%)	Mean 0%	SD 0%		
*Kidney: Renal Tubule: Lipoma		0/50 (0%)	0/50 (0%)	0/50 (0%)		0/50 (0%)	0/50 (0%)	0/50 (0%)		
Overall Incidence	Total	0/150 (0%)	Mean 0%	SD 0%	Total	0/150 (0%)	Mean 0%	SD 0%		
*Kidney: Renal Tubule: Liposarcoma								0/50 (0%)		
Overall Incidence	Total	0/50 (0%) 0/150 (0%)	0/50 (0%) Mean 0%	0/50 (0%) SD 0%	Total	0/50 (0%) 0/150 (0%)	0/50 (0%) Mean 0%	0/50 (0%) SD 0%		
*Kidney: Renal Tubule: Oncocytoma Benign		0/50 (0%)	0/50 (0%)	0/50 (0%)		0/50 (0%)	0/50 (0%)	0/50 (0%)		
Overall Incidence	Total	0/150 (0%)	Mean 0%	SD 0%	Total	0/150 (0%)	Mean 0%	SD 0%		

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC				Page: 17 Report Date: 11/07/2024				
			Male				Female	
*Kidney: Renal Tubule: Polyp Adenomatous		0/50 (0%)	0/50 (0%)	0/50 (0%)		0/50 (0%)	0/50 (0%)	0/50 (0%)
Overall Incidence	Total	0/150 (0%)	Mean 0%	SD 0%	Total	0/150 (0%)	Mean 0%	SD 0%
#Lacrimal Gland: Carcinoma		0/50 (0%)	0/50 (0%)	0/50 (0%)		0/50 (0%)	0/50 (0%)	0/50 (0%)
Overall Incidence	Total	0/150 (0%)	Mean 0%	SD 0%	Total	0/150 (0%)	Mean 0%	SD 0%
*Liver: Cholangioma Overall Incidence	Total	0/50 (0%) 0/150 (0%)	0/50 (0%) Mean 0%	0/50 (0%) SD 0%	Total	0/50 (0%) 5/150 (3.33%)	5/50 (10%) Mean 3.33%	0/50 (0%) SD 5.77%
*Liver: Hemangioma Overall Incidence	Total	0/50 (0%) 0/150 (0%)	0/50 (0%) Mean 0%	0/50 (0%) SD 0%	Total	0/50 (0%) 0/150 (0%)	0/50 (0%) Mean 0%	0/50 (0%) SD 0%
*Liver: Hepatocellular Adenoma		0/50 (0%)	1/50 (2%)	0/50 (0%)		0/50 (0%)	0/50 (0%)	2/50 (4%)
Overall Incidence	Total	1/150 (0.67%)	Mean 0.67%	SD 1.15%	Total	2/150 (1.33%)	Mean 1.33%	SD 2.31%
*Liver: Hepatocellular Carcinoma		0/50 (0%)	0/50 (0%)	0/50 (0%)		0/50 (0%)	0/50 (0%)	0/50 (0%)
Overall Incidence	Total	0/150 (0%)	Mean 0%	SD 0%	Total	0/150 (0%)	Mean 0%	SD 0%

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC			Toxico Tumor Incider	Page: 18 Report Date: 11/07/2024						
			Male			Female				
*Liver: Hepatocellular Carcinoma o	r Hepatobl	lastoma 0/50 (0%)	0/50 (0%)	0/50 (0%)		0/50 (0%)	0/50 (0%)	0/50 (0%)		
Overall Incidence	Total	0/150 (0%)	Mean 0%	SD 0%	Total	0/150 (0%)	Mean 0%	SD 0%		
*Liver: Hepatocellular Carcinoma o	r Hepatoce			0/50 (0%)		0/50 (22/)	0/50 (00/1)	0/50 (420)		
Overall Incidence	Total	0/50 (0%) 1/150 (0.67%)	1/50 (2%) Mean 0.67%	0/50 (0%) SD 1.15%	Total	0/50 (0%) 2/150 (1.33%)	0/50 (0%) Mean 1.33%	2/50 (4%) SD 2.31%		
*Liver: Hepatocellular Carcinoma, H Overall Incidence	lepatocell e Total	ular Adenoma, or Hepatol 0/50 (0%) 1/150 (0.67%)	blastoma 1/50 (2%) Mean 0.67%	0/50 (0%) SD 1.15%	Total	0/50 (0%) 2/150 (1.33%)	0/50 (0%) Mean 1.33%	2/50 (4%) SD 2.31%		
Lung: Alveolar/Bronchiolar Adeno	ma	2/50 (4%)	0/50 (0%)	0/50 (0%)		0/50 (0%)	0/50 (0%)	0/50 (0%)		
Overall Incidence	Total	2/150 (1.33%)	Mean 1.33%	SD 2.31%	Total	0/150 (0%)	Mean 0%	SD 0%		
*Lung: Alveolar/Bronchiolar Carcin	oma			0/50 /00/)		0/50 /00/)		0/50 (09/)		
Overall Incidence	Total	0/50 (0%) 0/150 (0%)	0/50 (0%) Mean 0%	0/50 (0%) SD 0%	Total	0/50 (0%) 0/150 (0%)	0/50 (0%) Mean 0%	0/50 (0%) SD 0%		
*Lung: Alveolar/Bronchiolar Carcin		veolar/Bronchiolar Adeno 2/50 (4%)		0/50 (0%)		0/50 (0%)	0/50 (0%)	0/50 (0%)		
Overall Incidence	Total	2/150 (1.33%)	Mean 1.33%	SD 2.31%	Total	0/150 (0%)	Mean 0%	SD 0%		

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC			Toxicol Tumor Incider		Page: 19 Report Date: 11/07/2024			
			Male				Female	
#Lymph Node, Mesenteric: Hemangiosarcoma Overall Incidence	Total	0/50 (0%) 1/150 (0.67%)	1/50 (2%) Mean 0.67%	0/50 (0%) SD 1.15%	Total	0/50 (0%) 0/150 (0%)	0/50 (0%) Mean 0%	0/50 (0%) SD 0%
#Mammary Gland: Adenocarcinoma		0/50 (0%)	0/50 (0%)	0/50 (0%)		4/50 (8%)	5/50 (10%)	5/50 (10%)
Overall Incidence	Total	0/150 (0%)	Mean 0%	SD 0%	Total	14/150 (9.33%)	Mean 9.33%	SD 1.15%
#Mammary Gland: Adenolipoma Overall Incidence	Total	0/50 (0%) 0/150 (0%)	0/50 (0%) Mean 0%	0/50 (0%) SD 0%	Total	0/50 (0%) 0/150 (0%)	0/50 (0%) Mean 0%	0/50 (0%) SD 0%
#Mammary Gland: Adenoma Overall Incidence		. ,		0/50 (0%) SD 0%	Total	2/50 (4%) 7/150 (4.67%)	1/50 (2%) Mean 4.67%	4/50 (8%) SD 3.06%
#Mammary Gland: Adenoma or Adenocarcinon		. ,				· · · ·		
Overall Incidence	Total	0/150 (0%)	Mean 0%	SD 0%	Total	21/150 (14%)	Mean 14%	SD 3.46%
#Mammary Gland: Fibroadenoma		0/50 (0%)	1/50 (2%)	2/50 (4%)		31/50 (62%)	28/50 (56%)	20/50 (40%)
Overall Incidence	Total	3/150 (2%)	Mean 2%	SD 2%	Total	79/150 (52.67%)	Mean 52.67%	SD 11.37%

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC			Toxicol Tumor Incider	Page: 20 Report Da	ate: 11/07/2024			
			Male				Female	
#Mammary Gland: Fibroma								
Overall Incidence	Total	0/50 (0%) 0/150 (0%)	0/50 (0%) Mean 0%	0/50 (0%) SD 0%	Total	0/50 (0%) 0/150 (0%)	0/50 (0%) Mean 0%	0/50 (0%) SD 0%
#Mammary Gland: Fibroma, Fibroadenoma or /								
Overall Incidence	Total	0/50 (0%) 3/150 (2%)	1/50 (2%) Mean 2%	2/50 (4%) SD 2%	Total	33/50 (66%) 85/150 (56.67%)	29/50 (58%) Mean 56.67%	23/50 (46%) SD 10.07%
#Mammary Gland: Fibroma, Fibroadenoma, Ad			1/50 (2%)	2/50 (4%)		35/50 (70%)	33/50 (66%)	27/50 (54%)
Overall Incidence	Total	3/150 (2%)	Mean 2%	SD 2%	Total	95/150 (63.33%)	Mean 63.33%	SD 8.33%
#Nerve Trigeminal: Schwannoma Malignant		1/50 (2%)	0/50 (0%)	0/50 (0%)		0/50 (0%)	0/50 (0%)	0/50 (0%)
Overall Incidence	Total	1/150 (0.67%)	Mean 0.67%	SD 1.15%	Total	0/150 (0%)	Mean 0%	SD 0%
#Oral Mucosa: Squamous Cell Carcinoma						0/50 /00/)	0/50 /00/)	0/50 /09/)
Overall Incidence	Total	0/50 (0%) 0/150 (0%)	0/50 (0%) Mean 0%	0/50 (0%) SD 0%	Total	0/50 (0%) 0/150 (0%)	0/50 (0%) Mean 0%	0/50 (0%) SD 0%
#Oral Mucosa, Tongue, Phary Squamous Cell Carcinoma		iva:						
Overall Incidence	Total	0/50 (0%) 1/150 (0.67%)	1/50 (2%) Mean 0.67%	0/50 (0%) SD 1.15%	Total	0/50 (0%) 0/150 (0%)	0/50 (0%) Mean 0%	0/50 (0%) SD 0%

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC			Toxicol Tumor Inciden		Page: 21 Report Date: 11/07/2024			
			Male			Female		
#Oral Mucosa, Tongue, Pharyr Squamous Cell Carcinoma, I								
-	-	0/50 (0%)	1/50 (2%)	0/50 (0%)		1/50 (2%)	0/50 (0%)	0/50 (0%)
Overall Incidence	Total	1/150 (0.67%)	Mean 0.67%	SD 1.15%	Total	1/150 (0.67%)	Mean 0.67%	SD 1.15%
*Ovary: Adenocarcinoma, Cystadeno								
Overall Incidence					Total	0/50 (0%) 0/150 (0%)	0/50 (0%) Mean 0%	0/50 (0%) SD 0%
*Ovary: Adenoma								
Overall Incidence					Total	0/50 (0%) 1/150 (0.67%)	1/50 (2%) Mean 0.67%	0/50 (0%) SD 1.15%
*Ovary: Cystadenoma						- ()	- ()	
Overall Incidence					Total	0/50 (0%) 0/150 (0%)	0/50 (0%) Mean 0%	0/50 (0%) SD 0%
*Ovary: Cystadenoma or Cystadenoo	carcinoma							
Overall Incidence					Total	0/50 (0%) 0/150 (0%)	0/50 (0%) Mean 0%	0/50 (0%) SD 0%
*Ovary:								
Granulosa-Theca Tumor Ber	lign					0/50 (0%)	0/50 (0%)	0/50 (0%)
Overall Incidence					Total	0/150 (0%)	Mean 0%	SD 0%
*: Denominator is number of animals		examined microscopically						

Version: Nov2024 Contract/Lab: All Laboratories T Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC	Toxicology Data Management System Fumor Incidence for Selected Control Animal Groups Route: INHALATION Vehicle: AIR		Page: 22 Report Date: 11/07/2024				
	Male		Female				
*Ovary:							
Granulosa-Theca Tumor Malignant		0/50 (0%)	0/50 (0%)	0/50 (0%)			
Overall Incidence	Total	0/150 (0%)	Mean 0%	SD 0%			
Ovary:							
Granulosa Cell Tumor Benign							
·		0/50 (0%)	0/50 (0%)	3/50 (6%)			
overall Incidence	Total	3/150 (2%)	Mean 2%	SD 3.46%			
Ovary:							
Granulosa Cell Tumor Malignant							
		0/50 (0%)	0/50 (0%)	0/50 (0%)			
Overall Incidence	Total	0/150 (0%)	Mean 0%	SD 0%			
Ovary:							
Granulosa Cell Tumor, Luteoma, Thecoma, or Sertoli Cell Tumor (Benign	n, Malignant, NOS)						
	7.1.1	1/50 (2%)	0/50 (0%)	4/50 (8%)			
Overall Incidence	Total	5/150 (3.33%)	Mean 3.33%	SD 4.16%			
Ovary:							
Granulosa Cell Tumor: Benign, Malignant, NOS							
Warell Incidence	T-1-1	0/50 (0%)	0/50 (0%)	3/50 (6%)			
Overall Incidence	Total	3/150 (2%)	Mean 2%	SD 3.46%			
Ovary:							
Luteoma							
	T-1-1	1/50 (2%)	0/50 (0%)	0/50 (0%)			
Dverall Incidence	Total	1/150 (0.67%)	Mean 0.67%	SD 1.15%			
: Denominator is number of animals with tissues examined microscopically							

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC			Toxicol Tumor Incider	Page: 23 Report Date: 11/07/2024					
			Male			Female			
*Ovary: Schwannoma Malignant									
Overall Incidence					Total	0/50 (0%) 0/150 (0%)	0/50 (0%) Mean 0%	0/50 (0%) SD 0%	
*Ovary: Sertoli Cell Tumor Benign									
Overall Incidence					Total	0/50 (0%) 0/150 (0%)	0/50 (0%) Mean 0%	0/50 (0%) SD 0%	
*Ovary: Thecoma Benign									
Overall Incidence					Total	0/50 (0%) 1/150 (0.67%)	0/50 (0%) Mean 0.67%	1/50 (2%) SD 1.15%	
*Pancreas: Adenocarcinoma							0/50 (00/)	0/50 (0%)	
Overall Incidence	Total	0/50 (0%) 0/150 (0%)	0/50 (0%) Mean 0%	0/50 (0%) SD 0%	Total	0/50 (0%) 0/150 (0%)	0/50 (0%) Mean 0%	0/50 (0%) SD 0%	
*Pancreas: Adenoma									
Overall Incidence	Total	0/50 (0%) 1/150 (0.67%)	1/50 (2%) Mean 0.67%	0/50 (0%) SD 1.15%	Total	0/50 (0%) 1/150 (0.67%)	1/50 (2%) Mean 0.67%	0/50 (0%) SD 1.15%	
*Pancreas: Adenoma or Adenocarcino	ma	0/50 (00/)	4/50 (00)	0/50 (22/)		0/50 (001)		0/50 (001)	
Overall Incidence	Total	0/50 (0%) 1/150 (0.67%)	1/50 (2%) Mean 0.67%	0/50 (0%) SD 1.15%	Total	0/50 (0%) 1/150 (0.67%)	1/50 (2%) Mean 0.67%	0/50 (0%) SD 1.15%	

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC			Toxico l Tumor Incider		Page: 24 Report Date: 11/07/2024			
			Male				Female	
*Parathyroid Gland: Adenoma Overall Incidence	Total	3/49 (6%) 3/142 (2.11%)	0/45 (0%) Mean 2.04%	0/48 (0%) SD 3.53%	Total	1/47 (2%) 1/140 (0.71%)	0/48 (0%) Mean 0.71%	0/45 (0%) SD 1.23%
#Peripheral Nerve: Paraganglioma Overall Incidence	Total	0/50 (0%) 0/150 (0%)	0/50 (0%) Mean 0%	0/50 (0%) SD 0%	Total	0/50 (0%) 0/150 (0%)	0/50 (0%) Mean 0%	0/50 (0%) SD 0%
#Peripheral Nerve: Schwannoma Malignant Overall Incidence	Total	0/50 (0%) 0/150 (0%)	0/50 (0%) Mean 0%	0/50 (0%) SD 0%	Total	0/50 (0%) 0/150 (0%)	0/50 (0%) Mean 0%	0/50 (0%) SD 0%
#Pharynx: Squamous Cell Carcinoma Overall Incidence	Total	0/50 (0%) 1/150 (0.67%)	1/50 (2%) Mean 0.67%	0/50 (0%) SD 1.15%	Total	0/50 (0%) 0/150 (0%)	0/50 (0%) Mean 0%	0/50 (0%) SD 0%
*Pituitary Gland: Pars Distalis Adenoma			11/49 (22%)	11/50 (22%)		20/50 (40%)	23/50 (46%)	18/50 (36%)
Overall Incidence	Total	31/149 (20.81%)	Mean 20.82%	SD 2.45%	Total	61/150 (40.67%)	Mean 40.67%	SD 5.03%
*Pituitary Gland: Pars Distalis Carcinoma	or Unspec	cified Site: 0/50 (0%)	1/49 (2%)	0/50 (0%)		1/50 (2%)	4/50 (8%)	0/50 (0%)
Overall Incidence	Total	1/149 (0.67%)	Mean 0.68%	SD 1.18%	Total	5/150 (3.33%)	Mean 3.33%	SD 4.16%

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC			Page: 25 Report Date: 11/07/2024					
			Male				Female	
*Pituitary Gland: Pars Distalis Carcinoma or Adenoma	or Unspec	ified Site:						
Overall Incidence	Total	9/50 (18%) 32/149 (21.48%)	12/49 (24%) Mean 21.5%	11/50 (22%) SD 3.27%	Total	21/50 (42%) 66/150 (44%)	27/50 (54%) Mean 44%	18/50 (36%) SD 9.17%
Pituitary Gland: Pars Distalis Schwannoma Malignant		ified Site:						0/50 (00()
Overall Incidence	Total	1/50 (2%) 1/149 (0.67%)	0/49 (0%) Mean 0.67%	0/50 (0%) SD 1.15%	Total	0/50 (0%) 0/150 (0%)	0/50 (0%) Mean 0%	0/50 (0%) SD 0%
Pituitary Gland: Pars Intermed Adenoma								
Overall Incidence	Total	0/50 (0%) 1/149 (0.67%)	1/49 (2%) Mean 0.68%	0/50 (0%) SD 1.18%	Total	0/50 (0%) 1/150 (0.67%)	1/50 (2%) Mean 0.67%	0/50 (0%) SD 1.15%
Pituitary Gland: Pars Intermed Carcinoma or Adenoma						-/ />		
Overall Incidence	Total	0/50 (0%) 1/149 (0.67%)	1/49 (2%) Mean 0.68%	0/50 (0%) SD 1.18%	Total	0/50 (0%) 1/150 (0.67%)	1/50 (2%) Mean 0.67%	0/50 (0%) SD 1.15%
Pituitary Gland: Pars Nervosa Schwannoma Malignant								
Overall Incidence	Total	0/50 (0%) 0/149 (0%)	0/49 (0%) Mean 0%	0/50 (0%) SD 0%	Total	0/50 (0%) 0/150 (0%)	0/50 (0%) Mean 0%	0/50 (0%) SD 0%
Prostate: Adenoma		1/50 (2%)	1/50 (2%)	0/50 (0%)				
Overall Incidence	Total	1/50 (2%) 2/150 (1.33%)	1/50 (2%) Mean 1.33%	0/50 (0%) SD 1.15%				

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC			Page: 26 Report Date: 11/07/2024							
			Male			Female				
*Prostate: Adenoma or Adenocarcinor	na									
Overall Incidence	Total	1/50 (2%) 2/150 (1.33%)	1/50 (2%) Mean 1.33%	0/50 (0% SD 1.15%	,					
*Salivary Glands: Schwannoma Malignant										
Overall Incidence	Total	0/50 (0%) 0/150 (0%)	0/50 (0%) Mean 0%	0/50 (0% SD 0%	o) Total	0/50 (0%) 0/150 (0%)	0/50 (0%) Mean 0%	0/50 (0%) SD 0%		
#Seminal Vesicle: Hemangiosarcoma										
Overall Incidence	Total	0/50 (0%) 0/150 (0%)	0/50 (0%) Mean 0%	0/50 (0% SD 0%	b)					
#Skeletal Muscle: Fibrosarcoma		2/50 (00/)	0/50 (00/)	0/50 (00)	、	4/50 (00/)	0/50 (00/)	0/50 (00/)		
Overall Incidence	Total	0/50 (0%) 0/150 (0%)	0/50 (0%) Mean 0%	0/50 (0% SD 0%	Total	1/50 (2%) 1/150 (0.67%)	0/50 (0%) Mean 0.67%	0/50 (0%) SD 1.15%		
#Skeletal Muscle: Hemangioma										
Overall Incidence	Total	0/50 (0%) 0/150 (0%)	0/50 (0%) Mean 0%	0/50 (0% SD 0%	5) Total	0/50 (0%) 0/150 (0%)	0/50 (0%) Mean 0%	0/50 (0%) SD 0%		
#Skeletal Muscle: Hemangiosarcoma		0/50 (00%)	0/50 (00/)	0/50 (00)	、	0/50 (0%)	0/50 (00/.)	0/50 (00/)		
Overall Incidence	Total	0/50 (0%) 0/150 (0%)	0/50 (0%) Mean 0%	0/50 (0% SD 0%) Total	0/50 (0%) 0/150 (0%)	0/50 (0%) Mean 0%	0/50 (0%) SD 0%		

Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC			Report Date: 11/07/2024					
			Male				Female	
#Skeletal Muscle: Liposarcoma		0/50 (0%)	0/50 (0%)	0/50 (0%)		0/50 (0%)	0/50 (0%)	1/50 (2%)
Overall Incidence	Total	0/150 (0%)	Mean 0%	SD 0%	Total	1/150 (0.67%)	Mean 0.67%	SD 1.15%
#Skeletal Muscle: Sarcoma		0/50 (0%)	0/50 (0%)	0/50 (0%)		0/50 (0%)	0/50 (0%)	0/50 (0%)
Overall Incidence	Total	0/150 (0%)	Mean 0%	SD 0%	Total	0/150 (0%)	Mean 0%	SD 0%
#Skin: Basal Cell Adenoma								
Overall Incidence	Total	1/50 (2%) 1/150 (0.67%)	0/50 (0%) Mean 0.67%	0/50 (0%) SD 1.15%	Total	0/50 (0%) 0/150 (0%)	0/50 (0%) Mean 0%	0/50 (0%) SD 0%
#Skin: Basal Cell Carcinoma		0/50 (0%)	1/50 (2%)	0/50 (0%)		0/50 (0%)	0/50 (0%)	1/50 (2%)
Overall Incidence	Total	1/150 (0.67%)	Mean 0.67%	SD 1.15%	Total	1/150 (0.67%)	Mean 0.67%	SD 1.15%
#Skin: Basal or Squamous Cell Ca Adenoma, Papilloma, Sq Pa Carcinoma, Sebaceous Glaı	rcinoma, B pilloma, Ke	asosquamous Tumor (Ma eratoacanthoma, Trichoer	lignant or Benign), Ba bithelioma, Adenoma,	asal Cell		0/50 (0%)	0/50 (0%)	1/50 (2%)
Overall Incidence	Total	13/150 (8.67%)	Mean 8.67%	SD 6.11%	Total	1/150 (0.67%)	Mean 0.67%	SD 1.15%
#Skin: Basal or Squamous Cell Ca Adenocarcinoma	rcinoma, B		lignant), or Sebaceou				0/50 /00/)	4/50 (00/)
		0/50 (0%)	1/50 (2%)	0/50 (0%)		0/50 (0%)	0/50 (0%)	1/50 (2%)

Toxicology Data Management System

Page: 27

#: Denominator is number of animals necropsied

Version: Nov2024

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC			Toxicol Tumor Incider	Page: 28 Report Da	te: 11/07/2024						
			Male				Female				
#Skin: Basosquamous Tumor (Benign), Basal Cell Adenoma, Adenoma, Papilloma, Sq Papilloma, Keratoacanthoma, Trichoepithelioma, or Sebaceous Gland Adenoma											
Overall Incidence	Total	7/50 (14%) 12/150 (8%)	0/50 (0%) Mean 8%	5/50 (10%) SD 7.21%	Total	0/50 (0%) 0/150 (0%)	0/50 (0%) Mean 0%	0/50 (0%) SD 0%			
#Skin: Fibroma											
Overall Incidence	Total	3/50 (6%) 3/150 (2%)	0/50 (0%) Mean 2%	0/50 (0%) SD 3.46%	Total	0/50 (0%) 1/150 (0.67%)	1/50 (2%) Mean 0.67%	0/50 (0%) SD 1.15%			
#Skin: Fibroma or Myxoma		3/50 (6%)	0/50 (0%)	0/50 (0%)		0/50 (0%)	1/50 (2%)	0/50 (0%)			
Overall Incidence	Total	3/150 (2%)	Mean 2%	SD 3.46%	Total	1/150 (0.67%)	Mean 0.67%	SD 1.15%			
#Skin: Fibroma, Fibrosarcoma, S		3/50 (6%)	eomorphic Fibrosard 5/50 (10%)			0/50 (0%)	1/50 (2%)	0/50 (0%)			
Overall Incidence	Total	9/150 (6%)	Mean 6%	SD 4%	Total	1/150 (0.67%)	Mean 0.67%	SD 1.15%			
#Skin: Fibroma, Fibrosarcoma, S Hemangiopericytoma	arcoma, Myx	coma, Myxosarcoma, Pleo	morphic Fibrosarcon	na, or							
Overall Incidence	Total	3/50 (6%) 9/150 (6%)	5/50 (10%) Mean 6%	1/50 (2%) SD 4%	Total	0/50 (0%) 1/150 (0.67%)	1/50 (2%) Mean 0.67%	0/50 (0%) SD 1.15%			
#Skin: Fibrosarcoma		0/50 (0%)	5/50 (10%)	0/50 (0%)		0/50 (0%)	0/50 (0%)	0/50 (0%)			
Overall Incidence	Total	5/150 (3.33%)	Mean 3.33%	SD 5.77%	Total	0/150 (0%)	Mean 0%	SD 0%			

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC				ogy Data Management ice for Selected Control A Route: INHALATION Vehicle: AIR	•		Page: 29 Report Da	9 Date: 11/07/2024	
			Male				Female		
#Skin: Fibrosarcoma, Sarcoma, My Overall Incidence	xosarcom a Total	a, or Pleomorphic Fibrosa 0/50 (0%) 6/150 (4%)	ircoma 5/50 (10%) Mean 4%	1/50 (2%) SD 5.29%	Total	0/50 (0%) 0/150 (0%)	0/50 (0%) Mean 0%	0/50 (0%) SD 0%	
#Skin: Hemangioma		0/50 (0%)	0/50 (0%)	1/50 (2%)		0/50 (0%)	0/50 (0%)	0/50 (0%)	
Overall Incidence	Total	1/150 (0.67%)	Mean 0.67%	SD 1.15%	Total	0/150 (0%)	Mean 0%	SD 0%	
#Skin: Hemangiopericytoma Overall Incidence	Total	0/50 (0%) 0/150 (0%)	0/50 (0%) Mean 0%	0/50 (0%) SD 0%	Total	0/50 (0%) 0/150 (0%)	0/50 (0%) Mean 0%	0/50 (0%) SD 0%	
#Skin: Keratoacanthoma Overall Incidence	Total	3/50 (6%) 6/150 (4%)	0/50 (0%) Mean 4%	3/50 (6%) SD 3.46%	Total	0/50 (0%) 0/150 (0%)	0/50 (0%) Mean 0%	0/50 (0%) SD 0%	
#Skin: Lipoma Overall Incidence	Total	1/50 (2%) 2/150 (1.33%)	0/50 (0%) Mean 1.33%	1/50 (2%) SD 1.15%	Total	0/50 (0%) 0/150 (0%)	0/50 (0%) Mean 0%	0/50 (0%) SD 0%	
#Skin: Liposarcoma		0/50 (0%)	0/50 (0%)	0/50 (0%)		0/50 (0%)	0/50 (0%)	0/50 (0%)	
Overall Incidence	Total	0/150 (0%)	Mean 0%	SD 0%	Total	0/150 (0%)	Mean 0%	SD 0%	

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC				ogy Data Management ace for Selected Control , Route: INHALATION Vehicle: AIR	-	Page: 30 Jps Report Date: 11/07/2024 Female				
			Male			Report Date: 11/07/2024				
#Skin: Neurofibrosarcoma or Sc	•	0/50 (0%)	0/50 (0%)	0/50 (0%)		()	()	()		
Overall Incidence	Total	0/150 (0%)	Mean 0%	SD 0%	Total	0/150 (0%)	Mean 0%	SD 0%		
#Skin: Neurofibrosarcoma, Neur	ofibroma, or s	Schwannoma (benign, ma 0/50 (0%)	lignant or NOS) 0/50 (0%)	0/50 (0%)		0/50 (0%)	0/50 (0%)	0/50 (0%)		
Overall Incidence	Total	0/150 (0%)	Mean 0%	SD 0%	Total	0/150 (0%)	Mean 0%	SD 0%		
#Skin: Osteosarcoma	T -1-1	0/50 (0%)	0/50 (0%)	0/50 (0%)	Tatal	()	()	()		
Overall Incidence	Total	0/150 (0%)	Mean 0%	SD 0%	Total	0/150 (0%)	Mean 0%	SD 0%		
#Skin: Papilloma		3/50 (6%)	0/50 (0%)	0/50 (0%)		0/50 (0%)	0/50 (0%)	0/50 (0%)		
Overall Incidence	Total	3/150 (2%)	Mean 2%	SD 3.46%	Total	0/150 (0%)	Mean 0%	SD 0%		
#Skin: Pilomatrixoma		0/50 (0%)	0/50 (0%)	0/50 (0%)		0/50 (0%)	0/50 (0%)	0/50 (0%)		
Overall Incidence	Total	0/150 (0%)	Mean 0%	SD 0%	Total	()	()			
#Skin: Pleomorphic Fibrosarcon	na	0/50 (0%)	0/50 (0%)	1/50 (2%)		0/50 (0%)	0/50 (0%)	0/50 (0%)		
Overall Incidence	Total	1/150 (0.67%)	Mean 0.67%	SD 1.15%	Total	0/150 (0%)	Mean 0%	SD 0%		

Version: Nov2024 Contract/Lab: All Laborato Species: RATS Strain: Harlan Sprague-Dav Length of Study: CHRONI	wley		Page: 31 Report Date: 11/07/2024					
			Male			Female 0/50 (0%) 0/50 (0%) 0/50 (0%) Total 0/150 (0%) Mean 0% SD 0% 0/50 (0%) 0/50 (0%) 0/50 (0%) SD 0% Total 0/150 (0%) 0/50 (0%) SD 0% 0/50 (0%) 0/50 (0%) Mean 0% SD 0% Total 0/150 (0%) 0/50 (0%) SD 0% 0/50 (0%) 0/50 (0%) Mean 0% SD 0% Total 0/150 (0%) 0/50 (0%) SD 0% 0/50 (0%) 0/50 (0%) SD 0% SD 0%		
#Skin: Sarcoma						- /		
Overall Incidence	Total	0/50 (0%) 0/150 (0%)	0/50 (0%) Mean 0%	0/50 (0%) SD 0%	Total	0/150 (0%)	Mean 0%	SD 0%
#Skin: Schwannoma Malignan		0/50 (0%)	0/50 (0%)	0/50 (0%)				
Overall Incidence	Total	0/150 (0%)	Mean 0%	SD 0%	Total	()	()	()
#Skin: Squamous Cell Carcino	ma	0/50 (0%)	0/50 (0%)	0/50 (0%)		0/50 (0%)	0/50 (0%)	0/50 (0%)
Overall Incidence	Total	0/150 (0%)	Mean 0%	SD 0%		()	()	()
Skin:		Carcinoma, Basosquamo	ous Tumor (malignant	or NOS),		0/50 (00/)	0/50 (00/)	
Overall Incidence	Total	0/50 (0%) 1/150 (0.67%)	1/50 (2%) Mean 0.67%	0/50 (0%) SD 1.15%	Total	()	()	· · /
≴Skin: Squamous Cell Papillon								
		0/50 (0%) 1/150 (0.67%)	0/50 (0%) Mean 0.67%	1/50 (2%) SD 1.15%	Total	0/50 (0%) 0/150 (0%)	0/50 (0%) Mean 0%	0/50 (0%) SD 0%
	Total	, ,						
Overall Incidence #Skin: Squamous Cell Papillon				1/50 (2%)		0/50 (0%)	0/50 (0%)	0/50 (0%)

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC				logy Data Management ince for Selected Control A Route: INHALATION Vehicle: AIR	•		Page: 32 Report Date: 11/07/2024		
			Male				Female		
#Skin: Squamous Cell Papilloma, I Overall Incidence	Papilloma, Total	or Keratoacanthoma 6/50 (12%) 10/150 (6.67%)	0/50 (0%) Mean 6.67%	4/50 (8%) SD 6.11%	Total	0/50 (0%) 0/150 (0%)	0/50 (0%) Mean 0%	0/50 (0%) SD 0%	
		, , ,				0,100 (0,0)			
#Skin: Squamous Cell Papilloma, I	Papilloma,	Squamous Cell Carcinom 6/50 (12%)	a or Keratoacanthom 0/50 (0%)	a 4/50 (8%)		0/50 (0%)	0/50 (0%)	0/50 (0%)	
Overall Incidence	Total	10/150 (6.67%)	Mean 6.67%	SD 6.11%	Total	0/150 (0%)	Mean 0%	SD 0%	
#Skin: Trichoepithelioma Overall Incidence	Total	0/50 (0%) 0/150 (0%)	0/50 (0%) Mean 0%	0/50 (0%) SD 0%	Total	0/50 (0%) 0/150 (0%)	0/50 (0%) Mean 0%	0/50 (0%) SD 0%	
#Skin: Sebaceous Gland: Adenoma Overall Incidence	Total	0/50 (0%) 1/150 (0.67%)	0/50 (0%) Mean 0.67%	1/50 (2%) SD 1.15%	Total	0/50 (0%) 0/150 (0%)	0/50 (0%) Mean 0%	0/50 (0%) SD 0%	
*Spleen: Hemangiosarcoma		0/50 (0%)	0/50 (0%)	0/50 (0%)		0/50 (0%)	0/50 (0%)	0/50 (0%)	
Overall Incidence	Total	0/150 (0%)	Mean 0%	SD 0%	Total	0/150 (0%)	Mean 0%	SD 0%	
#Stomach, Forestomach: Papilloma		0/50 (0%)	0/50 (0%)	0/50 (0%)		1/50 (2%)	1/50 (2%)	0/50 (0%)	
Overall Incidence	Total	0/150 (0%)	Mean 0%	SD 0%	Total	2/150 (1.33%)	Mean 1.33%	SD 1.15%	

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC				ogy Data Management ice for Selected Control Route: INHALATION Vehicle: AIR	Page: 33 Report Da	te: 11/07/2024		
			Male				Female	
#Stomach, Forestomach: Sarcoma			- / /				- /	
Overall Incidence	Total	0/50 (0%) 0/150 (0%)	0/50 (0%) Mean 0%	0/50 (0%) SD 0%	Total	0/50 (0%) 0/150 (0%)	0/50 (0%) Mean 0%	0/50 (0%) SD 0%
#Stomach, Forestomach: Squamous Cell Carcinoma c			0/50 (0%)	0/50 (0%)		0/50 (0%)	0/50 (0%)	0/50 (0%)
Overall Incidence	Total	0/150 (0%)	Mean 0%	SD 0%	Total	0/150 (0%)	Mean 0%	SD 0%
#Stomach, Forestomach: Squamous Cell Papilloma		0/50 (0%)	0/50 (0%)	0/50 (0%)		0/50 (0%)	0/50 (0%)	0/50 (0%)
Overall Incidence	Total	0/150 (0%)	Mean 0%	SD 0%	Total	0/150 (0%)	Mean 0%	SD 0%
#Stomach, Glandular: Sarcoma		1/50 (2%)	0/50 (0%)	0/50 (0%)		0/50 (0%)	0/50 (0%)	0/50 (0%)
Overall Incidence	Total	1/150 (0.67%)	Mean 0.67%	SD 1.15%	Total	0/150 (0%)	Mean 0%	SD 0%
*Testis: Adenoma		0/50 (//2/)	4/50 (001)	0/50 (00/)				
Overall Incidence	Total	2/50 (4%) 3/150 (2%)	1/50 (2%) Mean 2%	0/50 (0%) SD 2%				
*Thymus: Schwannoma Malignant		0/50 (0%)	0/50 (0%)	0/48 (0%)		1/50 (2%)	0/47 (0%)	0/50 (0%)
Overall Incidence	Total	0/148 (0%)	Mean 0%	SD 0%	Total	1/147 (0.68%)	Mean 0.67%	SD 1.15%

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC				logy Data Management nce for Selected Control A Route: INHALATION Vehicle: AIR			Page: 34 Report Date: 11/07/2024		
			Male			Female 0/50 (0%) 0/47 (0%) 0/50 (0%) 0/147 (0%) Mean 0% SD 0% 0/50 (0%) 0/47 (0%) 0/50 (0%) 0/50 (0%) 0/47 (0%) 0/50 (0%) 0/147 (0%) Mean 0% SD 0%			
*Thymus: Thymoma Benign Overall Incidence	Total	0/50 (0%) 0/148 (0%)	0/50 (0%) Mean 0%	0/48 (0%) SD 0%	Total				
						0/147 (078)			
*Thymus: Thymoma Malignant		0/50 (0%)	0/50 (0%)	0/48 (0%)		0/50 (0%)	0/47 (0%)	0/50 (0%)	
Overall Incidence	Total	0/148 (0%)	Mean 0%	SD 0%	Total	()		SD 0%	
*Thymus: Thymoma: Benign, Maligna Overall Incidence		0/50 (0%) 0/148 (0%)	0/50 (0%) Mean 0%	0/48 (0%) SD 0%	Total	0/50 (0%) 0/147 (0%)	0/47 (0%) Mean 0%	0/50 (0%) SD 0%	
						· · /		50 0%	
*Thyroid Gland: C-Cell: Adenoma Overall Incidence	Total	12/49 (24%) 21/149 (14.09%)	7/50 (14%) Mean 14.16%	2/50 (4%) SD 10.25%	Total	10/50 (20%) 24/150 (16%)	12/50 (24%) Mean 16%	2/50 (4%) SD 10.58%	
*Thyroid Gland: C-Cell: Carcinoma									
Overall Incidence	Total	0/49 (0%) 2/149 (1.34%)	1/50 (2%) Mean 1.33%	1/50 (2%) SD 1.15%	Total	1/50 (2%) 2/150 (1.33%)	1/50 (2%) Mean 1.33%	0/50 (0%) SD 1.15%	
*Thyroid Gland: C-Cell: Carcinoma or Adenoma		12/49 (24%)	8/50 (16%)	3/50 (6%)		11/50 (22%)	13/50 (26%)	2/50 (4%)	
Overall Incidence	Total	23/149 (15.44%)	Mean 15.5%	SD 9.26%	Total	26/150 (17.33%)	Mean 17.33%	SD 11.72%	

Version: Nov2024 **Toxicology Data Management System** Page: 35 Contract/Lab: All Laboratories Tumor Incidence for Selected Control Animal Groups Report Date: 11/07/2024 Species: RATS Route: INHALATION Strain: Harlan Sprague-Dawley Vehicle: AIR Length of Study: CHRONIC Male Female *Thyroid Gland: Follicular Cell: Adenoma 0/49 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/149 (0%) SD 0% SD 0% **Overall Incidence** Total Mean 0% Total 0/150 (0%) Mean 0% . *Thyroid Gland: Follicular Cell: Carcinoma 0/49 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) **Overall Incidence** Total 0/149 (0%) Mean 0% SD 0% Total 0/150 (0%) Mean 0% SD 0% *Thyroid Gland: Follicular Cell: Carcinoma or Adenoma 0/49 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) **Overall Incidence** Total 0/149 (0%) Mean 0% SD 0% Total 0/150 (0%) Mean 0% SD 0% **#Tissue NOS:** Schwannoma Malignant 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) SD 0% **Overall Incidence** Total 0/150 (0%) Mean 0% SD 0% Total 0/150 (0%) Mean 0% **#Tongue:**

Overall Incidence	Total	0/50 (0%) 0/150 (0%)	0/50 (0%) Mean 0%	0/50 (0%) SD 0%	Total	1/50 (2%) 1/150 (0.67%)	0/50 (0%) Mean 0.67%	0/50 (0%) SD 1.15%	
#Tongue: Papilloma									
Overall Incidence	Total	0/50 (0%) 1/150 (0.67%)	1/50 (2%) Mean 0.67%	0/50 (0%) SD 1.15%	Total	0/50 (0%) 0/150 (0%)	0/50 (0%) Mean 0%	0/50 (0%) SD 0%	
Fibrosarcoma									

*: Denominator is number of animals with tissues examined microscopically

Version: Nov2024 Contract/Lab: All Laborator Species: RATS Strain: Harlan Sprague-Dav Length of Study: CHRONIC	vley		Toxicol Tumor Incider		Page: 36 Report Date: 11/07/2024			
			Male			0/50 (0%) 0/50 (0%) 0/50 (0%) 0/150 (0%) Mean 0% SD 0% 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/150 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%)		
#Tongue: Squamous Cell Carcinoi	ma	0/50 (0%)	0/50 (0%)	0/50 (0%)		0/50 (0%)	0/50 (0%)	0/50 (0%)
Overall Incidence	Total	0/150 (0%)	Mean 0%	SD 0%	Total	0/150 (0%)	Mean 0%	SD 0%
#Tongue: Squamous Cell Carcino		a Squamous		0/50 (00/)		0/50 (00/)	0/50 (00()	0/50 (0)()
Overall Incidence	Total	0/50 (0%) 0/150 (0%)	0/50 (0%) Mean 0%	0/50 (0%) SD 0%	Total	()	()	()
#Tooth: Odontoma		0/50 (00/)	0/50 (0%/)	4/50 (09/)		0/50 (0%)	0/50 (00/.)	0/50 (0%)
Overall Incidence	Total	0/50 (0%) 1/150 (0.67%)	0/50 (0%) Mean 0.67%	1/50 (2%) SD 1.15%	Total	()		· · /
Urinary Bladder: Leiomyosarcoma								
Overall Incidence	Total	0/50 (0%) 0/150 (0%)	0/50 (0%) Mean 0%	0/50 (0%) SD 0%	Total	()	· · ·	()
Uterus: Adenocarcinoma								
Overall Incidence					Total	0/50 (0%) 2/150 (1.33%)	1/50 (2%) Mean 1.33%	1/50 (2%) SD 1.15%
*Uterus: Adenocarcinoma or Ade								
						0/50 (0%)	1/50 (2%)	1/50 (2%) SD 1.15%

Version : Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley	Toxicology Data Management System Tumor Incidence for Selected Control Animal Groups Route: INHALATION Vehicle: AIR		Page: 37 Report Date: 11/07/2024			
Length of Study: CHRONIC						
	Male		Female			
*Uterus:						
Adenoma Overall Incidence	Total	0/50 (0%) 0/150 (0%)	0/50 (0%) Mean 0%	0/50 (0%) SD 0%		
*Uterus: Adenoma, Adenocarcinoma, Sq Cell Carcinoma, or	Sq Cell Papilloma	0/50 (0%)	1/50 (2%)	2/50 (4%)		
Overall Incidence	Total	3/150 (2%)	Mean 2%	SD 2%		
*Uterus: Deciduoma Benign						
Overall Incidence	Total	0/50 (0%) 0/150 (0%)	0/50 (0%) Mean 0%	0/50 (0%) SD 0%		
'Uterus:						
Granular Cell Tumor Benign		0/50 (0%)	0/50 (0%)	0/50 (0%)		
Overall Incidence	Total	0/150 (0%)	Mean 0%	SD 0%		
'Uterus: Hemangioma						
		0/50 (0%)	0/50 (0%)	0/50 (0%)		
Overall Incidence	Total	0/150 (0%)	Mean 0%	SD 0%		
'Uterus:						
Polyp Stromal		1/50 (2%)	5/50 (10%)	7/50 (14%)		
Overall Incidence	Total	13/150 (8.67%)	Mean 8.67%	SD 6.11%		

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC	Toxicology Data Management System Tumor Incidence for Selected Control Animal Groups Route: INHALATION Vehicle: AIR		Page: 38 Report Da	te: 11/07/2024
	Male		Female	
*Uterus:				
Sarcoma		0/50 (0%)	0/50 (0%)	0/50 (0%)
Overall Incidence	Total	0/150 (0%)	0/50 (0%) Mean 0%	0/50 (0%) SD 0%
	ı ola	()		
'Uterus:				
Sarcoma Stromal				
		0/50 (0%)	0/50 (0%)	0/50 (0%)
Overall Incidence	Total	0/150 (0%)	Mean 0%	SD 0%
*Uterus:				
Sarcoma Stromal or Polyp Stromal		4/50 (00/)		7/50 (4.40/)
Overall Incidence	T-4-1	1/50 (2%)	5/50 (10%)	7/50 (14%)
Overall Incidence	Total	13/150 (8.67%)	Mean 8.67%	SD 6.11%
'Uterus:				
Schwannoma Malignant				
5		0/50 (0%)	0/50 (0%)	0/50 (0%)
Overall Incidence	Total	0/150 (0%)	Mean 0%	SD 0%
*Uterus:				
Sq Cell Carcinoma or Papilloma Squamous			0/50 (00/)	4/50 (00/)
		0/50 (0%)	0/50 (0%)	1/50 (2%)
Overall Incidence	Total	1/150 (0.67%)	Mean 0.67%	SD 1.15%
Uterus:				
Squamous Cell Carcinoma				
		0/50 (0%)	0/50 (0%)	1/50 (2%)
Overall Incidence	Total	1/150 (0.67%)	Mean 0.67%	SD 1.15%
	anniaellu	· · · · · · · · · · · · · · · · · · ·		
Denominator is number of animals with tissues examined microsoft. The paraminator is number of animals paceapsied.	copically			

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC			Tumor Incidence	gy Data Managem e for Selected Cont Route: INHALATIO Vehicle: AIR	Page: 39 Report Date: 11/07/2024			
			Male				Female	
*Uterus: Squamous Cell Papilloma								
Overall Incidence					Total	0/50 (0%) 0/150 (0%)	0/50 (0%) Mean 0%	0/50 (0%) SD 0%
#Vagina: Granular Cell Tumor Benigr								
Overall Incidence					Total	0/50 (0%) 1/150 (0.67%)	0/50 (0%) Mean 0.67%	1/50 (2%) SD 1.15%
#Vagina: Polyp								
Overall Incidence					Total	0/50 (0%) 0/150 (0%)	0/50 (0%) Mean 0%	0/50 (0%) SD 0%
#Vagina: Sarcoma								
Overall Incidence					Total	0/50 (0%) 0/150 (0%)	0/50 (0%) Mean 0%	0/50 (0%) SD 0%
#Vagina: Schwannoma Malignant								
Overall Incidence					Total	0/50 (0%) 1/150 (0.67%)	0/50 (0%) Mean 0.67%	1/50 (2%) SD 1.15%
#Zymbal's Gland: Adenoma		0/50 (00/)	0/50 (00/.)	0/50 (22/)		0/50 (0%)	0/50 (00/.)	0/50 (00/)
Overall Incidence	Total	0/50 (0%) 0/150 (0%)	0/50 (0%) Mean 0%	0/50 (0%) SD 0%	Total	0/50 (0%) 0/150 (0%)	0/50 (0%) Mean 0%	0/50 (0%) SD 0%

Contract/Lab: All Laboratorie Species: RATS Strain: Harlan Sprague-Dawl Length of Study: CHRONIC	ley			ogy Data Management ace for Selected Control A Route: INHALATION Vehicle: AIR		Page: 40 Report Dat	t e: 11/07/2024	
			Male				Female	
Adenoma, Adenocarcinor	-	0/50 (0%)	1/50 (2%)	1/50 (2%)	Table	0/50 (0%)	1/50 (2%)	0/50 (0%)
Adenoma, Adenocarcinor	oma, Sq Cell Ca Total			1/50 (2%) SD 1.15%	Total	0/50 (0%) 1/150 (0.67%)	1/50 (2%) Mean 0.67%	0/50 (0%) SD 1.15%
Adenoma, Adenocarcinor Overall Incidence	-	0/50 (0%)	1/50 (2%)	()	Total		()	()
Overall Incidence #Zymbal's Gland:	-	0/50 (0%)	1/50 (2%)	()	Total		()	()

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC

Toxicology Data Management System Tumor Incidence for Selected Control Animal Groups Route: ORAL Vehicle: FEED

				Stu	dy Summary		
Laboratory Name	Study Number	Study Start Date	Length of Study in Days	Number of Animals Total and (#/Cage)	Number Surviving and (Mean Life Span)	Maximum Mean Weekly Body Weight	Chemical
					Male		
Battelle Columbus Laboratory	051018801	02/17/11	733	50(2)	32(675)	525.8	Di(2-ethylhexyl) Phthalate
					Female		
Battelle Columbus Laboratory	051018801	02/18/11	736	50(4)	33(691)	329.5	Di(2-ethylhexyl) Phthalate

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC			Toxico Tumor Incide	Page: 42 Report Dat	e: 11/07/2024			
			Male				Female	
#All Organs: Benign Tumors Overall Incidence	Total	27/50 (54%) 27/50 (54%)	Mean 54%	37/50 (74%) 37/50 (74%)	Mean 74%	SD 0%		
		21/00 (04/0)		SD 0%	Total	. ,		
#All Organs: Malignant Tumors		13/50 (26%)				16/50 (32%)		
Overall Incidence	Total	13/50 (26%)	Mean 26%	SD 0%	Total	16/50 (32%)	Mean 32%	SD 0%
#All Organs: Malignant and Benign Tumc Overall Incidence		32/50 (64%) 32/50 (64%)	Mean 64%	SD 0%	Total	41/50 (82%) 41/50 (82%)	Mean 82%	SD 0%
#All Organs: Hemangioma		1/50 (2%)				0/50 (0%)		
Overall Incidence	Total	1/50 (2%)	Mean 2%	SD 0%	Total	0/50 (0%)	Mean 0%	SD 0%
#All Organs: Hemangiosarcoma		0/50 (0%)				0/50 (0%)		
Overall Incidence	Total	0/50 (0%)	Mean 0%	SD 0%	Total	0/50 (0%)	Mean 0%	SD 0%
#All Organs: Hemangiosarcoma or Hema	ngioma	1/50 (2%)				0/50 (0%)		
Overall Incidence	Total	1/50 (2%)	Mean 2%	SD 0%	Total	0/50 (0%)	Mean 0%	SD 0%

Contract/Lab: All Laborator Species: RATS Strain: Harlan Sprague-Daw Length of Study: CHRONIC	vley		Toxicc Tumor Incide		Page: 43 Report Date: 11/07/2024			
			Male				Female	
#All Organs: Histiocytic Sarcoma		0/50 (0%)			0/50 (0%)			
Overall Incidence	Total	0/50 (0%)	Mean 0%	SD 0%	Total	0/50 (0%)	Mean 0%	SD 0%
#All Organs: Leukemia: Granulocytic		0/50 (0%)				0/50 (0%)		
Overall Incidence	Total	0/50 (0%)	Mean 0%	SD 0%	Total	0/50 (0%)	Mean 0%	SD 0%
	•••••	• • • • • • • • • • • • • • • • • • • •					••••••	
#All Organs: Leukemia: Lymphocytic	, Monocytic, Mo	nonuclear, or Undifferer 0/50 (0%)	itiated			0/50 (0%)		SD 004
#All Organs: Leukemia: Lymphocytic Overall Incidence	, Monocytic, Mo l Total	nonuclear, or Undifferer 0/50 (0%) 0/50 (0%)	tiated Mean 0%	SD 0%	Total	0/50 (0%) 0/50 (0%)	Mean 0%	SD 0%
#All Organs: Leukemia: Lymphocytic Overall Incidence	, Monocytic, Mo Total Iistiocytic, Lymp	nonuclear, or Undifferer 0/50 (0%) 0/50 (0%) ohocytic, Mixed, NOS, La	itiated Mean 0%	SD 0%	Total	0/50 (0%) 0/50 (0%)	Mean 0%	
#All Organs: Leukemia: Lymphocytic Overall Incidence #All Organs: Malignant Lymphoma: H Undifferentiated Cell Typ	, Monocytic, Mo Total Iistiocytic, Lymp	nonuclear, or Undifferer 0/50 (0%) 0/50 (0%)	itiated Mean 0%	SD 0%	Total	0/50 (0%) 0/50 (0%)	Mean 0%	
#All Organs: Leukemia: Lymphocytic Overall Incidence #All Organs: Malignant Lymphoma: H Undifferentiated Cell Typ Overall Incidence	, Monocytic, Mo Total l istiocytic, Lymp De Total	nonuclear, or Undifferer 0/50 (0%) 0/50 (0%) ohocytic, Mixed, NOS, La 2/50 (4%) 2/50 (4%)	ntiated Mean 0% Irge Granular, or	SD 0%	Total	0/50 (0%) 0/50 (0%) 1/50 (2%) 1/50 (2%)	Mean 0%	
 #All Organs: Leukemia: Lymphocytic, Overall Incidence #All Organs: Malignant Lymphoma: H Undifferentiated Cell Typ Overall Incidence #All Organs: Malignant Schwannoma Overall Incidence 	, Monocytic, Mo r Total I istiocytic, Lymp De Total Total	nonuclear, or Undifferer 0/50 (0%) 0/50 (0%) hocytic, Mixed, NOS, La 2/50 (4%) 2/50 (4%) 3/50 (6%)	ntiated Mean 0% nrge Granular, or Mean 4% Mean 6%	SD 0% SD 0% SD 0%	Total Total Total	0/50 (0%) 0/50 (0%) 1/50 (2%) 1/50 (2%) 1/50 (2%) 1/50 (2%)	Mean 0%	
Overall Incidence #All Organs: Malignant Lymphoma: H Undifferentiated Cell Typ Overall Incidence #All Organs:	, Monocytic, Mo r Total l istiocytic, Lymp De Total Total	nonuclear, or Undifferer 0/50 (0%) 0/50 (0%) hocytic, Mixed, NOS, La 2/50 (4%) 2/50 (4%) 3/50 (6%)	ntiated Mean 0% nrge Granular, or Mean 4% Mean 6%	SD 0% SD 0% SD 0%	Total Total Total	0/50 (0%) 0/50 (0%) 1/50 (2%) 1/50 (2%) 1/50 (2%) 1/50 (2%)	Mean 0% Mean 2%	SD 0%

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC			Page: 44 Report Date: 11/07/2024					
			Male				Female	
#All Organs: Mesothelioma: Malignant		2/50 (4%)				0/50 (0%)		
Overall Incidence	Total	2/50 (4%)	Mean 4%	SD 0%	Total	0/50 (0%)	Mean 0%	SD 0%
*Adrenal Cortex: Adenoma		4/50 (20()						
Overall Incidence	Total	1/50 (2%) 1/50 (2%)	Mean 2%	SD 0%	Total	0/50 (0%) 0/50 (0%)	Mean 0%	SD 0%
*Adrenal Cortex: Carcinoma								
Overall Incidence	Total	0/50 (0%) 0/50 (0%)	Mean 0%	SD 0%	Total	0/50 (0%) 0/50 (0%)	Mean 0%	SD 0%
Adrenal Cortex: Carcinoma or Adenoma		1/50 (2%)				0/50 (0%)		
Overall Incidence	Total	1/50 (2%)	Mean 2%	SD 0%	Total	0/50 (0%)	Mean 0%	SD 0%
*Adrenal Medulla: Ganglioneuroma		0/50 (0%)						
Overall Incidence	Total	0/50 (0%) 0/50 (0%)	Mean 0%	SD 0%	Total	0/50 (0%) 0/50 (0%)	Mean 0%	SD 0%
*Adrenal Medulla: Pheochromocytoma Benign		4/50 (8%)				1/50 (2%)		
Overall Incidence	Total	4/50 (8%)	Mean 8%	SD 0%	Total	1/50 (2%)	Mean 2%	SD 0%

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC				blogy Data Manageme ence for Selected Contr Route: ORAL Vehicle: FEED		Page: 45 Report Date: 11/07/2024			
			Male				Female		
*Adrenal Medulla: Pheochromocytoma Comp	lex	0/50 (0%)				0/50 (0%)			
Overall Incidence	Total	0/50 (0%)	Mean 0%	SD 0%	Total	0/50 (0%)	Mean 0%	SD 0%	
*Adrenal Medulla: Pheochromocytoma Maligi	nant	1/50 (2%)				0/50 (0%)			
Overall Incidence	Total	1/50 (2%)	Mean 2%	SD 0%	Total	0/50 (0%)	Mean 0%	SD 0%	
*Adrenal Medulla: Pheochromocytoma: Beniç Overall Incidence	jn, Complex , Total	, Malignant, NOS 5/50 (10%) 5/50 (10%)	Mean 10%	SD 0%	Total	1/50 (2%) 1/50 (2%)	Mean 2%	SD 0%	
#Bone: Hemangiosarcoma Overall Incidence	Total	0/50 (0%) 0/50 (0%)	Mean 0%	SD 0%	Total	0/50 (0%) 0/50 (0%)	Mean 0%	SD 0%	
#Bone: Osteosarcoma		0/50 (0%)				0/50 (0%)			
Overall Incidence	Total	0/50 (0%)	Mean 0%	SD 0%	Total	0/50 (0%)	Mean 0%	SD 0%	
#Bone: Osteosarcoma or Osteoma		0/50 (0%)				0/50 (0%)			
	Total	0/50 (0%)	Mean 0%	SD 0%		0/50 (0%)		SD 0%	

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC			Toxico Tumor Incide	Page: 46 Report Date: 11/07/2024				
			Male			Female		
*Brain: Astrocytoma Overall Incidence	Total	0/50 (0%) 0/50 (0%)	Mean 0%	SD 0%	Total	0/50 (0%) 0/50 (0%)	Mean 0%	SD 0%
*Brain: Glioma		0/50 (0%)				0/50 (0%)		
Overall Incidence	Total	0/50 (0%)	Mean 0%	SD 0%	Total	0/50 (0%)	Mean 0%	SD 0%
*Brain: Glioma Malignant Overall Incidence	Total	4/50 (8%) 4/50 (8%)	Mean 8%	SD 0%	Total	0/50 (0%) 0/50 (0%)	Mean 0%	SD 0%
*Brain: Granular Cell Tumor Benign		3/50 (6%)				2/50 (4%)		
Overall Incidence	Total	3/50 (6%)	Mean 6%	SD 0%	Total	2/50 (4%)	Mean 4%	SD 0%
*Brain: Granular Cell Tumor Maligna		0/50 (0%)				0/50 (0%)		
Overall Incidence	Total	0/50 (0%)	Mean 0%	SD 0%	Total	0/50 (0%)	Mean 0%	SD 0%
*Brain: Meningioma Benign		0/50 (0%)				0/50 (0%)		
Overall Incidence	Total	0/50 (0%)	Mean 0%	SD 0%	Total	0/50 (0%)	Mean 0%	SD 0%

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC				nce for Selected Contr Route: ORAL Vehicle: FEED		Page: 47 Report Date: 11/07/2024		
			Male		Female			
*Brain: Meningioma Malignant		0/50 (0%)						
Overall Incidence	Total	0/50 (0%)	Mean 0%	SD 0%	Total	0/50 (0%) 0/50 (0%)	Mean 0%	SD 0%
*Brain: Meningioma: Benign, Maligr		0/50 (0%)				0/50 (0%)		
Overall Incidence	Total	0/50 (0%)	Mean 0%	SD 0%	Total	0/50 (0%)	Mean 0%	SD 0%
*Brain: Oligodendroglioma Malignai Overall Incidence		0/50 (0%) 0/50 (0%)	Mean 0%	SD 0%	Total	0/50 (0%) 0/50 (0%)	Mean 0%	SD 0%
Brain: Oligodendroglioma, Glioma,						0/50 (0%)		
Overall Incidence	Total	4/50 (8%)	Mean 8%	SD 0%	Total	0/50 (0%)	Mean 0%	SD 0%
*Brain: Schwannoma Malignant		0/50 (0%)				0/50 (0%)		
Overall Incidence	Total	0/50 (0%)	Mean 0%	SD 0%	Total	0/50 (0%)	Mean 0%	SD 0%
*Clitoral/Preputial Gland: Adenocarcinoma		1/49 (2%)				0/49 (0%)		
Overall Incidence	Total	1/49 (2.04%)	Mean 2.04%	SD 0%	Total	0/49 (0%)	Mean 0%	SD 0%

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC			Toxico Tumor Incide	Page: 48 Report Date: 11/07/2024				
			Male	<u>.</u>	Female			
*Clitoral/Preputial Gland: Adenoma Overall Incidence	Total	0/49 (0%) 0/49 (0					Magn 09/	SD 0%
		0/49 (0%)	Mean 0%	SD 0%	Total	0/49 (0%)	Mean 0%	50 0%
*Clitoral/Preputial Gland: Adenoma or Adenocarcinon	na	1/49 (2%)				0/49 (0%)		
Overall Incidence	Total	1/49 (2.04%)	Mean 2.04%	SD 0%	Total	0/49 (0%)	Mean 0%	SD 0%
*Clitoral/Preputial Gland: Squamous Cell Carcinoma		0/49 (0%)				0/49 (0%)		
Overall Incidence	Total	0/49 (0%)	Mean 0%	SD 0%	Total	0/49 (0%)	Mean 0%	SD 0%
Clitoral/Preputial Gland: Squamous Cell Papilloma		0/49 (0%)				1/49 (2%)		
Overall Incidence	Total	0/49 (0%)	Mean 0%	SD 0%	Total	1/49 (2.04%)	Mean 2.04%	SD 0%
'Epididymis: Sarcoma		0/50 (0%)						
Overall Incidence	Total	0/50 (0%)	Mean 0%	SD 0%				
#Eye: Leiomyoma		0/50 (0%)				0/50 (0%)		
Overall Incidence	Total	0/50 (0%)	Mean 0%	SD 0%	Total	0/50 (0%)	Mean 0%	SD 0%

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC				Page: 49 Report Date: 11/07/2024					
			Male			Female			
#Harderian Gland: Schwannoma Malignant		0/50 (0%)				0/50 (0%)			
Overall Incidence	Total	0/50 (0%)	Mean 0%	SD 0%	Total	0/50 (0%)	Mean 0%	SD 0%	
*Heart: Schwannoma Malignant		3/50 (6%)				1/50 (2%)			
Overall Incidence	Total	3/50 (6%)	Mean 6%	SD 0%	Total	1/50 (2%)	Mean 2%	SD 0%	
#Intestine Large: Cecum: Leiomyosarcoma Overall Incidence	Total	0/50 (0%) 0/50 (0%)	Mean 0%	SD 0%	Total	0/50 (0%) 0/50 (0%)	Mean 0%	SD 0%	
#Intestine Large: Cecum: Liposarcoma		0/50 (0%)				0/50 (0%)			
Overall Incidence	Total	0/50 (0%)	Mean 0%	SD 0%	Total	0/50 (0%)	Mean 0%	SD 0%	
#Intestine Large: Colon/Rectur Granular Cell Tumor Benign	m:	0/50 (0%)				0/50 (0%)			
Overall Incidence	Total	0/50 (0%)	Mean 0%	SD 0%	Total	0/50 (0%)	Mean 0%	SD 0%	
#Intestine Large: Colon/Rectur Leiomyoma		0/50 (0%)				0/50 (0%)			
Overall Incidence	Total	0/50 (0%)	Mean 0%	SD 0%	Total	0/50 (0%)	Mean 0%	SD 0%	
*: Denominator is number of animals						. ,			

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC				Page: 50 Report Date: 11/07/2024					
			Male			Female			
#Intestine Small: Any Site: Adenocarcinoma Overall Incidence	Total	1/50 (2%) 1/50 (2%)) Mean 2%	SD 0%	Total	0/50 (0%) 0/50 (0%)	Mean 0%	SD 0%	
#Intestine Small: Any Site:		()				()			
Adenoma or Adenocarcinon	na					- / /			
Overall Incidence	Total	1/50 (2% 1/50 (2%)) Mean 2%	SD 0%	Total	0/50 (0%) 0/50 (0%)	Mean 0%	SD 0%	
#Intestine Small: Any Site: Leiomyosarcoma									
Overall Incidence	Total	0/50 (0% 0/50 (0%)) Mean 0%	SD 0%	Total	0/50 (0%) 0/50 (0%)	Mean 0%	SD 0%	
#Intestine Small: Any Site: Leiomyosarcoma or Leiomy		0/50 (0%				0/50 (0%)			
Overall Incidence	Total	0/50 (0%)	Mean 0%	SD 0%	Total	0/50 (0%)	Mean 0%	SD 0%	
#Intestine Small: Jejunum: Adenocarcinoma						0/50 (00/)			
Overall Incidence	Total	1/50 (2% 1/50 (2%)	Mean 2%	SD 0%	Total	0/50 (0%) 0/50 (0%)	Mean 0%	SD 0%	
#Intestine Small: Jejunum: Leiomyoma		0/50 (0%				0/50 (0%)			
Overall Incidence	Total	0/50 (0%)) Mean 0%	SD 0%	Total	0/50 (0%)	Mean 0%	SD 0%	

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC				Page: 51 Report Date: 11/07/2024				
			Male	Female				
#Intestine Small: Jejunum: Leiomyosarcoma		0/50 (0%)				0/50 (0%)		
Overall Incidence	Total	0/50 (0%)	Mean 0%	SD 0%	Total	0/50 (0%)	Mean 0%	SD 0%
*Islets, Pancreatic: Adenoma								
Overall Incidence	Total	3/49 (6%) 3/49 (6.12%)	Mean 6.12%	SD 0%	Total	1/50 (2%) 1/50 (2%)	Mean 2%	SD 0%
*Islets, Pancreatic: Carcinoma								
Overall Incidence	Total	0/49 (0%) 0/49 (0%)	Mean 0%	SD 0%	Total	0/50 (0%) 0/50 (0%)	Mean 0%	SD 0%
*Islets, Pancreatic: Carcinoma or Adenoma		3/49 (6%)				1/50 (2%)		
Overall Incidence	Total	3/49 (6.12%)	Mean 6.12%	SD 0%	Total	1/50 (2%)	Mean 2%	SD 0%
*Kidney: Pelvis and Urotheliur Papilloma								
Overall Incidence	Total	0/50 (0%) 0/50 (0%)	Mean 0%	SD 0%	Total	0/50 (0%) 0/50 (0%)	Mean 0%	SD 0%
*Kidney: Renal Tubule: Adenoma		0/50 (0%)				0/50 (0%)		
Overall Incidence	Total	0/50 (0%)	Mean 0%	SD 0%	Total	0/50 (0%)	Mean 0%	SD 0%

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC	Route: ORAL ey Vehicle: FEED							Page: 52 Report Date: 11/07/2024		
			Male	Female						
*Kidney: Renal Tubule: Carcinoma Overall Incidence	Total	0/50 (0%) 0/50 (0%)	Mean 0%	SD 0%	Total	0/50 (0%) 0/50 (0%)	Mean 0%	SD 0%		
*Kidney: Renal Tubule: Carcinoma or Adenoma		0/50 (0%)				0/50 (0%)				
Overall Incidence	Total	0/50 (0%)	Mean 0%	SD 0%	Total	0/50 (0%)	Mean 0%	SD 0%		
*Kidney: Renal Tubule: Hemangioma Overall Incidence	Total	0/50 (0%) 0/50 (0%)	Mean 0%	SD 0%	Total	0/50 (0%) 0/50 (0%)	Mean 0%	SD 0%		
'Kidney: Renal Tubule: Lipoma		0/50 (0%)				0/50 (0%)				
Overall Incidence	Total	0/50 (0%)	Mean 0%	SD 0%	Total	0/50 (0%)	Mean 0%	SD 0%		
*Kidney: Renal Tubule: Liposarcoma		0/50 (0%)				0/50 (0%)				
Overall Incidence	Total	0/50 (0%)	Mean 0%	SD 0%	Total	0/50 (0%)	Mean 0%	SD 0%		
*Kidney: Renal Tubule: Oncocytoma Benign		0/50 (0%)				0/50 (0%)				
Overall Incidence	Total	0/50 (0%)	Mean 0%	SD 0%	Total	0/50 (0%)	Mean 0%	SD 0%		

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC				Page: 53 Report Date: 11/07/2024				
			Male	Female				
*Kidney: Renal Tubule: Polyp Adenomatous Overall Incidence	Total	1/50 (2%) 1/50 (2%)	Mean 2%	SD 0%	Total	0/50 (0%) 0/50 (0%)	Mean 0%	SD 0%
#Lacrimal Gland: Carcinoma		0/50 (0%)				0/50 (0%)		
Overall Incidence	Total	0/50 (0%)	Mean 0%	SD 0%	Total	0/50 (0%)	Mean 0%	SD 0%
*Liver: Cholangioma Overall Incidence	Total	0/50 (0%) 0/50 (0%)	Mean 0%	SD 0%	Total	1/50 (2%) 1/50 (2%)	Mean 2%	SD 0%
'Liver: Hemangioma Overall Incidence	Total	1/50 (2%) 1/50 (2%)	Mean 2%	SD 0%	Total	0/50 (0%) 0/50 (0%)	Mean 0%	SD 0%
*Liver: Hepatocellular Adenoma		0/50 (0%)				0/50 (0%)		
Overall Incidence	Total	0/50 (0%)	Mean 0%	SD 0%	Total	0/50 (0%)	Mean 0%	SD 0%
*Liver: Hepatocellular Carcinoma		0/50 (0%)				0/50 (0%)		
Overall Incidence	Total	0/50 (0%)	Mean 0%	SD 0%	Total	0/50 (0%)	Mean 0%	SD 0%

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC			Toxico Tumor Incide		Page: 54 Report Date: 11/07/2024				
			Male			Female			
*Liver: Hepatocellular Carcinoma	a or Hepatobla	stoma 0/50 (0%)				0/50 (0%)			
Overall Incidence	Total	0/50 (0%)	Mean 0%	SD 0%	Total	0/50 (0%)	Mean 0%	SD 0%	
'Liver: Hepatocellular Carcinoma						0/50 (0%)			
Overall Incidence	Total	0/50 (0%)	Mean 0%	SD 0%	Total	0/50 (0%)	Mean 0%	SD 0%	
Liver: Hepatocellular Carcinoma Overall Incidence	a, Hepatocellul Total	0/50 (0%) 0/50 (0%)	lastoma Mean 0%	SD 0%	Total	0/50 (0%) 0/50 (0%)	Mean 0%	SD 0%	
[•] Liver: Hepatocellular Carcinoma Overall Incidence	a, Hepatocellul Total	ar Adenoma, or Hepatob 0/50 (0%) 0/50 (0%)	lastoma Mean 0%			0/50 (0%)	Mean 0%	SD 0%	
^t Liver: Hepatocellular Carcinoma Overall Incidence ^t Lung: Alveolar/Bronchiolar Ade	a, Hepatocellul Total	ar Adenoma, or Hepatob 0/50 (0%) 0/50 (0%)	lastoma Mean 0%				Mean 0% Mean 0%	SD 0% SD 0%	
*Liver: Hepatocellular Carcinoma Overall Incidence *Lung:	a, Hepatocellul Total moma Total	ar Adenoma, or Hepatob 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%)	lastoma Mean 0%	SD 0%	Total	0/50 (0%) 0/50 (0%) 0/50 (0%)			
[*] Liver: Hepatocellular Carcinoma Overall Incidence [*] Lung: Alveolar/Bronchiolar Ade Overall Incidence [*] Lung: Alveolar/Bronchiolar Carc	a, Hepatocellul Total enoma Total cinoma Total	ar Adenoma, or Hepatob 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%)	lastoma Mean 0% Mean 0% Mean 0%	SD 0% SD 0% SD 0%	Total Total Total	0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%)	Mean 0% Mean 0%	SD 0% SD 0%	
*Liver: Hepatocellular Carcinoma Overall Incidence *Lung: Alveolar/Bronchiolar Ade Overall Incidence	a, Hepatocellul Total enoma Total cinoma Total	ar Adenoma, or Hepatob 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%)	lastoma Mean 0% Mean 0% Mean 0%	SD 0% SD 0% SD 0%	Total Total Total	0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%)	Mean 0% Mean 0%	SD 0% SD 0%	

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC	ey Vehicle: FEED							Page: 55 Report Date: 11/07/2024		
			Male	Female						
#Lymph Node, Mesenteric: Hemangiosarcoma Overall Incidence	Total	0/50 (0%) 0/50 (0%)	Mean 0%	SD 0%	Total	0/50 (0%) 0/50 (0%)	Mean 0%	SD 0%		
		· ,		50 0%	TOLAI	0/30 (0 %)				
#Mammary Gland: Adenocarcinoma		0/50 (0%)				8/50 (16%)				
Overall Incidence	Total	0/50 (0%)	Mean 0%	SD 0%	Total	8/50 (16%)	Mean 16%	SD 0%		
#Mammary Gland: Adenolipoma Overall Incidence	Total	0/50 (0%) 0/50 (0%)	Mean 0%	SD 0%	Total	0/50 (0%) 0/50 (0%)	Mean 0%	SD 0%		
		· · ·				. ,				
#Mammary Gland: Adenoma		0/50 (0%)				0/50 (0%)				
Overall Incidence	Total	0/50 (0%)	Mean 0%	SD 0%	Total	0/50 (0%)	Mean 0%	SD 0%		
#Mammary Gland: Adenoma or Adenocarcinon	na	0/50 (0%)				8/50 (16%)				
Overall Incidence	Total	0/50 (0%)	Mean 0%	SD 0%	Total	8/50 (16%)	Mean 16%	SD 0%		
#Mammary Gland: Fibroadenoma		0/50 (0%)				25/50 (50%)				
Overall Incidence	Total	0/50 (0%)	Mean 0%	SD 0%	Total	25/50 (50%)	Mean 50%	SD 0%		

Version: Nov2024 Contract/Lab: All Laboratorie Species: RATS Strain: Harlan Sprague-Dawl Length of Study: CHRONIC	ey	Toxicology Data Management System Tumor Incidence for Selected Control Animal Groups Route: ORAL Vehicle: FEED						Page: 56 Report Date: 11/07/2024		
			Male				Female			
#Mammary Gland: Fibroma		0/50 (0%)			0/50 (0%)					
Overall Incidence	Total	0/50 (0%)	Mean 0%	SD 0%	Total	0/50 (0%)	Mean 0%	SD 0%		
#Mammary Gland: Fibroma, Fibroadenoma d	or Adenoma	0/50 (0%)				25/50 (50%)				
Overall Incidence	Total	0/50 (0%)	Mean 0%	SD 0%	Total	25/50 (50%)	Mean 50%	SD 0%		
#Mammary Gland: Fibroma, Fibroadenoma, Overall Incidence	Adenocarcinor Total	ma, or Adenoma 0/50 (0%) 0/50 (0%)	Mean 0%	SD 0%	Total	29/50 (58%) 29/50 (58%)	Mean 58%	SD 0%		
#Nerve Trigeminal: Schwannoma Malignant Overall Incidence	Total	0/50 (0%) 0/50 (0%)	Mean 0%	SD 0%	Total	0/50 (0%) 0/50 (0%)	Mean 0%	SD 0%		
		()				0.00 (0.%)				
#Oral Mucosa: Squamous Cell Carcinom	a	0/50 (00/)				0/50 (00/)				
Squamous Cell Carcinom Overall Incidence	Total	0/50 (0%) 0/50 (0%)	Mean 0%	SD 0%	Total	0/50 (0%) 0/50 (0%)	Mean 0%	SD 0%		
	Total	0/50 (0%)				0/50 (0%)		SD 0%		

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC			Toxico Tumor Incide		Page: 57 Report Date: 11/07/2024			
			Male				Female	
#Oral Mucosa, Tongue, Pharynx, Squamous Cell Carcinoma, Pap						0/50 (0%)		
	otal	0/50 (0%)	Mean 0%	SD 0%	Total	0/50 (0%)	Mean 0%	SD 0%
*Ovary: Adenocarcinoma, Cystadenoma		adenocarcinoma				0/50 (0%)		
Overall Incidence					Total	0/50 (0%)	Mean 0%	SD 0%
*Ovary: Adenoma								
Overall Incidence					Total	0/50 (0%) 0/50 (0%)	Mean 0%	SD 0%
'Ovary: Cystadenoma						0/50 (0%)		
Overall Incidence					Total	0/50 (0%) 0/50 (0%)	Mean 0%	SD 0%
*Ovary: Cystadenoma or Cystadenocar	cinoma							
Overall Incidence					Total	0/50 (0%) 0/50 (0%)	Mean 0%	SD 0%
*Ovary: Granulosa-Theca Tumor Benigi	ייייי ו							
Overall Incidence					Total	0/50 (0%) 0/50 (0%)	Mean 0%	SD 0%

/ersion: Nov2024 Contract/Lab: All Laboratories	Toxicology Data Management System Tumor Incidence for Selected Control Animal Gro	oups		Page: 58 Report Date: 11/07/2024		
Species: RATS	Route: ORAL					
Strain: Harlan Sprague-Dawley	Vehicle: FEED					
ength of Study: CHRONIC						
	Male		Female			
Ovary:						
Granulosa-Theca Tumor Malignant			0/50 (00/)			
Overall Incidence	Tota	_	0/50 (0%)	Maan Ol	CD 00/	
Jverali incidence	Tota	۱۱ 	0/50 (0%)	Mean 0%	SD 0%	
Ovary: Granulosa Cell Tumor Benign						
			1/50 (2%)			
Overall Incidence	Tota	al	1/50 (2%)	Mean 2%	SD 0%	
Ovary: Granulosa Cell Tumor Malignant						
^c			0/50 (0%)			
Overall Incidence	Tota	al	0/50 (0%)	Mean 0%	SD 0%	
Ovary: Granulosa Cell Tumor, Luteoma, Thecoma, or Sertoli C	all Tumor (Bonian Molianont NOS)					
Granulosa Cell Tumor, Euleonia, Thecoma, or Serion C	en Tumor (Benigh, Manghant, NOS)		2/50 (4%)			
Overall Incidence	Tota	al	2/50 (4%)	Mean 4%	SD 0%	
Ovary:						
Granulosa Cell Tumor: Benign, Malignant, NOS						
			1/50 (2%)			
Overall Incidence	Tota		1/50 (2%)	Mean 2%	SD 0%	
Ovary:						
Luteoma						
			1/50 (2%)			
Overall Incidence	Tota	al	1/50 (2%)	Mean 2%	SD 0%	

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley			Toxicology Data Management System Tumor Incidence for Selected Control Animal Groups Route: ORAL Vehicle: FEED					Page: 59 Report Date: 11/07/2024		
Length of Study: CHRONIC										
			Male			Female				
*Ovary: Schwannoma Malignant										
Overall Incidence					Total	0/50 (0%) 0/50 (0%)	Mean 0%	SD 0%		
*Ovary: Sertoli Cell Tumor Benign										
Overall Incidence					Total	0/50 (0%) 0/50 (0%)	Mean 0%	SD 0%		
*Ovary: Thecoma Benign										
Overall Incidence					Total	0/50 (0%) 0/50 (0%)	Mean 0%	SD 0%		
*Pancreas: Adenocarcinoma		0/49 (0%)				0/50 (0%)				
Overall Incidence	Total	0/49 (0%)	Mean 0%	SD 0%	Total	0/50 (0%)	Mean 0%	SD 0%		
*Pancreas: Adenoma										
Overall Incidence	Total	1/49 (2%) 1/49 (2.04%)	Mean 2.04%	SD 0%	Total	0/50 (0%) 0/50 (0%)	Mean 0%	SD 0%		
*Pancreas: Adenoma or Adenocarcino		1/49 (2%)				0/50 (0%)				
Overall Incidence	Total	1/49 (2.04%)	Mean 2.04%	SD 0%	Total	0/50 (0%)	Mean 0%	SD 0%		

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC			Page: 60 Report Date: 11/07/2024					
			Male				Female	
*Parathyroid Gland: Adenoma Overall Incidence	Total	0/43 (0%) 0/43 (0%)	Mean 0%	SD 0%	Total	0/42 (0%) 0/42 (0%)	Mean 0%	SD 0%
#Peripheral Nerve: Paraganglioma								
Overall Incidence	Total	0/50 (0%) 0/50 (0%)	Mean 0%	SD 0%	Total	0/50 (0%) 0/50 (0%)	Mean 0%	SD 0%
#Peripheral Nerve: Schwannoma Malignant Overall Incidence	Total	0/50 (0%) 0/50 (0%)	Mean 0%	SD 0%	Total	0/50 (0%) 0/50 (0%)	Mean 0%	SD 0%
#Pharynx: Squamous Cell Carcinoma		0/50 (0%)				0/50 (0%)		
Overall Incidence	Total	0/50 (0%)	Mean 0%	SD 0%	Total	0/50 (0%)	Mean 0%	SD 0%
*Pituitary Gland: Pars Distalis Adenoma	or Unspecif	fied Site: 3/50 (6%)				13/49 (27%)		
Overall Incidence	Total	3/50 (6%)	Mean 6%	SD 0%	Total	13/49 (26.53%)	Mean 26.53%	SD 0%
*Pituitary Gland: Pars Distalis Carcinoma		fied Site:						
Overall Incidence	Total	0/50 (0%) 0/50 (0%)	Mean 0%	SD 0%	Total	0/49 (0%) 0/49 (0%)	Mean 0%	SD 0%

/ersion: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC					ology Data Manageme ence for Selected Contro Route: ORAL Vehicle: FEED	-		Page: 61 Report Date	: 11/07/2024
				Male				Female	
*Pituitary Gland: Pars Distalis Carcinoma or Adenoma	or Unspecif		(6%)				13/49 (27%)		
Overall Incidence	Total	3/50 (6%)	. ,	Mean 6%	SD 0%	Total	13/49 (26.53%)	Mean 26.53%	SD 0%
*Pituitary Gland: Pars Distalis Schwannoma Malignant		fied Site:	(0%)				0/49 (0%)		
Overall Incidence	Total	0/50 (0%)	. ,	Mean 0%	SD 0%	Total	0/49 (0%)	Mean 0%	SD 0%
*Pituitary Gland: Pars Interme Adenoma									
Overall Incidence	Total	1/50 (1/50 (2%)	(2%)	Mean 2%	SD 0%	Total	0/49 (0%) 0/49 (0%)	Mean 0%	SD 0%
Pituitary Gland: Pars Interme Carcinoma or Adenoma			(20())						
Overall Incidence	Total	1/50 (2%)	(2%)	Mean 2%	SD 0%	Total	0/49 (0%) 0/49 (0%)	Mean 0%	SD 0%
Pituitary Gland: Pars Nervos Schwannoma Malignant									
Overall Incidence	Total	0/50 (0%)	(0%)	Mean 0%	SD 0%	Total	0/49 (0%) 0/49 (0%)	Mean 0%	SD 0%
Prostate: Adenoma									
Overall Incidence	Total	1/50 (1/50 (2%)	(2%)	Mean 2%	SD 0%				

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC				ology Data Manageme ence for Selected Contr Route: ORAL Vehicle: FEED	-		Page: 62 Report Dat	e: 11/07/2024
			Male			·	Female	
*Prostate: Adenoma or Adenocarcinon	na	1/50 (2%)						
Overall Incidence	Total	1/50 (2%)	Mean 2%	SD 0%				
*Salivary Glands: Schwannoma Malignant		0/50 (0%)				0/49 (0%)		
Overall Incidence	Total	0/50 (0%)	Mean 0%	SD 0%	Total	0/49 (0%)	Mean 0%	SD 0%
#Seminal Vesicle: Hemangiosarcoma Overall Incidence	Total	0/50 (0%) 0/50 (0%)	Mean 0%	SD 0%				
		0/00 (0/0)						
#Skeletal Muscle: Fibrosarcoma		0/50 (0%)				0/50 (0%)		
Overall Incidence	Total	0/50 (0%)	Mean 0%	SD 0%	Total	0/50 (0%)	Mean 0%	SD 0%
#Skeletal Muscle: Hemangioma		0/50 (0%)				0/50 (0%)		
Overall Incidence	Total	0/50 (0%)	Mean 0%	SD 0%	Total	0/50 (0%)	Mean 0%	SD 0%
#Skeletal Muscle: Hemangiosarcoma								
Overall Incidence	Total	0/50 (0%) 0/50 (0%)	Mean 0%	SD 0%	Total	0/50 (0%) 0/50 (0%)	Mean 0%	SD 0%

/ersion: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC	1			ology Data Manageme ence for Selected Contr Route: ORAL Vehicle: FEED	-		Page: 63 Report Date: 11/07/2024				
			Male				Female	Report Date: 11/07/2024			
fSkeletal Muscle: Liposarcoma		0/50 (0%)				0/50 (0%)					
Overall Incidence	Total	0/50 (0%)	Mean 0%	SD 0%	Total	0/50 (0%)					
Skeletal Muscle: Sarcoma		0/50 (0%)				0/50 (0%)					
Overall Incidence	Total	0/50 (0%)	Mean 0%	SD 0%	Total	0/50 (0%)					
Skin: Basal Cell Adenoma											
Overall Incidence	Total	0/50 (0%) 0/50 (0%)	Mean 0%	SD 0%	Total	0/50 (0%) 0/50 (0%)	Mean 0%	SD 0%			
Skin: Basal Cell Carcinoma		0/50 (0%)				0/50 (0%)					
overall Incidence	Total	0/50 (0%)	Mean 0%	SD 0%	Total	0/50 (0%)	Mean 0%	SD 0%			
/Skin: Basal or Squamous Cell Ca Adenoma, Papilloma, Sq Pa Carcinoma, Sebaceous Gla	apilloma, Ker nd Adenoma	a, or Sebaceous Gland A 1/50 (2%)	pithelioma, Adenoma Adenocarcinoma	а,		0/50 (0%)					
Overall Incidence	Total	1/50 (2%)	Mean 2%	SD 0%	Total	0/50 (0%)					
Skin: Basal or Squamous Cell Ca Adenocarcinoma	ircinoma, Ba	sosquamous Tumor (M 0/50 (0%)	alignant), or Sebaced	ous Gland		0/50 (0%)					
		0/50 (0%)	Mean 0%	SD 0%	Total	0/50 (0%)					

Version: Nov2024				ology Data Manageme	-		Page: 64 Report Date: 11/07/2024 Female Mean 0% SD 0%		
Contract/Lab: All Laboratories			l umor Incide	ence for Selected Contr	ol Animal Groups		Female) Mean 0% SD 0%		
pecies: RATS				Route: ORAL					
train: Harlan Sprague-Dawley				Vehicle: FEED					
.ength of Study: CHRONIC									
			Male				Female		
Skin:									
Basosquamous Tumor (Ben Keratoacanthoma, Trichoep	ign), Basal (ithelioma, o	Cell Adenoma, Adenoma r Sebaceous Gland Aden	, Papilloma, Sq Pap Ioma	illoma,					
		1/50 (2%)				0/50 (0%)			
Overall Incidence	Total	1/50 (2%)	Mean 2%	SD 0%	Total	0/50 (0%)			
Skin:									
Fibroma		3/50 (6%)				0/50 (0%)			
Verall Incidence	Total	3/50 (6%)	Mean 6%	SD 0%	Total	0/50 (0%)	Mean 0%	SD 0%	
Skin:									
Fibroma or Myxoma		0/50 (00()				0/50 (00/)			
	Tatal	3/50 (6%)	Maga, 60/		Tetal	0/50 (0%)	Maar 00/		
Overall Incidence	Total	3/50 (6%)	Mean 6%	SD 0%	Total	0/50 (0%)	Mean 0%	SD 0%	
Skin: Fibroma, Fibrosarcoma, Sar	oomo Muxa	ma Muyacaraama ar Bl	comorphia Fibraca						
Fibrofila, Fibrosarcofila, Sar		3/50 (6%)	eomorphic Fibrosa	Coma		1/50 (2%)			
Overall Incidence	Total	3/50 (6%)	Mean 6%	SD 0%	Total	1/50 (2%)	Mean 2%	SD 0%	
Skin:									
Fibroma, Fibrosarcoma, Sar	coma, Myxo	oma, Myxosarcoma, Pleo	morphic Fibrosarco	ma, or					
Hemangiopericytoma		3/50 (6%)				1/50 (2%)			
Overall Incidence	Total	3/50 (6%)	Mean 6%	SD 0%	Total	1/50 (2%)	Mean 2%	SD 0%	
		. ,				. ,			
Skin: Fibrosarcoma									
		0/50 (0%)				0/50 (0%)			
Overall Incidence	Total	0/50 (0%)	Mean 0%	SD 0%	Total	0/50 (0%)	Mean 0%	SD 0%	

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC				ology Data Manageme ence for Selected Contr Route: ORAL Vehicle: FEED	-		Page: 65 Report Date: 11/07/2024 Female Mean 2% SD 0% Mean 0% SD 0%			
			Male				Female			
#Skin: Fibrosarcoma, Sarcoma, My Overall Incidence	xosarcoma , Total	or Pleomorphic Fibrosa 0/50 (0%) 0/50 (0%)	rcoma Mean 0%	SD 0%	Total	1/50 (2%) 1/50 (2%)	Mean 2%	SD 0%		
		0,00 (0,0)				1/00 (270)				
#Skin: Hemangioma		0/50 (0%)				0/50 (0%)				
Overall Incidence	Total	0/50 (0%)	Mean 0%	SD 0%	Total	0/50 (0%)	Mean 0%	SD 0%		
#Skin: Hemangiopericytoma Overall Incidence	Total	0/50 (0%) 0/50 (0%)	Mean 0%	SD 0%	Total	0/50 (0%) 0/50 (0%)	Mean 0%	SD 0%		
#Skin: Keratoacanthoma		1/50 (2%)				0/50 (0%)				
Overall Incidence	Total	1/50 (2%)	Mean 2%	SD 0%	Total	0/50 (0%)	Mean 0%	SD 0%		
#Skin: Lipoma		3/50 (6%)				0/50 (0%)				
Overall Incidence	Total	3/50 (6%)	Mean 6%	SD 0%	Total	0/50 (0%)	Mean 0%	SD 0%		
#Skin: Liposarcoma		0/50 (0%)				0/50 (0%)				
Overall Incidence	Total	0/50 (0%)	Mean 0%	SD 0%	Total	0/50 (0%)	Mean 0%	SD 0%		

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC				ology Data Manageme ence for Selected Contr Route: ORAL Vehicle: FEED			e: 11/07/2024	
			Male				Female	
#Skin: Neurofibrosarcoma or Schw	•	0/50 (0%)				0/50 (0%)		
Overall Incidence	Total	0/50 (0%)	Mean 0%	SD 0%	Total	0/50 (0%)	Mean 0%	SD 0%
#Skin: Neurofibrosarcoma, Neurofi						0/50 (0%)		
Overall Incidence	Total	0/50 (0%)	Mean 0%	SD 0%	Total	0/50 (0%)	Mean 0%	SD 0%
#Skin: Osteosarcoma Overall Incidence	Total	0/50 (0%) 0/50 (0%)	Mean 0%	SD 0%	Total	0/50 (0%) 0/50 (0%)	Mean 0%	SD 0%
#Skin: Papilloma		0/50 (0%)				0/50 (0%)		
Overall Incidence	Total	0/50 (0%)	Mean 0%	SD 0%	Total	0/50 (0%)	Mean 0%	SD 0%
#Skin: Pilomatrixoma		0/50 (0%)				0/50 (0%)		
Overall Incidence	Total	0/50 (0%)	Mean 0%	SD 0%	Total	0/50 (0%)	Mean 0%	SD 0%
#Skin: Pleomorphic Fibrosarcoma		0/50 (0%)				0/50 (0%)		
Overall Incidence	Total	0/50 (0%)	Mean 0%	SD 0%	Total	0/50 (0%)	Mean 0%	SD 0%

Version: Nov2024 Contract/Lab: All Laboratorie Species: RATS Strain: Harlan Sprague-Dawle Length of Study: CHRONIC				ology Data Manageme ence for Selected Contr Route: ORAL Vehicle: FEED	-		Page: 67 Report Dat	e: 11/07/2024
			Male				Female	
#Skin: Sarcoma		0/50 (0%)				1/50 (2%)		
Overall Incidence	Total	0/50 (0%)	Mean 0%	SD 0%	Total	1/50 (2%)	Mean 2%	SD 0%
#Skin: Schwannoma Malignant		0/50 (0%)				0/50 (0%)		
Overall Incidence	Total	0/50 (0%)	Mean 0%	SD 0%	Total	0/50 (0%)	Mean 0%	SD 0%
#Skin: Squamous Cell Carcinom Overall Incidence	a Total	0/50 (0%) 0/50 (0%)	Mean 0%	SD 0%	Total	0/50 (0%) 0/50 (0%)	Mean 0%	SD 0%
#Skin: Squamous Cell Carcinom or Carcinoma						0/50 (0%)		
Overall Incidence	Total	0/50 (0%)	Mean 0%	SD 0%	Total	0/50 (0%)	Mean 0%	SD 0%
≭Skin: Squamous Cell Papilloma		0/50 (0%)				0/50 (0%)		
Overall Incidence	Total	0/50 (0%)	Mean 0%	SD 0%	Total	0/50 (0%)	Mean 0%	SD 0%
#Skin: Squamous Cell Papilloma		0/50 (0%)				0/50 (0%)		
Overall Incidence	Total	0/50 (0%)	Mean 0%	SD 0%	Total	0/50 (0%)	Mean 0%	SD 0%

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC				ology Data Manageme ence for Selected Contr Route: ORAL Vehicle: FEED	-		Page: 68 Report Date: 11/07/2024				
		· · · · · · · · · · · · · · · · · · ·	Male				Female				
#Skin: Squamous Cell Papilloma, F	-	1/50 (2%)	Maar OV		Tetel	0/50 (0%)	Maga 00/				
Overall Incidence	Total	1/50 (2%)	Mean 2%	SD 0%	Total	0/50 (0%)	Mean 0%	SD 0%			
#Skin: Squamous Cell Papilloma, F	Papilloma, S	quamous Cell Carcinoma 1/50 (2%)	a or Keratoacanthor	na		0/50 (0%)					
Overall Incidence	Total	1/50 (2%)	Mean 2%	SD 0%	Total	0/50 (0%)	Mean 0%	SD 0%			
#Skin: Trichoepithelioma Overall Incidence	Total	0/50 (0%) 0/50 (0%)	Mean 0%	SD 0%	Total	0/50 (0%) 0/50 (0%)	Mean 0%	SD 0%			
#Skin: Sebaceous Gland: Adenoma		0/50 (0%)				0/50 (0%)					
Overall Incidence	Total	0/50 (0%)	Mean 0%	SD 0%	Total	0/50 (0%)	Mean 0%	SD 0%			
*Spleen: Hemangiosarcoma		0/50 (0%)				0/50 (0%)					
Overall Incidence	Total	0/50 (0%)	Mean 0%	SD 0%	Total	0/50 (0%)	Mean 0%	SD 0%			
#Stomach, Forestomach: Papilloma		0/50 (0%)				0/50 (0%)					
Overall Incidence	Total	0/50 (0%)	Mean 0%	SD 0%	Total	0/50 (0%)	Mean 0%	SD 0%			

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC				blogy Data Manageme ence for Selected Contr Route: ORAL Vehicle: FEED	-		Page: 69 Report Date: 11/07/2024				
			Male				Female	· · · · ·			
#Stomach, Forestomach: Sarcoma		0/50 (0%)				0/50 (0%)		05 av			
Overall Incidence	Total	0/50 (0%)	Mean 0%	SD 0%	Total	0/50 (0%)	Mean 0%	SD 0%			
#Stomach, Forestomach: Squamous Cell Carcinoma c	or Papilloma	a Squamous 0/50 (0%)				0/50 (0%)					
Overall Incidence	Total	0/50 (0%)	Mean 0%	SD 0%	Total	0/50 (0%)	Mean 0%	SD 0%			
#Stomach, Forestomach: Squamous Cell Papilloma Overall Incidence	Total	0/50 (0%) 0/50 (0%)	Mean 0%	SD 0%	Total	0/50 (0%) 0/50 (0%)	Mean 0%	SD 0%			
		()				()					
#Stomach, Glandular: Sarcoma		0/50 (0%)				0/50 (0%)					
Overall Incidence	Total	0/50 (0%)	Mean 0%	SD 0%	Total	0/50 (0%)	Mean 0%	SD 0%			
*Testis: Adenoma		7/50 (14%)									
Overall Incidence	Total	7/50 (14%)	Mean 14%	SD 0%							
*Thymus: Schwannoma Malignant		0/48 (0%)				0/49 (0%)					
Overall Incidence	Total	0/48 (0%)	Mean 0%	SD 0%	Total	0/49 (0%)	Mean 0%	SD 0%			

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC				nce for Selected Contr Route: ORAL Vehicle: FEED	-		Page: 70 Report Date: 11/07/2024				
			Male				Female				
*Thymus: Thymoma Benign Overall Incidence	Total	0/48 (0%) 0/48 (0%)	Mean 0%	SD 0%	Total	0/49 (0%) 0/49 (0%)	Mean 0%	SD 0%			
*Thymus: Thymoma Malignant		0/48 (0%)				0/49 (0%)					
Overall Incidence	Total	0/48 (0%)	Mean 0%	SD 0%	Total	0/49 (0%)	Mean 0%	SD 0%			
*Thymus: Thymoma: Benign, Malignar Overall Incidence	n t, NOS Total	0/48 (0%) 0/48 (0%)	Mean 0%	SD 0%	Total	0/49 (0%) 0/49 (0%)	Mean 0%	SD 0%			
Thyroid Gland: C-Cell: Adenoma	Total	13/50 (26%) 13/50 (26%)	Mean 26%	SD 0%	Total	12/50 (24%) 12/50 (24%)	Mean 24%	SD 0%			
Overall Incidence		(/		SD 0%		12/50 (24%)	Mean 24%	50 0%			
*Thyroid Gland: C-Cell: Carcinoma		2/50 (4%)				2/50 (4%)					
Overall Incidence	Total	2/50 (4%)	Mean 4%	SD 0%	Total	2/50 (4%)	Mean 4%	SD 0%			
*Thyroid Gland: C-Cell: Carcinoma or Adenoma		14/50 (28%)				14/50 (28%)					
Overall Incidence	Total	14/50 (28%)	Mean 28%	SD 0%	Total	14/50 (28%)	Mean 28%	SD 0%			

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC				ology Data Manageme ence for Selected Contr Route: ORAL Vehicle: FEED	-		Page: 71 Report Date: 11/07/202				
			Male				Female				
*Thyroid Gland: Follicular Cell Adenoma	:										
Overall Incidence	Total	0/50 (0%) 0/50 (0%)	Mean 0%	SD 0%	Total	0/50 (0%) 0/50 (0%)	Mean 0%	SD 0%			
*Thyroid Gland: Follicular Cell Carcinoma											
Overall Incidence	Total	0/50 (0%) 0/50 (0%)	Mean 0%	SD 0%	Total	0/50 (0%) 0/50 (0%)	Mean 0%	SD 0%			
*Thyroid Gland: Follicular Cell Carcinoma or Adenoma											
Overall Incidence	Total	0/50 (0%) 0/50 (0%)	Mean 0%	SD 0%	Total	0/50 (0%) 0/50 (0%)	Mean 0%	SD 0%			
#Tissue NOS: Schwannoma Malignant		0/50 (0%)				0/50 (0%)					
Overall Incidence	Total	0/50 (0%)	Mean 0%	SD 0%	Total	0/50 (0%)	Mean 0%	SD 0%			
#Tongue: Fibrosarcoma		0/50 (0%)				0/50 (0%)					
Overall Incidence	Total	0/50 (0%)	Mean 0%	SD 0%	Total	0/50 (0%)	Mean 0%	SD 0%			
#Tongue: Papilloma		0/50 (0%)				0/50 (0%)					
Overall Incidence	Total	0/50 (0%)	Mean 0%	SD 0%	Total	0/50 (0%)	Mean 0%	SD 0%			

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC				ence for Selected Contr Route: ORAL Vehicle: FEED	-		Page: 72 Report Date: 11/07/2024				
			Male				Female Mean 0% SD 0% Mean 0% SD 0%				
#Tongue: Squamous Cell Carcinoma		0/50 (0%)				0/50 (0%)					
Overall Incidence	Total	0/50 (0%)	Mean 0%	SD 0%	Total	0/50 (0%)	Mean 0%	SD 0%			
#Tongue: Squamous Cell Carcinoma c						0/50 (0%)					
Overall Incidence	Total	0/50 (0%)	Mean 0%	SD 0%	Total	0/50 (0%)	Mean 0%	SD 0%			
#Tooth: Odontoma		0/50 (0%)				0/50 (0%)					
Overall Incidence	Total	0/50 (0%)	Mean 0%	SD 0%	Total	0/50 (0%)	Mean 0%	SD 0%			
*Urinary Bladder: Leiomyosarcoma		0/50 (0%)				0/50 (0%)					
Overall Incidence	Total	0/50 (0%)	Mean 0%	SD 0%	Total	0/50 (0%)	Mean 0%	SD 0%			
*Uterus: Adenocarcinoma						0/50 (40/)					
Overall Incidence					Total	2/50 (4%) 2/50 (4%)					
*Uterus: Adenocarcinoma or Adenon											
Overall Incidence					Total	2/50 (4%) 2/50 (4%)	Mean 4%	SD 0%			
*: Denominator is number of animals	with tissues e	xamined microscopically									

Jterus: Adenoma Iverall Incidence Jterus:	Male	Total	0/50 (0%) 0/50 (0%)	Female Mean 0%	SD 0%
Adenoma Iverall Incidence	oma	Total	()		SD 0%
verall Incidence	oma	Total	()		SD 0%
	oma	Total	()		SD 0%
Iterus	oma				
Iterus:	oma				
	oma				
Adenoma, Adenocarcinoma, Sq Cell Carcinoma, or Sq Cell Papillor			2/50 (4%)		
verall Incidence		Total	2/50 (4%)	Mean 4%	SD 0%
Jterus:					
Deciduoma Benign			0/50 (0%)		
verall Incidence		Total	0/50 (0%)	Mean 0%	SD 0%
Jterus:					
Granular Cell Tumor Benign					
-			0/50 (0%)		
verall Incidence		Total	0/50 (0%)	Mean 0%	SD 0%
Jterus:					
Hemangioma					
			0/50 (0%)		
verall Incidence		Total	0/50 (0%)	Mean 0%	SD 0%
Jterus:					
Polyp Stromal					
			5/50 (10%)		05
verall Incidence		Total	5/50 (10%)	Mean 10%	SD 0%

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS		Toxicology Data Management System Tumor Incidence for Selected Control Animal Groups Route: ORAL					
Strain: Harlan Sprague-Dawley	Vehicle: FEED						
Length of Study: CHRONIC							
	Male			Female			
*Uterus:							
Sarcoma			4/50 (00/)				
Overall Incidence	т	otal	1/50 (2%) 1/50 (2%)	Mean 2%	SD 0%		
	،		()				
*Uterus:							
Sarcoma Stromal			0/50 (00/)				
Overall Incidence	т	otal	0/50 (0%) 0/50 (0%)	Mean 0%	SD 0%		
'Uterus:							
Sarcoma Stromal or Polyp Stromal			5/50 (10%)				
Overall Incidence	т	otal	5/50 (10%)	Mean 10%	SD 0%		
*Uterus: Schwannoma Malignant							
			0/50 (0%)				
Overall Incidence		otal	0/50 (0%)	Mean 0%	SD 0%		
'Uterus:							
Sq Cell Carcinoma or Papilloma Squamous							
			0/50 (0%)				
Overall Incidence		otal	0/50 (0%)	Mean 0%	SD 0%		
'Uterus:							
Squamous Cell Carcinoma							
			0/50 (0%)				
Overall Incidence	Т	otal	0/50 (0%)	Mean 0%	SD 0%		

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC	,			ology Data Manageme ence for Selected Contr Route: ORAL Vehicle: FEED		Page: 75 Report Date: 11/07/2024		
			Male				Female	
*Uterus:								
Squamous Cell Papilloma						0/50 (0%)		
Overall Incidence					Total	0/50 (0%)	Mean 0%	SD 0%
#Vagina:								
Granular Cell Tumor Benig	n							
• ••• ••						0/50 (0%)		05.00/
Overall Incidence					Total	0/50 (0%)	Mean 0%	SD 0%
#Vagina:								
Polyp								
• ••• ••					T ()	0/50 (0%)	M 00/	00.004
Overall Incidence					Total	0/50 (0%)	Mean 0%	SD 0%
#Vagina:								
Sarcoma								
• ••• ••						0/50 (0%)		05.00/
Overall Incidence					Total	0/50 (0%)	Mean 0%	SD 0%
#Vagina:								
Schwannoma Malignant								
						0/50 (0%)		
Overall Incidence					Total	0/50 (0%)	Mean 0%	SD 0%
#Zymbal's Gland: Adenoma								
		0/50 (0%)				0/50 (0%)		
Overall Incidence	Total	0/50 (0%)	Mean 0%	SD 0%	Total	0/50 (0%)	Mean 0%	SD 0%

Version: Nov2024 Contract/Lab: All Laborator Species: RATS Strain: Harlan Sprague-Daw Length of Study: CHRONIC	wley			ology Data Manageme ence for Selected Contr Route: ORAL Vehicle: FEED		Page: 76 Report Dat	:e: 11/07/2024		
			Male				Female		
#Zymbal's Gland: Adenoma, Adenocarcino	oma, Sq Cell Ca	rcinoma, or Sq Cell Pa _l 0/50 (0%)	pilloma			0/50 (0%)			
#Zymbal's Gland: Adenoma, Adenocarcino Overall Incidence	oma, Sq Cell Ca Total	· • •	pilloma Mean 0%	SD 0%	Total	0/50 (0%) 0/50 (0%)	Mean 0%	SD 0%	
Adenoma, Adenocarcino		0/50 (0%) 0/50 (0%)		SD 0%	Total	0/50 (0%)	Mean 0%	SD 0%	
Adenoma, Adenocarcino Overall Incidence #Zymbal's Gland:		0/50 (0%)		SD 0%	Total	()	Mean 0%	SD 0%	

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC

Toxicology Data Management System Tumor Incidence for Selected Control Animal Groups Route: PERINATAL AND POSTNATAL Vehicle: FEED

				Stu	dy Summary		
Laboratory Name	Study Number	Study Start Date	Length of Study in Days	Number of Animals Total and (#/Cage)	Number Surviving and (Mean Life Span)	Maximum Mean Weekly Body Weight	Chemical
					Male		
Battelle Columbus Laboratory	051018802	06/27/11	729	50(2)	25(648)	593.4	Di(2-ethylhexyl) Phthalate
Battelle Columbus Laboratory	052071203	12/12/11	729	50(2)	25(652)	589.0	Tris(Chloropropyl)phosphate
					Female		
Battelle Columbus Laboratory	051018802	06/28/11	732	50(4)	31(684)	376.1	Di(2-ethylhexyl) Phthalate
Battelle Columbus Laboratory	052071203	12/13/11	731	50(4)	22(629)	380.1	Tris(Chloropropyl)phosphate

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC			Toxicol Tumor Incider Route:	Page: 78 Report Da	te: 11/07/2024					
			Male			Female				
#All Organs: Benign Tumors		28/50 (56%)	25/50 (50%)			41/50 (82%)	41/50 (82%)			
Overall Incidence	Total	53/100 (53%)	Mean 53%	SD 4.24%	Total	82/100 (82%)	Mean 82%	SD 0%		
#All Organs: Malignant Tumors										
Overall Incidence	Total	15/50 (30%)	9/50 (18%)		Total	14/50 (28%)	10/50 (20%)			
	Total	24/100 (24%)	Mean 24%	SD 8.49%	Total	24/100 (24%)	Mean 24%	SD 5.66%		
#All Organs: Malignant and Benign Tum	iors		00/50 (00%()			44/50 (000/)	40/50 (000/)			
Overall Incidence	Total	36/50 (72%) 66/100 (66%)	30/50 (60%) Mean 66%	SD 8.49%	Total	44/50 (88%) 90/100 (90%)	46/50 (92%) Mean 90%	SD 2.83%		
#All Organs: Hemangioma										
Overall Incidence	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	Total	1/50 (2%) 2/100 (2%)	1/50 (2%) Mean 2%	SD 0%		
#All Organs:										
Hemangiosarcoma		0/50 (0%)	0/50 (0%)			1/50 (2%)	0/50 (0%)			
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	1/100 (1%)	Mean 1%	SD 1.41%		
#All Organs: Hemangiosarcoma or Hem										
Overall Incidence	Tatal	0/50 (0%)	0/50 (0%)		Tatal	2/50 (4%)	1/50 (2%)			
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	3/100 (3%)	Mean 3%	SD 1.41%		

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawle Length of Study: CHRONIC			Toxico Tumor Incider Route:	Page: 79 Report Date: 11/07/2024				
			Male		Female			
#All Organs: Histiocytic Sarcoma								
Overall Incidence	Total	0/50 (0%) 1/100 (1%)	1/50 (2%) Mean 1%	SD 1.41%	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%
All Organs: Leukemia: Granulocytic								
Overall Incidence	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%
All Organs: Leukemia: Lymphocytic, N		ononuclear, or Undifferen 0/50 (0%)				1/50 (2%)	2/50 (4%)	
Overall Incidence	Total	1/100 (1%)	Mean 1%	SD 1.41%	Total	3/100 (3%)	Mean 3%	SD 1.41%
All Organs: Malignant Lymphoma: His Undifferentiated Cell Type	tiocytic, Lym		-					
overall Incidence	Total	0/50 (0%) 2/100 (2%)	2/50 (4%) Mean 2%	SD 2.83%	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%
All Organs: Malignant Schwannoma								
overall Incidence	Total	6/50 (12%) 6/100 (6%)	0/50 (0%) Mean 6%	SD 8.49%	Total	3/50 (6%) 3/100 (3%)	0/50 (0%) Mean 3%	SD 4.24%
All Organs: Mesothelioma: Benign, Ma		i						
		1/50 (2%)	1/50 (2%)			0/50 (0%)	0/50 (0%)	

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC			Toxicol Tumor Incider Route:		Page: 80 Report Date: 11/07/2024			
			Male				Female	
#All Organs: Mesothelioma: Malignant		1/50 (2%)	1/50 (2%)			0/50 (0%)	0/50 (0%)	
Overall Incidence	Total	2/100 (2%)	Mean 2%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%
*Adrenal Cortex: Adenoma								
Overall Incidence	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%
		· · ·				()		
*Adrenal Cortex: Carcinoma								
		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/50 (0%)	
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%
*Adrenal Cortex: Carcinoma or Adenoma								
Overall Incidence	Total	0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%
*Adrenal Medulla: Ganglioneuroma								
• ••• ••		0/50 (0%)	0/50 (0%)	65		1/50 (2%)	0/50 (0%)	05 <i>i i i i i i</i>
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	1/100 (1%)	Mean 1%	SD 1.41%
*Adrenal Medulla: Pheochromocytoma Benign		5/50 (10%)	6/50 (12%)			0/50 (0%)	0/50 (0%)	
Overall Incidence	Total	5/50 (10%) 11/100 (11%)	Mean 11%	SD 1.41%	Total	0/50 (0%)	0/50 (0%) Mean 0%	SD 0%

ies vley C		Tumor Incider		Page: 81 Report Date: 11/07/2024			
		Male			Female		
mplex		0/50 (00/)			0/50 (00/)	0/50 (00/)	
Total	1/100 (1%)	Mean 1%	SD 1.41%	Total	0/100 (0%)	Mean 0%	SD 0%
lignant							
Total	0/50 (0%)	0/50 (0%)	SD 0%	Total	0/50 (0%)	0/50 (0%)	SD 0%
					()		
nign, Complex,		6/50 (129/)			0/50 (0%/)	0/50 (09/)	
Total	12/100 (12%)	Mean 12%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%
Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%
	0/50 (0%)	0/50 (0%)			0/50 (0%)	0/50 (0%)	
Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%
ma	0/50 (0%/)				0/50 (00/)	0/50 (00/)	
Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%
	nplex Total ignant Total nign, Complex, Total Total	nplex 1/50 (2%) Total 1/100 (1%) ignant 0/50 (0%) Total 0/100 (0%) nign, Complex, Malignant, NOS 6/50 (12%) Total 12/100 (12%) Total 12/100 (12%) 0/50 (0%) Total 0/100 (0%) Total 0/100 (0%) Na 0/50 (0%)	es Tumor Incider Route: //ey ////////////////////////////////	es Tumor Incidence for Selected Contro Route: PERINATAL AND PO Vehicle: FEED Male nplex 1/50 (2%) 0/50 (0%) Total 1/100 (1%) Mean 1% SD 1.41% ignant 0/50 (0%) 0/50 (0%) Total 0/100 (0%) Mean 0% SD 0% nign, Complex, Malignant, NOS 6/50 (12%) 6/50 (12%) Total 12/100 (12%) Mean 12% SD 0% 0/50 (0%) 0/50 (0%) Total 0/100 (0%) Mean 0% SD 0% 0/50 (0%) 0/50 (0%) Total 0/100 (0%) Mean 0% SD 0% 0/50 (0%) 0/50 (0%) Total 0/100 (0%) Mean 0% SD 0%	Route: PERINATAL AND POSTNATAL Vehicle: FEED nplex 1/50 (2%) 0/50 (0%) Total 1/100 (1%) Mean 1% SD 1.41% Total ignant 0/50 (0%) 0/50 (0%) Total 0/100 (0%) Mean 0% SD 0% Total nign, Complex, Malignant, NOS 6/50 (12%) 6/50 (12%) Total 12/100 (12%) Mean 12% SD 0% Total 0/50 (0%) 0/50 (0%) Total 0/100 (0%) Mean 0% SD 0% Total 0/50 (0%) 0/50 (0%) Total 0/100 (0%) Mean 0% SD 0% Total 0/50 (0%) 0/50 (0%) Total 0/100 (0%) Mean 0% SD 0% Total	es Tumor Incidence for Selected Control Animal Groups Route: PERINATAL AND POSTNATAL Vehicle: FEED Male nplex 1/50 (2%) 0/50 (0%) 0/50 (0%) Total 1/100 (1%) Mean 1% SD 1.41% Total 0/100 (0%) ignant 0/50 (0%) 0/50 (0%) SD 0% Total 0/100 (0%) nign, Complex, Malignant, NOS 6/50 (12%) 6/50 (12%) 0/50 0% Total 0/100 (0%) 10/100 (12%) Mean 12% SD 0% Total 0/100 (0%) 10/100 (0%) 0/50 (0%) Mean 0% SD 0% Total 0/100 (0%) 10/100 (0%) Mean 0% SD 0% Total 0/100 (0%)	es Tumor Incidence for Selected Control Animal Groups Route: PERINATAL AND POSTNATAL Nety: Vehicle: FEED Male Female nplex 1/50 0/50 </td

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC			Toxico Tumor Incider Route:		Page: 82 Report Date: 11/07/2024			
			Male				Female	
*Brain: Astrocytoma Overall Incidence	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%
*Brain: Glioma Overall Incidence	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%
*Brain: Glioma Malignant Overall Incidence	Total	0/50 (0%) 0/100 (0%)		SD 0%		0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%
*Brain: Granular Cell Tumor Benign Overall Incidence	Total	0/50 (0%) 1/100 (1%)	1/50 (2%) Mean 1%	SD 1.41%	Total	1/50 (2%) 1/100 (1%)	0/50 (0%) Mean 1%	SD 1.41%
*Brain: Granular Cell Tumor Maligna		()			Total	0/50 (0%)	0/50 (0%)	
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%
*Brain: Meningioma Benign		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/50 (0%)	
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%

*: Denominator is number of animals with tissues examined microscopically

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC			Page: 83 Report Date: 11/07/2024					
			Male		Female			
*Brain: Meningioma Malignant		0/50 (0%)	1/50 (2%)			1/50 (2%)	0/50 (0%)	
Overall Incidence	Total	1/100 (1%)	Mean 1%	SD 1.41%	Total	1/100 (1%)	Mean 1%	SD 1.41%
*Brain: Meningioma: Benign, Malig		0/50 (0%)	1/50 (2%)			1/50 (2%)	0/50 (0%)	
Overall Incidence	Total	1/100 (1%)	Mean 1%	SD 1.41%	Total	1/100 (1%)	Mean 1%	SD 1.41%
*Brain: Oligodendroglioma Maligna		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/50 (0%)	
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%
*Brain: Oligodendroglioma, Glioma Overall Incidence			0/50 (0%) Mean 0%	SD 0%	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%
*Brain: Schwannoma Malignant		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/50 (0%)	
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%
*Clitoral/Preputial Gland: Adenocarcinoma		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/46 (0%)	
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/96 (0%)	Mean 0%	SD 0%

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC			Page: 84 Report Date: 11/07/2024					
			Male				Female	
*Clitoral/Preputial Gland: Adenoma		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/46 (0%)	
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/96 (0%)	Mean 0%	SD 0%
*Clitoral/Preputial Gland: Adenoma or Adenocarcinom		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/46 (0%)	
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/96 (0%)	Mean 0%	SD 0%
*Clitoral/Preputial Gland: Squamous Cell Carcinoma		0/50 (0%)	1/50 (2%)			0/50 (0%)	0/46 (0%)	
Overall Incidence	Total	1/100 (1%)	Mean 1%	SD 1.41%	Total	0/96 (0%)	Mean 0%	SD 0%
*Clitoral/Preputial Gland: Squamous Cell Papilloma		1/50 (2%)	0/50 (0%)			0/50 (0%)	0/46 (0%)	
Overall Incidence	Total	1/100 (1%)	Mean 1%	SD 1.41%	Total	0/96 (0%)	Mean 0%	SD 0%
*Epididymis: Sarcoma		0/49 (0%)	0/50 (0%)					
Overall Incidence	Total	0/99 (0%)	Mean 0%	SD 0%				
#Eye: Leiomyoma		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/50 (0%)	
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%

,		Tumor Incider	nce for Selected Contro		Page: 85 Report Date: 11/07/2024		
		Male	Female				
	0/50 (0%)	0/50 (0%)			0/50 (0%)	0/50 (0%)	
Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%
Total	2/50 (4%) 2/100 (2%)	0/50 (0%) Mean 2%	SD 2.83%	Total	0/49 (0%) 0/99 (0%)	0/50 (0%) Mean 0%	SD 0%
Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%
	0/50 (0%)	0/50 (0%)			0/50 (0%)	1/50 (2%)	SD 1.41%
ım: n	0/50 (0%)	0/50 (0%)			0/50 (0%)	0/50 (0%)	
Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%
ım:							
Total	()	0/50 (0%) Mean 0%	SD 0%	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%
	Total Total Total Total Im: n Total	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Tumor Incider Route: Male 0/50 (0%) 0/50 (0%) Total 0/100 (0%) 2/50 (4%) 0/50 (0%) Mean 0% 2/100 (2%) Mean 2% Total 0/50 (0%) 0/50 (0%) Mean 2% Total 0/50 (0%) 0/50 (0%) Total 0/50 (0%) 0/50 (0%) Mean 0% Im: 0/50 (0%) 0/50 (0%) Mean 0% Im: 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%)	Tumor Incidence for Selected Contra Route: PERINATAL AND PO Wehicle: FEED Male	Male Total 0/50 (0%) 0/50 (0%) Mean 0% SD 0% Total Total 0/100 (0%) Mean 0% SD 0% Total Total 2/50 (4%) 0/50 (0%) Mean 2% SD 2.83% Total Total 2/100 (2%) Mean 2% SD 0% Total Mean 0% SD 0% Total Total 0/50 (0%) 0/50 (0%) Mean 0% SD 0% Total 0/50 (0%) 0/50 (0%) Mean 0% SD 0% Total m: 0/50 (0%) 0/50 (0%) Total Total 0/50 (0%) 0/50 (0%) Mean 0% SD 0% Total	Tumor Incidence for Selected Control Animal Groups Route: PERINATAL AND POSTNATAL Vehicle: FEED Male	Tumor Incidence for Selected Control Animal Groups Route: PERINATAL AND POSTNATAL Vehicle: FEED Report Da Male Female 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) Mean 0% SD 0% Total 0/100 (0%) Mean 0% SD 0% Total 0/49 (0%) 0/50 (0%) Mean 0% Total 2/100 (2%) Mean 2% SD 2.83% Total 0/49 (0%) 0/50 (0%) Mean 0% Total 0/50 (0%) 0/50 (0%) Mean 0% SD 0% Total 0/100 (0%) Mean 0% 0/50 (0%) 0/50 (0%) 0/50 (0%) Mean 0% SD 0% Total 0/100 (0%) Mean 0% 0/100 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) Mean 0% SD 0% Total 0/100 (0%) Mean 1% m: 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) Mean 0% m: 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%)

Version: Nov2024 Contract/Lab: All Laboratorie Species: RATS Strain: Harlan Sprague-Dawle Length of Study: CHRONIC			Tumor Incider	ogy Data Manageme ice for Selected Contro PERINATAL AND PO Vehicle: FEED		Page: 86 Report Date: 11/07/2024		
			Male				Female	
#Intestine Small: Any Site: Adenocarcinoma		0/50 / /0/)	0/50 (00/)			2/52 (22/)	0/50 (00/)	
Overall Incidence	Total	2/50 (4%) 2/100 (2%)	0/50 (0%) Mean 2%	SD 2.83%	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%
#Intestine Small: Any Site: Adenoma or Adenocarcin								
Overall Incidence	Total	2/50 (4%) 2/100 (2%)	0/50 (0%) Mean 2%	SD 2.83%	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%
#Intestine Small: Any Site: Leiomyosarcoma Overall Incidence	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%
#Intestine Small: Any Site: Leiomyosarcoma or Leior		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/50 (0%)	
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%
#Intestine Small: Jejunum: Adenocarcinoma								
Overall Incidence	Total	2/50 (4%) 2/100 (2%)	0/50 (0%) Mean 2%	SD 2.83%	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%
#Intestine Small: Jejunum: Leiomyoma								
Overall Incidence	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC			Page: 87 Report Date: 11/07/2024					
			Male			·	Female	
#Intestine Small: Jejunum: Leiomyosarcoma		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/50 (0%)	
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%
*Islets, Pancreatic: Adenoma								
Overall Incidence	Total	2/50 (4%) 6/100 (6%)	4/50 (8%) Mean 6%	SD 2.83%	Total	3/49 (6%) 3/98 (3.06%)	0/49 (0%) Mean 3.06%	SD 4.33%
	Total					· · · ·		
*Islets, Pancreatic: Carcinoma		0/50 (00/)	0/50 (00/)				0/40 (00/)	
Overall Incidence	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	Total	0/49 (0%) 0/98 (0%)	0/49 (0%) Mean 0%	SD 0%
*Islets, Pancreatic: Carcinoma or Adenoma								
Overall Incidence	Total	2/50 (4%) 6/100 (6%)	4/50 (8%) Mean 6%	SD 2.83%	Total	3/49 (6%) 3/98 (3.06%)	0/49 (0%) Mean 3.06%	SD 4.33%
*Kidney: Pelvis and Urotheliur Papilloma								
		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/50 (0%)	
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%
*Kidney: Renal Tubule: Adenoma								
Overall Incidence	Total	1/50 (2%)	0/50 (0%) Mean 1%	SD 1.41%	Total	0/50 (0%)	0/50 (0%)	SD 09/
Overall Incidence	Total	1/100 (1%)			Total	0/100 (0%)	Mean 0%	SD 0%

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC			Page: 88 Report Date: 11/07/2024						
			Male			Female			
*Kidney: Renal Tubule: Carcinoma		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/50 (0%)		
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%	
*Kidney: Renal Tubule: Carcinoma or Adenoma									
Overall Incidence	Total	1/50 (2%) 1/100 (1%)	0/50 (0%) Mean 1%	SD 1.41%	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	
*Kidney: Renal Tubule: Hemangioma									
Overall Incidence	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	
*Kidney: Renal Tubule: Lipoma									
Overall Incidence	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	
*Kidney: Renal Tubule: Liposarcoma									
Overall Incidence	Total	0/50 (0%) 1/100 (1%)	1/50 (2%) Mean 1%	SD 1.41%	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	
		(<i>'</i>							
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%	

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC	,		Page: 89 Report Da	Page: 89 Report Date: 11/07/2024				
			Male				Female	
*Kidney: Renal Tubule: Polyp Adenomatous Overall Incidence	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%
#Lacrimal Gland: Carcinoma		0/50 (0%)	0/50 (0%)			1/50 (2%)	0/50 (0%)	
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	1/100 (1%)	Mean 1%	SD 1.41%
*Liver: Cholangioma Overall Incidence	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	Total	1/49 (2%) 2/99 (2.02%)	1/50 (2%) Mean 2.02%	SD 0.03%
*Liver: Hemangioma		0/50 (0%)	0/50 (0%)			0/49 (0%)	0/50 (0%)	
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/99 (0%)	Mean 0%	SD 0%
*Liver: Hepatocellular Adenoma		0/50 (0%)	1/50 (2%)			1/49 (2%)	1/50 (2%)	
Overall Incidence	Total	1/100 (1%)	Mean 1%	SD 1.41%	Total	2/99 (2.02%)	Mean 2.02%	SD 0.03%
*Liver: Hepatocellular Carcinoma		1/50 (2%)	0/50 (0%)			0/49 (0%)	0/50 (0%)	
Overall Incidence	Total	1/100 (1%)	Mean 1%	SD 1.41%	Total	0/99 (0%)	Mean 0%	SD 0%

.....

*: Denominator is number of animals with tissues examined microscopically

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC			Page: 90 Report Date: 11/07/2024						
			Male			Female			
*Liver: Hepatocellular Carcinoma	or Hepatobla	stoma							
Overall Incidence	Total	1/50 (2%) 1/100 (1%)	0/50 (0%) Mean 1%	SD 1.41%	Total	0/49 (0%) 0/99 (0%)	0/50 (0%) Mean 0%	SD 0%	
*Liver:									
Hepatocellular Carcinoma	or Hepatocel	llular Adenoma 1/50 (2%)	1/50 (2%)			1/49 (2%)	1/50 (2%)		
Overall Incidence	Total	2/100 (2%)	Mean 2%	SD 0%	Total	2/99 (2.02%)	Mean 2.02%	SD 0.03%	
*Liver: Hepatocellular Carcinoma,		lar Adenoma, or Hepatobl	astoma						
Overall Incidence	Total	1/50 (2%) 2/100 (2%)	1/50 (2%) Mean 2%	SD 0%	Total	1/49 (2%) 2/99 (2.02%)	1/50 (2%) Mean 2.02%	SD 0.03%	
*Lung: Alveolar/Bronchiolar Aden		0/50 (0%)	0/50 (0%)			0/49 (0%)	0/50 (0%)		
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/99 (0%)	Mean 0%	SD 0%	
*Lung: Alveolar/Bronchiolar Carci									
Overall Incidence	Total	0/50 (0%) 1/100 (1%)	1/50 (2%) Mean 1%	SD 1.41%	Total	0/49 (0%) 0/99 (0%)	0/50 (0%) Mean 0%	SD 0%	
*Lung: Alveolar/Bronchiolar Carci		eolar/Bronchiolar Adenon 0/50 (0%)				0/49 (0%)	0/50 (0%)		
Overall Incidence	Total	1/100 (1%)	Mean 1%	SD 1.41%	Total	0/99 (0%)	Mean 0%	SD 0%	

*: Denominator is number of animals with tissues examined microscopically #: Denominator is number of animals necropsied

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC			Page: 91 Report Date: 11/07/2024						
			Male			Female			
#Lymph Node, Mesenteric: Hemangiosarcoma		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/50 (0%)		
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%	
#Mammary Gland: Adenocarcinoma		1/50 (2%)	0/50 (0%)			1/50 (2%)	1/50 (2%)		
Overall Incidence	Total	1/100 (1%)	Mean 1%	SD 1.41%	Total	2/100 (2%)	Mean 2%	SD 0%	
#Mammary Gland: Adenolipoma									
Overall Incidence	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	
#Mammary Gland: Adenoma		0/50 (0%)	0/50 (0%)			1/50 (2%)	0/50 (0%)		
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	1/100 (1%)	Mean 1%	SD 1.41%	
#Mammary Gland: Adenoma or Adenocarcinon									
Overall Incidence	Total	1/50 (2%) 1/100 (1%)	0/50 (0%) Mean 1%	SD 1.41%	Total	2/50 (4%) 3/100 (3%)	1/50 (2%) Mean 3%	SD 1.41%	
#Mammary Gland: Fibroadenoma									
Overall Incidence	Total	2/50 (4%) 4/100 (4%)	2/50 (4%) Mean 4%	SD 0%	Total	28/50 (56%) 57/100 (57%)	29/50 (58%) Mean 57%	SD 1.41%	

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC		Toxicology Data Management System Tumor Incidence for Selected Control Animal Groups Route: PERINATAL AND POSTNATAL Vehicle: FEED						Page: 92 Report Date: 11/07/2024		
			Male				Female			
#Mammary Gland: Fibroma		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/50 (0%)			
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%		
#Mammary Gland: Fibroma, Fibroadenoma or A		2/50 (4%)	2/50 (4%)			29/50 (58%)	29/50 (58%)			
Overall Incidence	Total	4/100 (4%)	Mean 4%	SD 0%	Total	58/100 (58%)	Mean 58%	SD 0%		
#Mammary Gland: Fibroma, Fibroadenoma, Ade	enocarcino	ma, or Adenoma 3/50 (6%)	2/50 (4%)			30/50 (60%)	30/50 (60%)			
Overall Incidence	Total	5/100 (5%)	Mean 5%	SD 1.41%	Total	60/100 (60%)	Mean 60%	SD 0%		
#Nerve Trigeminal: Schwannoma Malignant		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/50 (0%)			
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%		
#Oral Mucosa: Squamous Cell Carcinoma		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/50 (0%)			
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%		
#Oral Mucosa, Tongue, Pharyr Squamous Cell Carcinoma		va: 0/50 (0%)	0/50 (0%)			0/50 (0%)	0/50 (0%)			
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%		

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC	,		Toxicol Tumor Inciden Route:	Page: 93 Report Date: 11/07/2024				
			Male			Female		
#Oral Mucosa, Tongue, Phary Squamous Cell Carcinoma,								
•	•	0/50 (0%)	0/50 (0%)			0/50 (0%)	0/50 (0%)	
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%
*Ovary: Adenocarcinoma, Cystaden								
						0/50 (0%)	0/50 (0%)	
Overall Incidence					Total	0/100 (0%)	Mean 0%	SD 0%
'Ovary: Adenoma								
Overall Incidence					Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%
[•] Ovary: Cystadenoma								
Overall Incidence					Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%
Ovary: Cystadenoma or Cystadenc	ocarcinoma							
						0/50 (0%)	0/50 (0%)	
Overall Incidence					Total	0/100 (0%)	Mean 0%	SD 0%
'Ovary: Granulosa-Theca Tumor Be	enign							
	-					0/50 (0%)	1/50 (2%)	
Overall Incidence					Total	1/100 (1%)	Mean 1%	SD 1.41%
*: Denominator is number of animals		examined microscopically						

Version: Nov2024 Contract/Lab: All Laboratories T Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC	Toxicology Data Management System umor Incidence for Selected Control Animal Groups Route: PERINATAL AND POSTNATAL Vehicle: FEED	Page: 94 Report Date: 11/07/2024					
	Male		Female				
*Ovary:							
Granulosa-Theca Tumor Malignant		0/50 (0%)	0/50 (0%)				
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%			
*Ovary:							
Granulosa Cell Tumor Benign		1/50 (20/)	0/50 (00/)				
Overall Incidence	Total	1/50 (2%) 1/100 (1%)	0/50 (0%) Mean 1%	SD 1.41%			
		· · ·					
'Ovary: Granulosa Cell Tumor Malignant							
-		1/50 (2%)	0/50 (0%)				
Overall Incidence	Total	1/100 (1%)	Mean 1%	SD 1.41%			
Ovary:		••••••					
Granulosa Cell Tumor, Luteoma, Thecoma, or Sertoli Cell Tumor (Benign	, Malignant, NOS)						
		2/50 (4%)	0/50 (0%)				
Overall Incidence	Total	2/100 (2%)	Mean 2%	SD 2.83%			
Ovary:							
Granulosa Cell Tumor: Benign, Malignant, NOS							
		2/50 (4%)	0/50 (0%)				
Overall Incidence	Total	2/100 (2%)	Mean 2%	SD 2.83%			
Övary:							
Luteoma							
		0/50 (0%)	0/50 (0%)				
Dverall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%			
: Denominator is number of animals with tissues examined microscopically							
Denominator is number of animals with issues examined microscopically							

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC			Toxicol Tumor Incider Route:	Page: 95 Report Date: 11/07/2024				
			Male			Female		
*Ovary: Schwannoma Malignant								
Overall Incidence					Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%
*Ovary: Sertoli Cell Tumor Benign								
Overall Incidence					Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%
*Ovary: Thecoma Benign								
Overall Incidence					Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%
*Pancreas: Adenocarcinoma								
Overall Incidence	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	Total	0/49 (0%) 0/98 (0%)	0/49 (0%) Mean 0%	SD 0%
*Pancreas: Adenoma								
Overall Incidence	Total	10/50 (20%) 19/100 (19%)	9/50 (18%) Mean 19%	SD 1.41%	Total	0/49 (0%) 0/98 (0%)	0/49 (0%) Mean 0%	SD 0%
*Pancreas: Adenoma or Adenocarcino								
Overall Incidence	Total	10/50 (20%) 19/100 (19%)	9/50 (18%) Mean 19%	SD 1.41%	Total	0/49 (0%) 0/98 (0%)	0/49 (0%) Mean 0%	SD 0%

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC			Page: 96 Report Date: 11/07/2024						
			Male			Female			
*Parathyroid Gland: Adenoma		0/42 (0%)	0/49 (0%)			0/42 (0%)	0/44 (0%)		
Overall Incidence	Total	0/91 (0%)	Mean 0%	SD 0%	Total	0/86 (0%)	Mean 0%	SD 0%	
#Peripheral Nerve: Paraganglioma		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/50 (0%)		
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%	
#Peripheral Nerve: Schwannoma Malignant		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/50 (0%)		
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%	
#Pharynx: Squamous Cell Carcinoma		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/50 (0%)		
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%	
*Pituitary Gland: Pars Distalis Adenoma		ified Site:							
		4/50 (8%)	7/50 (14%)			15/49 (31%)	11/50 (22%)		
Overall Incidence	Total	11/100 (11%)	Mean 11%	SD 4.24%	Total	26/99 (26.26%)	Mean 26.31%	SD 6.09%	

SD 1.44%

*Pituitary Gland: Pars Distalis or Unspecified Site: Carcinoma

(0%) (0%) (2%) (0%) 0/50 0/50 1/49 0/50 **Overall Incidence** Total 0/100 (0%) Mean 0% SD 0% 1/99 (1.01%) Mean 1.02% Total

*: Denominator is number of animals with tissues examined microscopically

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC		Toxicology Data Management System Tumor Incidence for Selected Control Animal Groups Route: PERINATAL AND POSTNATAL Vehicle: FEED				Page: 97 Report Date: 11/07/2024			
			Male				9 (27.27%) Mean 27.33% SD 7.53% 0/49 (0%) 0/50 (0%) 99 (0%) Mean 0% SD 0% 0/49 (0%) 0/50 (0%) 99 (0%) Mean 0% SD 0% 0/49 (0%) 0/50 (0%)		
*Pituitary Gland: Pars Distalis o Carcinoma or Adenoma	or Unspeci	ified Site: 4/50 (8%)	7/50 (14%)			16/49 (33%)	11/50 (22%)		
Overall Incidence	Total	11/100 (11%)	Mean 11%	SD 4.24%	Total	27/99 (27.27%)	Mean 27.33%		
*Pituitary Gland: Pars Distalis of Schwannoma Malignant			0/50 (0%)						
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/99 (0%)			
*Pituitary Gland: Pars Intermed Adenoma	lia:	0/50 (0%)	0/50 (0%)			0/49 (0%)	0/50 (0%)		
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	()			
*Pituitary Gland: Pars Intermed Carcinoma or Adenoma		0/50 (0%)	0/50 (0%)			()	()		
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/99 (0%)			
*Pituitary Gland: Pars Nervosa Schwannoma Malignant		0/50 (0%)	0/50 (0%)			0/49 (0%)	0/50 (0%)		
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/99 (0%)	Mean 0%	SD 0%	
*Prostate: Adenoma		0/50 (0%)	0/50 (0%)						
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%					

*: Denominator is number of animals with tissues examined microscopically #: Denominator is number of animals necropsied

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC		Toxicology Data Management System Tumor Incidence for Selected Control Animal Groups Route: PERINATAL AND POSTNATAL Vehicle: FEED				Page: 98 Report Date: 11/07/2024		
			Male				Female	
*Prostate: Adenoma or Adenocarci Overall Incidence	inoma Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%				
Salivary Glands:								
Schwannoma Malignant	:							
Overall Incidence	Total	2/50 (4%) 2/100 (2%)	0/50 (0%) Mean 2%	SD 2.83%	Total	0/49 (0%) 0/99 (0%)	0/50 (0%) Mean 0%	SD 0%
/Seminal Vesicle: Hemangiosarcoma		0.50 (00)						
Overall Incidence	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%				
Skeletal Muscle: Fibrosarcoma								
Overall Incidence	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%
Skeletal Muscle: Hemangioma								
Overall Incidence	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	Total	1/50 (2%) 1/100 (1%)	0/50 (0%) Mean 1%	SD 1.41%
≮Skeletal Muscle: Hemangiosarcoma		·····				·····		
Overall Incidence	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC		Toxicology Data Management System Tumor Incidence for Selected Control Animal Groups Route: PERINATAL AND POSTNATAL Vehicle: FEED				Page: 99 Report Date: 11/07/2024			
			Male				Female		
#Skeletal Muscle: Liposarcoma		2/50 /02/)	0/50 (00/)			0/50 (00/)	0/50 /00/)		
Overall Incidence	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	
#Skeletal Muscle: Sarcoma									
Overall Incidence	Total	1/50 (2%) 1/100 (1%)	0/50 (0%) Mean 1%	SD 1.41%	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	
#Skin: Basal Cell Adenoma									
Overall Incidence	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	
#Skin: Basal Cell Carcinoma		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/50 (0%)		
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%	
#Skin: Basal or Squamous Cell Car Adenoma, Papilloma, Sq Pap Carcinoma, Sebaceous Glan	cinoma, Ba billoma, Ker d Adenoma	sosquamous Tumor (Mal atoacanthoma, Trichoepi a, or Sebaceous Gland Ad 4/50 (8%)	ignant or Benign), B thelioma, Adenoma, enocarcinoma 3/50 (6%)	asal Cell		1/50 (2%)	0/50 (0%)		
Overall Incidence	Total	7/100 (7%)	Mean 7%	SD 1.41%	Total	1/100 (1%)	Mean 1%	SD 1.41%	
#Skin: Basal or Squamous Cell Care Adenocarcinoma	cinoma, Ba	sosquamous Tumor (Mal	ignant), or Sebaceou	ıs Gland					
	Tatal	1/50 (2%)	0/50 (0%)		T - 1 - 1	1/50 (2%)	0/50 (0%)		
Overall Incidence	Total	1/100 (1%)	Mean 1%	SD 1.41%	Total	1/100 (1%)	Mean 1%	SD 1.41%	

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC			Page: 100 Report Date: 11/07/2024					
			Male				•	
#Skin: Basosquamous Tumor (Be Keratoacanthoma, Trichoe	nign), Basal pithelioma, c	Cell Adenoma, Adenoma or Sebaceous Gland Aden	, Papilloma, Sq Papil oma	loma,				
Overall Incidence	Total	3/50 (6%) 6/100 (6%)	3/50 (6%) Mean 6%	SD 0%	Total	0/50 (0%) 0/100 (0%)	Mean 0%	
#Skin:								
Fibroma		3/50 (6%)	4/50 (8%)			0/50 (0%)	1/50 (2%)	
Overall Incidence	Total	7/100 (7%)	Mean 7%	SD 1.41%	Total	1/100 (1%)	Mean 1%	
≭Skin: Fibroma or Myxoma								
· ···· · ···· · ··· , · · ···		3/50 (6%)	4/50 (8%)			0/50 (0%)	1/50 (2%)	
Overall Incidence	Total	7/100 (7%)	Mean 7%	SD 1.41%	Total	1/100 (1%)		
#Skin: Fibroma, Fibrosarcoma, Sa								
		3/50 (6%)	4/50 (8%)	, on a		1/50 (2%)	2/50 (4%)	
Overall Incidence	Total	7/100 (7%)	Mean 7%	SD 1.41%	Total	3/100 (3%)	Mean 3%	
#Skin: Fibroma, Fibrosarcoma, Sa Hemangiopericytoma								
		3/50 (6%)	4/50 (8%)			1/50 (2%)	2/50 (4%)	
Overall Incidence	Total	7/100 (7%)	Mean 7%	SD 1.41%	Total	3/100 (3%)	Mean 3%	SD 1.41%
#Skin: Fibrosarcoma						4/50 (20/)	1/50 (20/)	
Overall Incidence	Tetal	0/50 (0%)	0/50 (0%)		Tatal	1/50 (2%)	()	
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	2/100 (2%)		

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC			Tumor Incider	logy Data Manageme nee for Selected Contro PERINATAL AND PO Vehicle: FEED	ol Animal Groups		te: 11/07/2024				
			Male				Page: 101 Report Date: 11/07/2024 Female 1/50 (2%) Mean 2% SD 0% 0/50 (0%) Mean 0% SD 0% 0/50 (0%) Mean 0% SD 0% 0/50 (0%) Mean 0% SD 0%				
#Skin: Fibrosarcoma, Sarcoma, Myxosarcoma, or Pleomorphic Fibrosarcoma											
	, cour comu	0/50 (0%)	0/50 (0%)			1/50 (2%)	1/50 (2%)				
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	2/100 (2%)	Mean 2%				
#Skin: Hemangioma											
nemangionia		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/50 (0%)				
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	()	SD 0%			
#Skin: Hemangiopericytoma											
		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/50 (0%)				
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%			
#Skin: Keratoacanthoma											
		2/50 (4%)	2/50 (4%)			0/50 (0%)					
Overall Incidence	Total	4/100 (4%)	Mean 4%	SD 0%	Total	0/100 (0%)					
#Skin: Lipoma											
		0/50 (0%)	0/50 (0%)			1/50 (2%)	()				
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	1/100 (1%)	Mean 1%	SD 1.41%			
≭Skin: Liposarcoma		4/50 (00/)				0/50 (00/)	0/50 (0%)				
	T . (.)	1/50 (2%)	0/50 (0%)		T . (.)	0/50 (0%)	0/50 (0%)				
Overall Incidence	Total	1/100 (1%)	Mean 1%	SD 1.41%	Total	0/100 (0%)	Mean 0%	SD 0%			

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC			Tumor Inciden	ogy Data Manageme ce for Selected Contr PERINATAL AND PC Vehicle: FEED	ol Animal Groups		Page: 102 Report Date: 11/07/2024				
			Male				Female				
#Skin: Neurofibrosarcoma or Schw Overall Incidence	annoma (m Total	alignant or NOS) 2/50 (4%) 2/100 (2%)	0/50 (0%) Mean 2%	SD 2.83%	Total	1/50 (2%) 1/100 (1%)	0/50 (0%) Mean 1%	SD 1.41%			
		. ,				()					
#Skin: Neurofibrosarcoma, Neurofi	broma, or S	Schwannoma (benign, ma 2/50 (4%)	lignant or NOS) 0/50 (0%)			1/50 (2%)	0/50 (0%)				
Overall Incidence	Total	2/100 (2%)	Mean 2%	SD 2.83%	Total	1/100 (1%)	Mean 1%	SD 1.41%			
#Skin: Osteosarcoma Overall Incidence	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%			
#Skin: Papilloma		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/50 (0%)				
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%			
#Skin: Pilomatrixoma		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/50 (0%)				
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%			
#Skin: Pleomorphic Fibrosarcoma		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/50 (0%)				
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%			

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC		Toxicology Data Management System Tumor Incidence for Selected Control Animal Groups Route: PERINATAL AND POSTNATAL Vehicle: FEED					Page: 103 Report Date: 11/07/2024 Female 0/50 (0%) Mean 0% SD 0% 0/50 (0%) Mean 1% SD 1.41% 0/50 (0%) Mean 1% SD 1.41%		
			Male		Female				
#Skin: Sarcoma		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/50 (0%)		
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%		
#Skin: Schwannoma Malignant		2/50 (4%)	0/50 (0%)			1/50 (2%)			
Overall Incidence	Total	2/100 (2%)	Mean 2%	SD 2.83%	Total	1/100 (1%)	Mean 1%		
#Skin: Squamous Cell Carcinoma		1/50 (2%)	0/50 (0%)			1/50 (2%)			
Overall Incidence	Total	1/100 (1%)	Mean 1%	SD 1.41%	Total	1/100 (1%)	Mean 1%		
#Skin: Squamous Cell Carcinoma, I or Carcinoma						1/50 (2%)			
Overall Incidence	Total	1/100 (1%)	Mean 1%	SD 1.41%	Total	1/100 (1%)	Mean 1%		
#Skin: Squamous Cell Papilloma									
Overall Incidence	Total	0/50 (0%) 1/100 (1%)	1/50 (2%) Mean 1%	SD 1.41%	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	
#Skin: Squamous Cell Papilloma or			1/50 (2%)			0/50 (0%)	0/50 (0%)		
Overall Incidence	Total	1/100 (1%)	Mean 1%	SD 1.41%	Total	0/100 (0%)	Mean 0%	SD 0%	

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC			Tumor Incider	ogy Data Manageme nce for Selected Contr PERINATAL AND PC Vehicle: FEED	ol Animal Groups		Page: 104 Report Date: 11/07/2024				
			Male				Female 50 0% 0/50 0% 50 0% 0/50 0% 50 0% Mean 0% SD 0% 50 (2%) 0/50 (0%) 50 (2%) 0/50 (0%) 50 (0%) Mean 1% SD 1.41% 50 (0%) 0/50 (0%) 50 (0%) 0/50 (0%) 50 (0%) 0/50 (0%) 50 (0%) 0/50 (0%) 49 (2%) 0/49 (0%)				
#Skin: Squamous Cell Papilloma, F Overall Incidence	'apilloma, o Total	r Keratoacanthoma 2/50 (4%) 5/100 (5%)	3/50 (6%) Mean 5%	SD 1.41%	Total	0/50 (0%) 0/100 (0%)	()	SD 0%			
						()					
Squamous Cell Papilloma, F	apilloma, S	quamous Cell Carcinoma 3/50 (6%)		а		1/50 (2%)	0/50 (0%)				
Overall Incidence	Total	6/100 (6%)	3/50 (6%) Mean 6%	SD 0%	Total	1/100 (1%)	· · ·	SD 1.41%			
#Skin: Trichoepithelioma Overall Incidence	Total	1/50 (2%) 1/100 (1%)	0/50 (0%) Mean 1%	SD 1.41%	Total	0/50 (0%) 0/100 (0%)	()	SD 0%			
#Skin: Sebaceous Gland: Adenoma											
Overall Incidence	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	Total	0/50 (0%) 0/100 (0%)	· · ·	SD 0%			
*Spleen: Hemangiosarcoma		0/50 (0%)	0/50 (0%)								
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	1/98 (1.02%)	()	SD 1.44%			
#Stomach, Forestomach: Papilloma		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/50 (0%)				
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%			

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC		Toxicology Data Management System Tumor Incidence for Selected Control Animal Groups Route: PERINATAL AND POSTNATAL Vehicle: FEED						e: 11/07/2024
			Male			Female		
#Stomach, Forestomach: Sarcoma		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/50 (0%)	
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%
#Stomach, Forestomach: Squamous Cell Carcinoma o			0/50 (0%)			0/50 (0%)	0/50 (0%)	
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%
#Stomach, Forestomach: Squamous Cell Papilloma		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/50 (0%)	
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%
#Stomach, Glandular: Sarcoma		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/50 (0%)	
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%
*Testis: Adenoma		3/49 (6%)	0/50 (0%)					
Overall Incidence	Total	3/99 (3.03%)	Mean 3.06%	SD 4.33%				
*Thymus: Schwannoma Malignant		0/47 (0%)	0/49 (0%)			0/46 (0%)	0/50 (0%)	
Overall Incidence	Total	0/96 (0%)	Mean 0%	SD 0%	Total	0/96 (0%)	Mean 0%	SD 0%

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC			Tumor Incider	logy Data Manageme nce for Selected Contr PERINATAL AND PO Vehicle: FEED	ol Animal Groups		e: 11/07/2024	
			Male				Female	
*Thymus: Thymoma Benign Overall Incidence	Total	0/47 (0%) 0/96 (0%)	0/49 (0%) Mean 0%	SD 0%	Total	0/46 (0%) 0/96 (0%)	0/50 (0%) Mean 0%	SD 0%
*Thymus: Thymoma Malignant Overall Incidence	Total	0/47 (0%) 0/96 (0%)	0/49 (0%) Mean 0%	SD 0%	Total	0/46 (0%) 0/96 (0%)	0/50 (0%) Mean 0%	SD 0%
		0/47 (0%) 0/96 (0%)		SD 0%	Total	0/46 (0%) 0/96 (0%)	0/50 (0%) Mean 0%	SD 0%
*Thyroid Gland: C-Cell: Adenoma Overall Incidence		10/50 (20%) 19/100 (19%)	9/50 (18%) Mean 19%	SD 1.41%	Total	8/49 (16%) 18/99 (18.18%)	10/50 (20%) Mean 18.16%	SD 2.6%
*Thyroid Gland: C-Cell: Carcinoma Overall Incidence	Total	1/50 (2%) 1/100 (1%)	0/50 (0%) Mean 1%	SD 1.41%	Total	0/49 (0%) 2/99 (2.02%)	2/50 (4%) Mean 2%	SD 2.83%
*Thyroid Gland: C-Cell: Carcinoma or Adenoma		10/50 (20%)	9/50 (18%)			8/49 (16%)	12/50 (24%)	

SD 1.41%

Total

20/99 (20.2%)

Mean 20.16%

SD 5.43%

*: Denominator is number of animals with tissues examined microscopically

Total

19/100 (19%)

Mean 19%

#: Denominator is number of animals necropsied

Overall Incidence

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC	,	Toxicology Data Management System Tumor Incidence for Selected Control Animal Groups Route: PERINATAL AND POSTNATAL Vehicle: FEED					Page: 107 Report Date: 11/07/2024 Female						-		
			Male				Female								
*Thyroid Gland: Follicular Ce Adenoma	II:	0/50 (0%)	0/50 (0%)			0/49 (0%)	1/50 (2%)								
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	1/99 (1.01%)	Mean 1%	SD 1.41%							
*Thyroid Gland: Follicular Ce Carcinoma															
Overall Incidence	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	Total	0/49 (0%) 0/99 (0%)	0/50 (0%) Mean 0%	SD 0%							
*Thyroid Gland: Follicular Ce Carcinoma or Adenoma Overall Incidence	II: Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	Total	0/49 (0%) 1/99 (1.01%)	1/50 (2%) Mean 1%	SD 1.41%							
#Tissue NOS: Schwannoma Malignant Dverall Incidence	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%							
#Tongue: Fibrosarcoma		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/50 (0%)								
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%							
≭Tongue: Papilloma		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/50 (0%)								
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%							

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC		Toxicology Data Management System Tumor Incidence for Selected Control Animal Groups Route: PERINATAL AND POSTNATAL Vehicle: FEED					Page: 108 Report Date: 11/07/2024				
			Male				Female				
#Tongue: Squamous Cell Carcinoma		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/50 (0%)				
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%			
#Tongue: Squamous Cell Carcinoma	or Papillom	a Squamous 0/50 (0%)	0/50 (0%)			0/50 (0%)	0/50 (0%)				
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%			
#Tooth: Odontoma Overall Incidence	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%			
*Urinary Bladder: Leiomyosarcoma		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/50 (0%)				
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%			
*Uterus: Adenocarcinoma							0/50 /00/)				
Overall Incidence					Total	3/50 (6%) 6/100 (6%)	3/50 (6%) Mean 6%	SD 0%			
*Uterus: Adenocarcinoma or Adeno	ma					2/50 (0)()	2/50 (00/)				
Overall Incidence					Total	3/50 (6%) 6/100 (6%)	3/50 (6%) Mean 6%	SD 0%			
*: Denominator is number of animal	s with tissues e	examined microscopically									

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC	Toxicology Data Management System Tumor Incidence for Selected Control Animal Group Route: PERINATAL AND POSTNATAL Vehicle: FEED	Tumor Incidence for Selected Control Animal Groups Route: PERINATAL AND POSTNATAL				
	Male		Female			
*Uterus:						
Adenoma Overall Incidence	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%		
 'Uterus: Adenoma, Adenocarcinoma, Sq Cell Carcinoma, or	Sq Cell Papilloma					
Overall Incidence	Total	3/50 (6%) 6/100 (6%)	3/50 (6%) Mean 6%	SD 0%		
*Uterus: Deciduoma Benign						
Overall Incidence	Total	1/50 (2%) 1/100 (1%)	0/50 (0%) Mean 1%	SD 1.41%		
'Uterus: Granular Cell Tumor Benign						
Overall Incidence	Total	1/50 (2%) 1/100 (1%)	0/50 (0%) Mean 1%	SD 1.41%		
*Uterus: Hemangioma						
Overall Incidence	Total	0/50 (0%) 1/100 (1%)	1/50 (2%) Mean 1%	SD 1.41%		
'Uterus: Polyp Stromal						
Overall Incidence	Total	8/50 (16%) 13/100 (13%)	5/50 (10%) Mean 13%	SD 4.24%		

Toxicology Data Management System Tumor Incidence for Selected Control Animal Gr Route: PERINATAL AND POSTNATAL Vehicle: FEED		Page: 110 Report Date: 11/07/2024			
Male			F	emale	
Tot	al	0/50 (0%) 0/100 (0%)	0/50 Mear	(0%) n 0%	SD 0%
Tot	al	0/50 (0%) 0/100 (0%)			SD 0%
		-/	- /	(,,,,,)	
Tota	al	8/50 (16%) 13/100 (13%)		· · ·	SD 4.24%
		4/50 (004)	0/50	(00()	
Tot	al	1/100 (1%)	Mea	า 1%์	SD 1.41%
Tot	al	0/50 (0%) 0/100 (0%)	0/50 Meai	(0%) n 0%	SD 0%
		0/50 (00()	0/50	(00()	
Tot		0/100 (0%)	Mea	. ,	SD 0%
	Tumor Incidence for Selected Control Animal Gro Route: PERINATAL AND POSTNATAL Vehicle: FEED Male Tota Tota Tota Tota Tota	Tumor Incidence for Selected Control Animal Groups Route: PERINATAL AND POSTNATAL Vehicle: FEED Male Total Total Total Total Total Total	Tumor Incidence for Selected Control Animal Groups Route: PERINATAL AND POSTNATAL Vehicle: FEED Male 0/50 (0%) Total 0/50 (0%) 0/100 (0%) Total 0/50 (0%) Total 0/100 (0%) Total 0/100 (0%) Total 1/50 (2%) Total 1/100 (1%) Total 0/100 (0%) Total 0/100 (0%)	Male Fr Male Fr 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) Mean Total 0/50 (0%) 0/50 (0%) Mean 0/50 (0%) Total 0/50 (0%) Mean 0/50 (0%) Mean 0/50 (0%) Male 0/50 (0%) Mean 0/50 (0%)	Tumor Incidence for Selected Control Animal Groups Report Da Route: PERINATAL AND POSTNATAL Vehicle: FEED Female Male Female 0/50 0%0 0/50 0%0 Total 0/100 0%0 Mean 0% 0/100 0%0 0/50 (0%) Male Female 0/50 (0%) Male Formale 0/50 (0%) 0/50 (0%) 0/50 (0%) Mean 0% Total 0/100 0% Mean 0% Total 1/50 (2%) 0/50 (0%) Total 1/50 (2%) 0/50 (0%) Total 1/50 (2%) 0/50 (0%) Total 0/100 0% Mean 1% Mean 1% 0/50 0% 0/50 0% Mean 0% Mean 0%

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC			Tumor Inciden	ogy Data Manageme ce for Selected Contr PERINATAL AND PC Vehicle: FEED	Page: 111 Report Date: 11/07/2024			
			Male				Female	
*Uterus: Squamous Cell Papilloma								
Overall Incidence					Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%
#Vagina: Granular Cell Tumor Benigi								
Overall Incidence					Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%
#Vagina: Polyp								
Overall Incidence					Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%
#Vagina: Sarcoma								
Overall Incidence					Total	0/50 (0%) 1/100 (1%)	1/50 (2%) Mean 1%	SD 1.41%
≭Vagina: Schwannoma Malignant								
Overall Incidence					Total	1/50 (2%) 1/100 (1%)	0/50 (0%) Mean 1%	SD 1.41%
#Zymbal's Gland: Adenoma								
Overall Incidence	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%

Version: Nov2024 Contract/Lab: All Laborate Species: RATS Strain: Harlan Sprague-Da Length of Study: CHRON	awley		Toxico Tumor Incider Route:	Page: 112 Report Date: 11/07/2024				
			Male				Female	
#Zymbal's Gland: Adenoma, Adenocarci	noma, Sq Cell Ca	rcinoma, or Sq Cell Papil 1/50 (2%)	loma 0/50 (0%)			0/50 (0%)	0/50 (0%)	
Overall Incidence	Total	1/100 (1%)	Mean 1%	SD 1.41%	Total	0/100 (0%)	Mean 0%	SD 0%
#Zymbal's Gland: Carcinoma								
		1/50 (2%)	0/50 (0%)			0/50 (0%)	0/50 (0%)	
Overall Incidence	Total	1/100 (1%)	Mean 1%	SD 1.41%	Total	0/100 (0%)	Mean 0%	SD 0%

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC

Toxicology Data Management System Tumor Incidence for Selected Control Animal Groups Route: PERINATAL AND POSTNATAL Vehicle: WATER

				Stu	dy Summary		
Laboratory Name	Study Number	Study Start Date	Length of Study in Days	Number of Animals Total and (#/Cage)	Number Surviving and (Mean Life Span)	Maximum Mean Weekly Body Weight	Chemical
					Male		
Battelle Columbus Laboratory	050303803	01/30/12	729	50(2)	12(621)	610.8	Sodium Tungstate Dihydrate
Battelle Columbus Laboratory	051105403	07/05/15	732	50(2)	16(650)	657.1	Sulfolane
					Female		
Battelle Columbus Laboratory	050303803	01/31/12	730	50(5)	30(667)	393.3	Sodium Tungstate Dihydrate
Battelle Columbus Laboratory	051105403	07/05/15	734	50(4)	21(670)	438.1	Sulfolane

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC		Toxicology Data Management System Tumor Incidence for Selected Control Animal Groups Route: PERINATAL AND POSTNATAL Vehicle: WATER				Page: 114 Report Date: 11/07/2024			
			Male				Female		
#All Organs: Benign Tumors		29/50 (58%)	29/50 (58%)			39/50 (78%)	43/50 (86%)		
Overall Incidence	Total	58/100 (58%)	Mean 58%	SD 0%	Total	82/100 (82%)	Mean 82%	SD 5.66%	
#All Organs: Malignant Tumors		14/50 (28%)	8/50 (16%)			17/50 (34%)	15/50 (30%)		
Overall Incidence	Total	22/100 (22%)	Mean 22%	SD 8.49%	Total	32/100 (32%)	Mean 32%	SD 2.83%	
#All Organs: Malignant and Benign Tumo Overall Incidence		36/50 (72%) 68/100 (68%)	32/50 (64%) Mean 68%	SD 5.66%	Total	47/50 (94%) 92/100 (92%)	45/50 (90%) Mean 92%	SD 2.83%	
#All Organs: Hemangioma Overall Incidence	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	
						()		50 0%	
#All Organs: Hemangiosarcoma		1/50 (2%)	1/50 (2%)			0/50 (0%)	0/50 (0%)		
Overall Incidence	Total	2/100 (2%)	Mean 2%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%	
#All Organs: Hemangiosarcoma or Hemai		1/50 (2%)	1/50 (2%)			0/50 (0%)	0/50 (0%)		
Overall Incidence	Total	2/100 (2%)	Mean 2%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%	

Version: Nov2024 Contract/Lab: All Laboratorie Species: RATS Strain: Harlan Sprague-Dawle Length of Study: CHRONIC		Toxicology Data Management System Tumor Incidence for Selected Control Animal Groups Route: PERINATAL AND POSTNATAL Vehicle: WATER				Page: 115 Report Date: 11/07/2024			
			Male				Female		
#All Organs: Histiocytic Sarcoma									
Overall Incidence	Total	0/50 (0%) 1/100 (1%)	1/50 (2%) Mean 1%	SD 1.41%	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	
#All Organs: Leukemia: Granulocytic									
Overall Incidence	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	
#All Organs: Leukemia: Lymphocytic, I						0/50 (0%)	0/50 (0%)		
Overall Incidence	Total	1/100 (1%)	Mean 1%	SD 1.41%	Total	0/100 (0%)	Mean 0%	SD 0%	
#All Organs: Malignant Lymphoma: His Undifferentiated Cell Type	tiocytic, Lym	phocytic, Mixed, NOS, La 1/50 (2%)	rge Granular, or 0/50 (0%)			2/50 (4%)	2/50 (4%)		
Overall Incidence	Total	1/100 (1%)	Mean 1%	SD 1.41%	Total	4/100 (4%)	Mean 4%	SD 0%	
#All Organs:		4/50 (20/)	0/50 (0%)			2/50 (4%)	0/50 (0%)		
Malignant Schwannoma									
Overall Incidence	Total	1/50 (2%) 1/100 (1%)	Mean 1%	SD 1.41%	Total	2/100 (2%)	Mean 2%	SD 2.83%	
Malignant Schwannoma Overall Incidence #All Organs: Mesothelioma: Benign, Ma		1/100 (1%)	Mean 1%			2/100 (2%)	Mean 2%		

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC			Tumor Incider	ogy Data Manageme nce for Selected Contr PERINATAL AND PC Vehicle: WATER		Page: 116 Report Date: 11/07/2024			
			Male				Female		
#All Organs: Mesothelioma: Malignant		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/50 (0%)		
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%	
*Adrenal Cortex: Adenoma		0/50 /00()					0/40 (0%)		
Overall Incidence	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	Total	0/50 (0%) 0/99 (0%)	0/49 (0%) Mean 0%	SD 0%	
*Adrenal Cortex: Carcinoma		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/49 (0%)		
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/99 (0%)	Mean 0%	SD 0%	
*Adrenal Cortex: Carcinoma or Adenoma		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/49 (0%)		
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/99 (0%)	Mean 0%	SD 0%	
*Adrenal Medulla: Ganglioneuroma		1/50 (2%)	0/50 (0%)			0/50 (0%)	0/49 (0%)		
Overall Incidence	Total	1/100 (1%)	Mean 1%	SD 1.41%	Total	0/99 (0%)	Mean 0%	SD 0%	
*Adrenal Medulla: Pheochromocytoma Benign		10/50 (20%)	10/50 (20%)			1/50 (2%)	1/49 (2%)		
Overall Incidence	Total	20/100 (20%)	Mean 20%	SD 0%	Total	2/99 (2.02%)	Mean 2.02%	SD 0.03%	

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC			Toxicol Tumor Incider Route:	Page: 117 Report Date: 11/07/2024					
			Male		Female				
*Adrenal Medulla: Pheochromocytoma Compl	ex	0/50 (0%)	0/50 (0%)			0/50 (0%)	0/49 (0%)		
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/99 (0%)	Mean 0%	SD 0%	
*Adrenal Medulla: Pheochromocytoma Malign	ant	2/50 (4%)	0/50 (0%)			1/50 (2%)	1/49 (2%)		
Overall Incidence	Total	2/100 (2%)	Mean 2%	SD 2.83%	Total	2/99 (2.02%)	Mean 2.02%	SD 0.03%	
*Adrenal Medulla: Pheochromocytoma: Benig Overall Incidence	n, Complex Total	x, Malignant, NOS 12/50 (24%) 22/100 (22%)	10/50 (20%) Mean 22%	SD 2.83%	Total	2/50 (4%) 4/99 (4.04%)	2/49 (4%) Mean 4.04%	SD 0.06%	
#Bone: Hemangiosarcoma Overall Incidence	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	
#Bone: Osteosarcoma		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/50 (0%)		
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%	
#Bone: Osteosarcoma or Osteoma		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/50 (0%)		
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%	

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC		Toxicology Data Management System Tumor Incidence for Selected Control Animal Groups Route: PERINATAL AND POSTNATAL Vehicle: WATER				Page: 118 Report Date: 11/07/2024				
			Male				Female			
*Brain: Astrocytoma		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/50 (0%)			
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%		
*Brain: Glioma										
Overall Incidence	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%		
*Brain: Glioma Malignant Overall Incidence	Total	2/50 (4%) 2/100 (2%)	0/50 (0%) Mean 2%	SD 2.83%	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%		
*Brain: Granular Cell Tumor Benign		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/50 (0%)			
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%		
*Brain: Granular Cell Tumor Maligna		1/50 (2%)	0/50 (0%)			0/50 (0%)	0/50 (0%)			
Overall Incidence	Total	1/100 (1%)	Mean 1%	SD 1.41%	Total	0/100 (0%)	Mean 0%	SD 0%		
*Brain: Meningioma Benign		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/50 (0%)			
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%		

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC		Toxicology Data Management System Tumor Incidence for Selected Control Animal Groups Route: PERINATAL AND POSTNATAL Vehicle: WATER					Page: 119 Report Date: 11/07/2024			
			Male				Female			
*Brain: Meningioma Malignant		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/50 (0%)			
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%		
*Brain: Meningioma: Benign, Malign	ant, NOS	0/50 (0%)	0/50 (0%)			0/50 (0%)	0/50 (0%)			
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%		
*Brain: Oligodendroglioma Malignar Overall Incidence		0/50 (0%) 1/100 (1%)	1/50 (2%) Mean 1%	SD 1.41%	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%		
*Brain: Oligodendroglioma, Glioma, Overall Incidence		·····	1/50 (2%) Mean 3%	SD 1.41%	Total		0/50 (0%) Mean 0%	SD 0%		
		3/100 (376)								
*Brain: Schwannoma Malignant		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/50 (0%)			
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%		
*Clitoral/Preputial Gland: Adenocarcinoma		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/48 (0%)			
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/98 (0%)	Mean 0%	SD 0%		

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC			Toxicole Tumor Inciden Route:		Page: 120 Report Date: 11/07/2024					
			Male			Female				
*Clitoral/Preputial Gland: Adenoma		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/48 (0%)			
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/98 (0%)	Mean 0%	SD 0%		
*Clitoral/Preputial Gland: Adenoma or Adenocarcinon	na	0/50 /0%/	0/50 (09/)			0/50 (00()	0/48 (0%)			
Overall Incidence	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	Total	0/50 (0%) 0/98 (0%)	0/48 (0%) Mean 0%	SD 0%		
*Clitoral/Preputial Gland: Squamous Cell Carcinoma		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/48 (0%)			
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/98 (0%)	Mean 0%	SD 0%		
*Clitoral/Preputial Gland: Squamous Cell Papilloma		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/48 (0%)			
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/98 (0%)	Mean 0%	SD 0%		
*Epididymis: Sarcoma		0/50 (0%)	0/50 (0%)							
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%						
#Eye: Leiomyoma		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/50 (0%)			
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%		

	Toxicology Data Management System Tumor Incidence for Selected Control Animal Groups Route: PERINATAL AND POSTNATAL Vehicle: WATER						Page: 121 Report Date: 11/07/2024		
		Male				Female			
	0/50 (0%)	0/50 (0%)			0/50 (0%)	0/50 (0%)			
Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%		
Total	0/100 (0%)	Mean 0%	SD 0%	Total	2/99 (2.02%)	Mean 2%	SD 2.83%		
	0/50 (0%)	0/50 (0%)			0/50 (0%)	1/50 (2%)			
	()				()		SD 1.41%		
Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%		
m: 1						0/50 (00/.)			
Total	0/50 (0%)	0/50 (0%) Mean 0%	SD 0%	Total	0/50 (0%)	0/50 (0%) Mean 0%	SD 0%		
m:						0/50 (0%)			
Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%		
	Total Total Total Total m: Total m:	0/50 (0%) Total 0/100 (0%) 0/50 (0%) (0%) Total 0/100 (0%) m: 0/50 (0%) m: 0/50 (0%) 0/50 (0%) (0%)	Tumor Inciden Route: Male 0/50 (0%) 0/50 (0%) Total 0/100 (0%) 0/50 (0%) 0/50 (0%) Total 0/100 (0%) 0/50 (0%) 0/50 (0%) Total 0/100 (0%) Mean 0% 0/50 (0%) Total 0/50 (0%) 0/50 (0%) 0/50 (0%) Mean 0% Mean 0% Total 0/50 (0%) 0/50 (0%) 0/50 (0%) Mean 0% Mean 0% m: 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%)	Tumor Incidence for Selected Contr Route: PERINATAL AND PC Male Male 0/50 (0%) 0/50 (0%) Total 0/100 (0%) Mean 0% SD 0% 0/50 (0%) 0/50 (0%) Mean 0% SD 0% Total 0/100 (0%) 0/50 (0%) Mean 0% SD 0% Total 0/100 (0%) 0/50 (0%) Mean 0% SD 0% Total 0/100 (0%) 0/50 (0%) Mean 0% SD 0% Total 0/100 (0%) 0/50 (0%) Mean 0% SD 0% m: 0/50 (0%) 0/50 (0%) Mean 0% SD 0% 0/50 (0%) 0/50 (0%) Mean 0% SD 0%	Tumor Incidence for Selected Control Animal Groups Route: PERINATAL AND POSTNATAL Vehicle: WATER Male	Tumor Incidence for Selected Control Animal Groups Route: PERINATAL AND POSTNATAL Vehicle: WATER Male	Male Female 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) Male Female 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) Mean 0% SD 0% Total 0/100 (0%) Mean 0% 0/100 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) Mean 0% SD 0% Total 2/50 (4%) 0/49 (0%) Total 0/100 (0%) 0/50 (0%) 0/50 (0%) SD 0% Total 2/50 (0%) Mean 2% Total 0/100 (0%) 0/50 (0%) 0/50 (0%) SD 0% Total 1/100 (1%) Mean 2% Total 0/100 (0%) 0/50 (0%) SD 0% Total 0/100 (0%) Mean 1% Total 0/100 (0%) 0/50 (0%) SD 0% Total 0/100 (0%) Mean 0% Total 0/100 (0%) 0/50 (0%) SD 0% Total 0/100 (0%) Mean 0% Total 0/100 (0%) Mean 0% SD 0% Total		

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC	Laboratories Tumor Incidence for Selected Control Animal C Route: PERINATAL AND POSTNATAL ague-Dawley Vehicle: WATER				gue-Dawley Route: PERINATAL AND POSTNATAL Vehicle: WATER					Page: 122 Report Date: 11/07/2024			
			Male				Female						
#Intestine Small: Any Site: Adenocarcinoma		1/50 (2%)	1/50 (2%)			0/50 (0%)	0/50 (0%)						
Overall Incidence	Total	2/100 (2%)	Mean 2%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%					
#Intestine Small: Any Site: Adenoma or Adenocarcinor													
Overall Incidence	Total	1/50 (2%) 2/100 (2%)	1/50 (2%) Mean 2%	SD 0%	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%					
#Intestine Small: Any Site: Leiomyosarcoma Overall Incidence	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%					
#Intestine Small: Any Site: Leiomyosarcoma or Leiomy Overall Incidence		0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%					
#Intestine Small: Jejunum: Adenocarcinoma		1/50 (2%)	1/50 (2%)			0/50 (0%)	0/50 (0%)						
Overall Incidence	Total	2/100 (2%)	Mean 2%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%					
#Intestine Small: Jejunum: Leiomyoma		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/50 (0%)						
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%					

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC		Toxicology Data Management System Tumor Incidence for Selected Control Animal Groups Route: PERINATAL AND POSTNATAL Vehicle: WATER						Page: 123 Report Date: 11/07/2024		
			Male				Female			
#Intestine Small: Jejunum: Leiomyosarcoma Overall Incidence	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%		
						· · ·				
*Islets, Pancreatic: Adenoma		2/50 (4%)	3/50 (6%)			1/50 (2%)	0/48 (0%)			
Overall Incidence	Total	5/100 (5%)	Mean 5%	SD 1.41%	Total	1/98 (1.02%)	Mean 1%	SD 1.41%		
*Islets, Pancreatic: Carcinoma		1/50 (2%)	0/50 (0%)			1/50 (2%)	0/48 (0%)			
Overall Incidence	Total	1/100 (1%)	Mean 1%	SD 1.41%	Total	1/98 (1.02%)	Mean 1%	SD 1.41%		
*Islets, Pancreatic: Carcinoma or Adenoma Overall Incidence	Total	3/50 (6%) 6/100 (6%)	3/50 (6%) Mean 6%	SD 0%	Total	2/50 (4%) 2/98 (2.04%)	0/48 (0%) Mean 2%	SD 2.83%		
		()								
*Kidney: Pelvis and Urotheliun Papilloma	n:	0/50 (0%)	0/50 (0%)			0/50 (0%)	0/49 (0%)			
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/99 (0%)	Mean 0%	SD 0%		
*Kidney: Renal Tubule: Adenoma		2/50 (4%)	1/50 (2%)			0/50 (0%)	0/49 (0%)			
Overall Incidence	Total	3/100 (3%)	Mean 3%	SD 1.41%	Total	0/99 (0%)	Mean 0%	SD 0%		

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC		Toxicology Data Management System Tumor Incidence for Selected Control Animal Groups Route: PERINATAL AND POSTNATAL Vehicle: WATER						Page: 124 Report Date: 11/07/2024		
			Male			Female				
*Kidney: Renal Tubule: Carcinoma		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/49 (0%)			
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/99 (0%)	Mean 0%	SD 0%		
*Kidney: Renal Tubule: Carcinoma or Adenoma		2/50 (4%)	1/50 (2%)			0/50 (0%)	0/49 (0%)			
Overall Incidence	Total	3/100 (3%)	Mean 3%	SD 1.41%	Total	0/99 (0%)	Mean 0%	SD 0%		
*Kidney: Renal Tubule: Hemangioma Overall Incidence	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	Total	0/50 (0%) 0/99 (0%)	0/49 (0%) Mean 0%	SD 0%		
*Kidney: Renal Tubule: Lipoma Overall Incidence	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	Total	0/50 (0%) 0/99 (0%)	0/49 (0%) Mean 0%	SD 0%		
*Kidney: Renal Tubule: Liposarcoma		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/49 (0%)			
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/99 (0%)	Mean 0%	SD 0%		
*Kidney: Renal Tubule: Oncocytoma Benign		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/49 (0%)			
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/99 (0%)	Mean 0%	SD 0%		

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC			Page: 125 Report Date: 11/07/2024					
			Male				Female	
*Kidney: Renal Tubule: Polyp Adenomatous		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/49 (0%)	
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/99 (0%)	Mean 0%	SD 0%
#Lacrimal Gland: Carcinoma		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/50 (0%)	
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%
*Liver: Cholangioma		1/50 (2%)	0/50 (0%)			0/50 (0%)	0/49 (0%)	
Overall Incidence	Total	1/100 (1%)	Mean 1%	SD 1.41%	Total	0/99 (0%)	Mean 0%	SD 0%
*Liver: Hemangioma		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/49 (0%)	
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/99 (0%)	Mean 0%	SD 0%
*Liver: Hepatocellular Adenoma		1/50 (2%)	0/50 (0%)			1/50 (2%)	0/49 (0%)	
Overall Incidence	Total	1/100 (1%)	Mean 1%	SD 1.41%	Total	1/99 (1.01%)	Mean 1%	SD 1.41%
*Liver: Hepatocellular Carcinoma		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/49 (0%)	
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/99 (0%)	Mean 0%	SD 0%

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC	,		Tumor Incider	logy Data Manageme Ince for Selected Contro PERINATAL AND PC Vehicle: WATER	Page: 126 Report Date: 11/07/2024			
			Male				Female	
*Liver: Hepatocellular Carcinoma o		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/49 (0%)	
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/99 (0%)	Mean 0%	SD 0%
*Liver: Hepatocellular Carcinoma o	or Hepatocel	lular Adenoma 1/50 (2%)	0/50 (0%)			1/50 (2%)	0/49 (0%)	
Overall Incidence	Total	1/100 (1%)	Mean 1%	SD 1.41%	Total	1/99 (1.01%)	Mean 1%	SD 1.41%
*Liver: Hepatocellular Carcinoma, Overall Incidence	Hepatocellu Total		astoma 0/50 (0%) Mean 1%	SD 1.41%	Total	1/50 (2%) 1/99 (1.01%)	0/49 (0%) Mean 1%	SD 1.41%
'Lung: Alveolar/Bronchiolar Adeno		1/50 (2%)	0/50 (0%)			0/50 (0%)	0/49 (0%)	
Overall Incidence	Total	1/100 (1%)	Mean 1%	SD 1.41%	Total	0/99 (0%)	Mean 0%	SD 0%
*Lung: Alveolar/Bronchiolar Carciı		1/50 (2%)	0/50 (0%)			0/50 (0%)	0/49 (0%)	
Overall Incidence	Total	1/100 (1%)	Mean 1%	SD 1.41%	Total	0/99 (0%)	Mean 0%	SD 0%
*Lung: Alveolar/Bronchiolar Carciı	noma or Alve	eolar/Bronchiolar Adenom 2/50 (4%)	na 0/50 (0%)			0/50 (0%)	0/49 (0%)	
Overall Incidence	Total	2/100 (2%)	Mean 2%	SD 2.83%	Total	0/99 (0%)	Mean 0%	SD 0%

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC			Page: 127 Report Date: 11/07/2024					
			Male				Female	
#Lymph Node, Mesenteric: Hemangiosarcoma		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/50 (0%)	
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%
#Mammary Gland: Adenocarcinoma		0/50 (0%)	0/50 (0%)			2/50 (4%)	1/50 (2%)	
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	3/100 (3%)	Mean 3%	SD 1.41%
#Mammary Gland: Adenolipoma		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/50 (0%)	
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%
#Mammary Gland: Adenoma		0/50 (0%)	0/50 (0%)			3/50 (6%)	1/50 (2%)	
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	4/100 (4%)	Mean 4%	SD 2.83%
#Mammary Gland: Adenoma or Adenocarcinom		0/50 (0%)	0/50 (0%)			5/50 (10%)	2/50 (4%)	
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	7/100 (7%)	Mean 7%	SD 4.24%
#Mammary Gland: Fibroadenoma		0/50 (0%)	2/50 (4%)			30/50 (60%)	32/50 (64%)	
Overall Incidence	Total	2/100 (2%)	Mean 2%	SD 2.83%	Total	62/100 (62%)	Mean 62%	SD 2.83%

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC			Tumor Incider	logy Data Manageme nce for Selected Contr PERINATAL AND PC Vehicle: WATER	Page: 128 Report Date: 11/07/2024			
			Male				Female	
#Mammary Gland: Fibroma	Total	0/50 (0%)	0/50 (0%)		Tatal	0/50 (0%)	1/50 (2%) Mean 1%	
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	1/100 (1%)	wean 1%	SD 1.41%
#Mammary Gland: Fibroma, Fibroadenoma or A	denoma	0/50 (0%)	2/50 (4%)			32/50 (64%)	33/50 (66%)	
Overall Incidence	Total	2/100 (2%)	Mean 2%	SD 2.83%	Total	65/100 (65%)	Mean 65%	SD 1.41%
#Mammary Gland: Fibroma, Fibroadenoma, Ad Overall Incidence			2/50 (4%) Mean 2%	SD 2.83%	Total	34/50 (68%) 67/100 (67%)	33/50 (66%) Mean 67%	SD 1.41%
#Nerve Trigeminal: Schwannoma Malignant Overall Incidence	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%
#Oral Mucosa: Squamous Cell Carcinoma		()				()	0/50 (0%)	
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%
#Oral Mucosa, Tongue, Pharyı Squamous Cell Carcinoma			0/50 (0%)			0/50 (0%)	0/50 (0%)	
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%

/ersion: Nov2024 Contract/Lab: All Laboratorie: Species: RATS Strain: Harlan Sprague-Dawle Length of Study: CHRONIC			Toxicole Tumor Inciden Route:	Page: 129 Report Date: 11/07/2024				
			Male			Female		
Oral Mucosa, Tongue, Phar Squamous Cell Carcinoma								
Overall Incidence	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%
		()		0/0 0/0	ιυιαι	0/100 (0 /0)		
Ovary: Adenocarcinoma, Cystade	noma, or Cys	stadenocarcinoma					e// e	
Overall Incidence					Total	0/50 (0%) 0/98 (0%)	0/48 (0%) Mean 0%	SD 0%
Ovary: Adenoma								
Overall Incidence					Total	0/50 (0%) 0/98 (0%)	0/48 (0%) Mean 0%	SD 0%
Ovary: Cystadenoma								
Overall Incidence					Total	0/50 (0%) 0/98 (0%)	0/48 (0%) Mean 0%	SD 0%
Ovary: Cystadenoma or Cystader	ocarcinoma							
Overall Incidence					Total	0/50 (0%) 0/98 (0%)	0/48 (0%) Mean 0%	SD 0%
Ovary: Granulosa-Theca Tumor B	enian							
	enign					0/50 (0%)	0/48 (0%)	
Overall Incidence					Total	0/98 (0%)	Mean 0%	SD 0%

Version: Nov2024 Contract/Lab: All Laboratories Tr Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC	Toxicology Data Management System umor Incidence for Selected Control Animal Groups Route: PERINATAL AND POSTNATAL Vehicle: WATER	Page: 130 Report Date: 11/07/2024					
	Male		Female				
*Ovary:							
Granulosa-Theca Tumor Malignant		1/50 (2%)	0/48 (0%)				
Overall Incidence	Total	1/98 (1.02%)	Mean 1%	SD 1.41%			
			••••••				
*Ovary:							
Granulosa Cell Tumor Benign		0/50 (0%)	0/48 (0%)				
Overall Incidence	Total	0/98 (0%)	Mean 0%	SD 0%			
		. ,					
*Ovary:							
Granulosa Cell Tumor Malignant		1/50 (2%)	0/48 (0%)				
Overall Incidence	Total	1/98 (1.02%)	Mean 1%	SD 1.41%			
*Ovary: Granulosa Cell Tumor, Luteoma, Thecoma, or Sertoli Cell Tumor (Benign,	Malignant NOS)						
Granulosa Cen Tullior, Luceonia, meconia, or Serion Cell Tullior (Delligh,	, manghan, NOS)	1/50 (2%)	0/48 (0%)				
Overall Incidence	Total	1/98 (1.02%)	Mean 1%	SD 1.41%			
······							
*Ovary: Granulosa Cell Tumor: Benign, Malignant, NOS							
		1/50 (2%)	0/48 (0%)				
Overall Incidence	Total	1/98 (1.02%)	Mean 1%	SD 1.41%			
'Ovary:							
Luteoma							
		0/50 (0%)	0/48 (0%)				
Overall Incidence	Total	0/98 (0%)	Mean 0%	SD 0%			
*: Denominator is number of animals with tissues examined microscopically							
Dependent of a number of animals managed a							

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC			Toxico Tumor Incider Route:	Page: 131 Report Date: 11/07/2024				
					Female			
*Ovary: Schwannoma Malignant								
Overall Incidence					Total	0/50 (0%) 0/98 (0%)	0/48 (0%) Mean 0%	SD 0%
*Ovary: Sertoli Cell Tumor Benign								
Overall Incidence					Total	0/50 (0%) 0/98 (0%)	0/48 (0%) Mean 0%	SD 0%
*Ovary: Thecoma Benign								
Overall Incidence					Total	0/50 (0%) 0/98 (0%)	0/48 (0%) Mean 0%	SD 0%
*Pancreas: Adenocarcinoma							- / / /	
Overall Incidence	Total	1/50 (2%) 1/100 (1%)	0/50 (0%) Mean 1%	SD 1.41%	Total	0/50 (0%) 0/98 (0%)	0/48 (0%) Mean 0%	SD 0%
*Pancreas: Adenoma								
Overall Incidence	Total	14/50 (28%) 18/100 (18%)	4/50 (8%) Mean 18%	SD 14.14%	Total	0/50 (0%) 0/98 (0%)	0/48 (0%) Mean 0%	SD 0%
*Pancreas: Adenoma or Adenocarcino	ma					0/50 (00/.)		
Overall Incidence	Total	14/50 (28%) 18/100 (18%)	4/50 (8%) Mean 18%	SD 14.14%	Total	0/50 (0%) 0/98 (0%)	0/48 (0%) Mean 0%	SD 0%

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC			Toxicol Tumor Incider Route:	Page: 132 Report Date: 11/07/2024				
			Male				Female	
*Parathyroid Gland: Adenoma		0/43 (0%)	0/44 (0%)			0/46 (0%)	1/43 (2%)	
Overall Incidence	Total	0/87 (0%)	Mean 0%	SD 0%	Total	1/89 (1.12%)	Mean 1.16%	SD 1.64%
#Peripheral Nerve: Paraganglioma		0/50 (0%)					0/50 (0%)	
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	0/50 (0%) Mean 0%	SD 0%
#Peripheral Nerve: Schwannoma Malignant		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/50 (0%)	
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%
#Pharynx: Squamous Cell Carcinoma		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/50 (0%)	
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%
*Pituitary Gland: Pars Distalis Adenoma		fied Site:						
Overall Incidence	Total	8/50 (16%) 17/100 (17%)	9/50 (18%) Mean 17%	SD 1.41%	Total	16/50 (32%) 30/100 (30%)	14/50 (28%) Mean 30%	SD 2.83%
*Pituitary Gland: Pars Distalis Carcinoma								
Overall Incidence	Total	1/50 (2%) 1/100 (1%)	0/50 (0%) Mean 1%	SD 1.41%	Total	1/50 (2%) 1/100 (1%)	0/50 (0%) Mean 1%	SD 1.41%

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC			Tumor Incider	logy Data Manageme nce for Selected Contro PERINATAL AND PC Vehicle: WATER	ol Animal Groups		Page: 133 Report Da	i te: 11/07/2024
			Male				Female	
*Pituitary Gland: Pars Distalis Carcinoma or Adenoma	or Unspeci		0/50 (40%)			47/50 (0.49/)	44/50 (000()	
Overall Incidence	Total	9/50 (18%) 18/100 (18%)	9/50 (18%) Mean 18%	SD 0%	Total	17/50 (34%) 31/100 (31%)	14/50 (28%) Mean 31%	SD 4.24%
*Pituitary Gland: Pars Distalis Schwannoma Malignant							0/50 (0%)	
Overall Incidence	Total	0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%
*Pituitary Gland: Pars Interme Adenoma								
Overall Incidence	Total	1/50 (2%) 1/100 (1%)	0/50 (0%) Mean 1%	SD 1.41%	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%
*Pituitary Gland: Pars Interme Carcinoma or Adenoma		1/50 (2%)	0/50 (0%)			0/50 (0%)	0/50 (0%)	
Overall Incidence	Total	1/100 (1%)	Mean 1%	SD 1.41%	Total	0/100 (0%)	Mean 0%	SD 0%
*Pituitary Gland: Pars Nervosa Schwannoma Malignant								
Overall Incidence	Total	1/50 (2%) 1/100 (1%)	0/50 (0%) Mean 1%	SD 1.41%	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%
*Prostate: Adenoma		0/50 (0%)	0/50 (0%)					
Overall Incidence	Total	0/50 (0%)	0/50 (0%) Mean 0%	SD 0%				

Version: Nov2024 Contract/Lab: All Laboratorie Species: RATS Strain: Harlan Sprague-Daw Length of Study: CHRONIC	ley		Tumor Incider	logy Data Manageme nce for Selected Contr PERINATAL AND PC Vehicle: WATER	ol Animal Groups		Page: 134 Report Dat	Page: 134 Report Date: 11/07/2024 Female			
		,	Male				Female				
*Prostate: Adenoma or Adenocarcir	noma	0/50 (0%)	0/50 (0%)								
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%							
*Salivary Glands: Schwannoma Malignant											
Overall Incidence	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	Total	0/50 (0%) 0/100 (0%)	()	SD 0%			
#Seminal Vesicle: Hemangiosarcoma		4/50 (00()									
Overall Incidence	Total	1/50 (2%) 1/100 (1%)	0/50 (0%) Mean 1%	SD 1.41%							
#Skeletal Muscle: Fibrosarcoma											
Overall Incidence	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%			
#Skeletal Muscle: Hemangioma											
Overall Incidence	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%			
#Skeletal Muscle: Hemangiosarcoma							- /				
Overall Incidence	Total	0/50 (0%) 1/100 (1%)	1/50 (2%) Mean 1%	SD 1.41%	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%			

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawle Length of Study: CHRONIC			Tumor Incide	blogy Data Manageme ence for Selected Contr : PERINATAL AND PC Vehicle: WATER	ol Animal Groups		Page: 135 Report Dat	Report Date: 11/07/2024 remale (0%) n 0% SD 0% (0%) n 0% SD 0% (0%) (0%) (0%) (0%) (0%) (0%) (0%) (0%)			
			Male				Female				
#Skeletal Muscle: Liposarcoma		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/50 (0%)				
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%				
#Skeletal Muscle: Sarcoma											
Overall Incidence	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%			
#Skin: Basal Cell Adenoma Overall Incidence	Total		0/50 (0%) Mean 0%	SD 0%	Total	0/50 (0%) 0/100 (0%)					
#Skin: Basal Cell Carcinoma		()				()					
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%			
#Skin: Basal or Squamous Cell C Adenoma, Papilloma, Sq P Carcinoma, Sebaceous Gla	arcinoma, Ba apilloma, Ker	sosquamous Tumor (Ma ratoacanthoma, Trichoe a, or Sebaceous Gland A 1/50 (2%)	alignant or Benign), E pithelioma, Adenoma	Basal Cell		0/50 (0%)	0/50 (0%)				
Overall Incidence	Total	1/100 (1%)	Mean 1%	SD 1.41%	Total	0/100 (0%)	Mean 0%	SD 0%			
#Skin: Basal or Squamous Cell Ca Adenocarcinoma			alignant), or Sebaceo								
			1/50 (2%)			0/50 (0%)	0/50 (0%)				

Version: Nov2024			Toxico	logy Data Manageme	Page: 136						
Contract/Lab: All Laboratories				nce for Selected Contr			Female 0/50 (0%) Mean 0% SD 0% 0/50 (0%) Mean 1% SD 1.41%				
Species: RATS			Route:	PERINATAL AND PC	STNATAL						
Strain: Harlan Sprague-Dawley				Vehicle: WATER							
Length of Study: CHRONIC											
			Male				Female				
#Skin: Basosquamous Tumor (Ben Keratoacanthoma, Trichoep				lloma,							
		1/50 (2%)	3/50 (6%)			0/50 (0%)	0/50 (0%)				
Overall Incidence	Total	4/100 (4%)	Mean 4%	SD 2.83%	Total	0/100 (0%)	Mean 0%	SD 0%			
#Skin:											
Fibroma		3/50 (6%)	2/50 (4%)			1/50 (2%)	0/50 (0%)				
Overall Incidence	Total	5/100 (5%)	Mean 5%	SD 1.41%	Total	1/100 (1%)	()	SD 1.41%			
#Skin: Fibroma or Myxoma			- / / / / / / / /								
Overall Incidence	Total	3/50 (6%) 5/100 (5%)	2/50 (4%) Mean 5%	SD 1.41%	Total	1/50 (2%) 1/100 (1%)	0/50 (0%) Mean 1%	SD 1.41%			
		, ,				·····					
#Skin: Fibroma, Fibrosarcoma, Sar	coma. Mvx	oma. Myxosarcoma. or Ple	eomorphic Fibrosard	coma							
,,,	, ,,	3/50 (6%)	3/50 (6%)			2/50 (4%)	1/50 (2%)				
Overall Incidence	Total	6/100 (6%)	Mean 6%	SD 0%	Total	3/100 (3%)	Mean 3%	SD 1.41%			
#Skin:											
Fibroma, Fibrosarcoma, Sar Hemangiopericytoma	coma, Myxo	oma, Myxosarcoma, Pleor	norphic Fibrosarcor	na, or							
3 1 1 1 1		3/50 (6%)	3/50 (6%)			3/50 (6%)	1/50 (2%)				
Overall Incidence	Total	6/100 (6%)	Mean 6%	SD 0%	Total	4/100 (4%)	Mean 4%	SD 2.83%			
#Skin: Fibrosarcoma											
		0/50 (0%)	0/50 (0%)			1/50 (2%)	1/50 (2%)				
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	2/100 (2%)	Mean 2%	SD 0%			

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC			Tumor Incider	logy Data Manageme nee for Selected Contro PERINATAL AND PO Vehicle: WATER	ol Animal Groups		Page: 137 Report Date: 11/07/2024				
			Male				Female				
#Skin:											
Fibrosarcoma, Sarcoma, My	xosarcoma	0/50 (0%)	1/50 (2%)			1/50 (2%)	1/50 (2%)				
Overall Incidence	Total	1/100 (1%)	Mean 1%	SD 1.41%	Total	2/100 (2%)	Mean 2%	SD 0%			
#Skin: Hemangioma											
-		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/50 (0%)				
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%			
#Skin: Hemangiopericytoma											
		0/50 (0%)	0/50 (0%)			1/50 (2%)	0/50 (0%)				
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	1/100 (1%)	Mean 1%	SD 1.41%			
#Skin: Keratoacanthoma											
		1/50 (2%)	3/50 (6%)			0/50 (0%)	0/50 (0%)				
Overall Incidence	Total	4/100 (4%)	Mean 4%	SD 2.83%	Total	0/100 (0%)	Mean 0%	SD 0%			
#Skin: Lipoma											
		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/50 (0%)				
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%			
#Skin: Liposarcoma		0/50 (00%)					0/50 (00/)				
.	T ()	0/50 (0%)	0/50 (0%)	00.00/	-	0/50 (0%)	0/50 (0%)	OD 00/			
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%			

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC			Toxicolo Tumor Incideno Route: I		Page: 138 Report Date: 11/07/2024				
			Male				Female		
#Skin: Neurofibrosarcoma or Schw Overall Incidence	•	alignant or NOS) 0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	
	Total	0/100 (0%)				()			
#Skin: Neurofibrosarcoma, Neurofi	broma, or S	chwannoma (benign, ma 0/50 (0%)	ignant or NOS) 0/50 (0%)			0/50 (0%)	0/50 (0%)		
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%	
#Skin: Osteosarcoma		0/50 (0%)	0/50 (0%)			1/50 (2%)	0/50 (0%)		
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	1/100 (1%)	Mean 1%	SD 1.41%	
#Skin: Papilloma		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/50 (0%)		
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%	
#Skin: Pilomatrixoma		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/50 (0%)		
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%	
#Skin: Pleomorphic Fibrosarcoma		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/50 (0%)		
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%	

Version: Nov2024 Contract/Lab: All Laboratorie Species: RATS Strain: Harlan Sprague-Dawle Length of Study: CHRONIC		Toxicology Data Management System Tumor Incidence for Selected Control Animal Groups Route: PERINATAL AND POSTNATAL Vehicle: WATER						Page: 139 Report Date: 11/07/2024			
			Male				Female				
#Skin: Sarcoma		0/50 (0%)	1/50 (2%)			0/50 (0%)	0/50 (0%)				
Overall Incidence	Total	1/100 (1%)	Mean 1%	SD 1.41%	Total	0/100 (0%)	Mean 0%	SD 0%			
#Skin: Schwannoma Malignant		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/50 (0%)				
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%			
#Skin: Squamous Cell Carcinom		0/50 (0%)	1/50 (2%)			0/50 (0%)	0/50 (0%)				
Overall Incidence	Total	1/100 (1%)	Mean 1%	SD 1.41%	Total	0/100 (0%)	Mean 0%	SD 0%			
#Skin: Squamous Cell Carcinom or Carcinoma	a, Basal Cell C	Carcinoma, Basosquamoບ 0/50 (0%)	is Tumor (malignant 1/50 (2%)	or NOS),		0/50 (0%)	0/50 (0%)				
Overall Incidence	Total	1/100 (1%)	Mean 1%	SD 1.41%	Total	0/100 (0%)	Mean 0%	SD 0%			
#Skin: Squamous Cell Papilloma		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/50 (0%)				
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%			
#Skin:		0/50 (0%)									
Squamous Cell Papilloma			0/50 (0%)			0/50 (0%)	0/50 (0%)				

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC			Tumor Incider	ogy Data Manageme nce for Selected Contro PERINATAL AND PO Vehicle: WATER	ol Animal Groups		Page: 140 Report Dat	40 Date: 11/07/2024	
			Male				Female		
#Skin:		. Kanada ang							
Squamous Cell Papilloma, P	apilioma, o	r Keratoacantnoma 1/50 (2%)	3/50 (6%)			0/50 (0%)	0/50 (0%)		
Overall Incidence	Total	4/100 (4%)	Mean 4%	SD 2.83%	Total	0/100 (0%)	Mean 0%	SD 0%	
#Skin:									
Squamous Cell Papilloma, F	apilloma, S	quamous Cell Carcinoma	or Keratoacanthom	а					
	-	1/50 (2%)	4/50 (8%)			0/50 (0%)	0/50 (0%)		
Overall Incidence	Total	5/100 (5%)	Mean 5%	SD 4.24%	Total	0/100 (0%)	Mean 0%	SD 0%	
#Skin:									
Trichoepithelioma									
		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/50 (0%)		
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%	
#Skin: Sebaceous Gland:									
Adenoma									
		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/50 (0%)		
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%	
Spleen:									
Hemangiosarcoma									
		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/49 (0%)		
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/99 (0%)	Mean 0%	SD 0%	
∜Stomach, Forestomach: Papilloma									
		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/50 (0%)		
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%	

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC			Toxicology Data Management System Tumor Incidence for Selected Control Animal Groups Route: PERINATAL AND POSTNATAL Vehicle: WATER				Page: 141 Report Date: 11/07/2024 Female				
			Male				Female				
#Stomach, Forestomach: Sarcoma		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/50 (0%)				
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%			
#Stomach, Forestomach: Squamous Cell Carcinoma c						0/50 (00/)	0/50 (0)()				
Overall Incidence	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%			
#Stomach, Forestomach: Squamous Cell Papilloma Overall Incidence	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%			
#Stomach, Glandular: Sarcoma Overall Incidence	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%			
*Testis: Adenoma		1/50 (2%)	0/50 (0%)								
Overall Incidence	Total	1/100 (1%)	Mean 1%	SD 1.41%							
*Thymus: Schwannoma Malignant		0/48 (0%)	0/48 (0%)			0/47 (0%)	0/43 (0%)				
Overall Incidence	Total	0/96 (0%)	Mean 0%	SD 0%	Total	0/90 (0%)	Mean 0%	SD 0%			

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC		Toxicology Data Management System Tumor Incidence for Selected Control Animal Groups Route: PERINATAL AND POSTNATAL Vehicle: WATER						te: 11/07/2024
			Male			Female		
*Thymus: Thymoma Benign		0/48 (0%)	0/48 (0%)			0/47 (0%)	0/43 (0%)	
Overall Incidence	Total	0/96 (0%)	Mean 0%	SD 0%	Total	0/90 (0%)	Mean 0%	SD 0%
*Thymus: Thymoma Malignant		0/48 (0%)	0/48 (0%)			0/47 (0%)	0/43 (0%)	
Overall Incidence	Total	0/96 (0%)	Mean 0%	SD 0%	Total	0/90 (0%)	Mean 0%	SD 0%
*Thymus: Thymoma: Benign, Malignai		0/48 (0%)	0/48 (0%)			0/47 (0%)	0/43 (0%)	
Overall Incidence	Total	0/96 (0%)	Mean 0%	SD 0%	Total	0/90 (0%)	Mean 0%	SD 0%
*Thyroid Gland: C-Cell: Adenoma		4/50 (8%)	8/50 (16%)			5/50 (10%)	6/50 (12%)	
Overall Incidence	Total	12/100 (12%)	Mean 12%	SD 5.66%	Total	11/100 (11%)	Mean 11%	SD 1.41%
*Thyroid Gland: C-Cell: Carcinoma								
Overall Incidence	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	Total	2/50 (4%) 3/100 (3%)	1/50 (2%) Mean 3%	SD 1.41%
*Thyroid Gland: C-Cell: Carcinoma or Adenoma		4/50 (8%)	8/50 (16%)			7/50 (14%)	7/50 (14%)	
Overall Incidence	Total	12/100 (12%)	Mean 12%	SD 5.66%	Total	14/100 (14%)	Mean 14%	SD 0%

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC	,	Toxicology Data Management System Tumor Incidence for Selected Control Animal Groups Route: PERINATAL AND POSTNATAL Vehicle: WATER									
			Male				Female 0 (0%) 0/45 (0%) is (0%) Mean 0% SD 0% 0 (0%) 0/45 (0%) SD 0% 0 (0%) 0/50 (0%) SD 0% 0 (0%) 0/50 (0%) SD 0%				
*Thyroid Gland: Follicular Cel Adenoma	II:										
Overall Incidence	Total	0/50 (0%) 0/95 (0%)	0/45 (0%) Mean 0%	SD 0%	Total	0/95 (0%)	Mean 0%				
*Thyroid Gland: Follicular Cel Carcinoma											
• • • • • •	T	0/50 (0%)	0/45 (0%)	00.00/	-	()		OD 00/			
Overall Incidence	Total	0/95 (0%)	Mean 0%	SD 0%	Total	0/95 (0%)					
*Thyroid Gland: Follicular Cel Carcinoma or Adenoma	11:										
		0/50 (0%)	0/45 (0%)			()	()				
Overall Incidence	Total	0/95 (0%)	Mean 0%	SD 0%	Total	0/95 (0%)					
#Tissue NOS: Schwannoma Malignant											
_		0/50 (0%)	0/50 (0%)			()	()				
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)					
#Tongue: Fibrosarcoma											
		0/50 (0%)	0/50 (0%)			()	0/50 (0%)				
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%			
#Tongue: Papilloma											
		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/50 (0%)				
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%			

*: Denominator is number of animals with tissues examined microscopically #: Denominator is number of animals necropsied

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC			Tumor Inciden	ogy Data Managem ce for Selected Cont PERINATAL AND PO Vehicle: WATER	rol Animal Groups DSTNATAL		Page: 144 Report Date: 11/07/2024 Female 0/50 (0%) Mean 0% SD 0%				
			Male				Female				
#Tongue: Squamous Cell Carcinoma Overall Incidence	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	Total	0/50 (0%) 0/100 (0%)	()	SD 0%			
		·····									
Overall Incidence	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%			
#Tooth: Odontoma Overall Incidence	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%			
Urinary Bladder: Leiomyosarcoma Overall Incidence	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	Total	0/50 (0%) 0/96 (0%)	0/46 (0%) Mean 0%	SD 0%			
Uterus: Adenocarcinoma						3/50 (6%)	5/49 (10%)				
Overall Incidence					Total	8/99 (8.08%)	Mean 8.1%	SD 2.97%			
^t Uterus: Adenocarcinoma or Adenor							5/40 (40%)				
Overall Incidence *: Denominator is number of animals	with tissues	examined microscopically			Total	3/50 (6%) 8/99 (8.08%)	5/49 (10%) Mean 8.1%	SD 2.97%			

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC	Toxicology Data Management System Tumor Incidence for Selected Control Animal Grou Route: PERINATAL AND POSTNATAL Vehicle: WATER	Tumor Incidence for Selected Control Animal Groups Route: PERINATAL AND POSTNATAL				
	Male		Female			
*Uterus:						
Adenoma Overall Incidence	Total	0/50 (0%) 0/99 (0%)	0/49 (0%) Mean 0%	SD 0%		
'Uterus: Adenoma, Adenocarcinoma, Sq Cell Carcinoma, o	r Sq Cell Papilloma					
Overall Incidence	Total	5/50 (10%) 12/99 (12.12%)	7/49 (14%) Mean 12.14%	SD 3.03%		
Uterus: Deciduoma Benign						
Dverall Incidence	Total	0/50 (0%) 0/99 (0%)	0/49 (0%) Mean 0%	SD 0%		
Uterus: Granular Cell Tumor Benign		0/50 (00/)	4/40 (00/)			
Overall Incidence	Total	0/50 (0%) 1/99 (1.01%)	1/49 (2%) Mean 1.02%	SD 1.44%		
Uterus: Hemangioma						
Overall Incidence	Total	0/50 (0%) 0/99 (0%)	0/49 (0%) Mean 0%	SD 0%		
Uterus: Polyp Stromal						
Overall Incidence	Total	5/50 (10%) 9/99 (9.09%)	4/49 (8%) Mean 9.08%	SD 1.3%		

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC	Toxicology Data Management System Tumor Incidence for Selected Control Animal Gro Route: PERINATAL AND POSTNATAL Vehicle: WATER	ups	Page: 146 Report Dat	e: 11/07/2024
	Male		Female	
*Uterus: Sarcoma				
Overall Incidence	Tota	0/50 (0%) I 0/99 (0%)	0/49 (0%) Mean 0%	SD 0%
*Uterus: Sarcoma Stromal				
Overall Incidence	Tota	1/50 (2%) I 1/99 (1.01%)	0/49 (0%) Mean 1%	SD 1.41%
*Uterus: Sarcoma Stromal or Polyp Stromal		- ()		
Overall Incidence	Tota	6/50 (12%) I 10/99 (10.1%)	4/49 (8%) Mean 10.08%	SD 2.71%
*Uterus: Schwannoma Malignant		0/50 (00())	4/40 (0%)	
Overall Incidence	Tota		1/49 (2%) Mean 1.02%	SD 1.44%
*Uterus: Sq Cell Carcinoma or Papilloma Squamous				
Overall Incidence	Tota	2/50 (4%) I 4/99 (4.04%)	2/49 (4%) Mean 4.04%	SD 0.06%
*Uterus: Squamous Cell Carcinoma		0/50 (101)	0/40 / //2/)	
Overall Incidence	Tota	2/50 (4%) I 4/99 (4.04%)	2/49 (4%) Mean 4.04%	SD 0.06%
*: Denominator is number of animals with tissues examined microscopic	allv			

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC			Tumor Incider	ogy Data Manageme nce for Selected Contro PERINATAL AND PO Vehicle: WATER	Page: 147 Report Date: 11/07/2024			
			Male				Female	
*Uterus: Squamous Cell Papilloma								
Overall Incidence					Total	0/50 (0%) 0/99 (0%)	0/49 (0%) Mean 0%	SD 0%
#Vagina: Granular Cell Tumor Benign								
Overall Incidence					Total	0/50 (0%) 0/97 (0%)	0/47 (0%) Mean 0%	SD 0%
#Vagina: Polyp								
Overall Incidence					Total	1/50 (2%) 1/97 (1.03%)	0/47 (0%) Mean 1%	SD 1.41%
#Vagina: Sarcoma								
Overall Incidence					Total	0/50 (0%) 0/97 (0%)	0/47 (0%) Mean 0%	SD 0%
#Vagina: Schwannoma Malignant								
Overall Incidence					Total	0/50 (0%) 0/97 (0%)	0/47 (0%) Mean 0%	SD 0%
#Zymbal's Gland: Adenoma								
Overall Incidence	Total	0/50 (0%) 1/100 (1%)	1/50 (2%) Mean 1%	SD 1.41%	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%

Contract/Lab: All Laborate Species: RATS Strain: Harlan Sprague-Da Length of Study: CHRON	awley		Toxico Tumor Incider Route:		Page: 148 Report Date: 11/07/2024			
			Male				Female	
•	inoma, Sq Cell Ca	rcinoma, or Sq Cell Papil 1/50 (2%)				0/50 (0%)	0/50 (0%)	
•	i noma, Sq Cell Ca Total	rcinoma, or Sq Cell Papil 1/50 (2%) 4/100 (4%)	loma 3/50 (6%) Mean 4%	SD 2.83%	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%
·		1/50 (2%)	3/50 (6%)	SD 2.83%	Total	()	()	SD 0%
Adenoma, Adenocarci Overall Incidence #Zymbal's Gland:		1/50 (2%)	3/50 (6%)	SD 2.83%	Total	()	()	SD 0%

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC

Toxicology Data Management System Tumor Incidence for Selected Control Animal Groups Route: PERINATAL AND POSTNATAL GAVAGE Vehicle: METHYLCELLULOSE

	Study Summary										
Laboratory Name	Study Number	Study Start Date	Length of Study in Days	Number of Animals Total and (#/Cage)	Number Surviving and (Mean Life Span)	Maximum Mean Weekly Body Weight	Chemical				
					Male						
Battelle Columbus Laboratory	050005803	07/03/12	730	50(2)	15(656)	628.4	Black Cohosh				
Battelle Columbus Laboratory	052032305	05/07/12	729	50(2)	29(669)	597.1	Resveratrol				
					Female						
Battelle Columbus Laboratory	050005803	07/02/12	729	50(5)	28(679)	426.6	Black Cohosh				
Battelle Columbus Laboratory	052032305	05/08/12	730	50(5)	34(690)	394.3	Resveratrol				

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC			Toxicol Tumor Incider Route: PER Vel		Page: 150 Report Date: 11/07/2024				
			Male		Female				
#All Organs: Benign Tumors		30/50 (60%)	33/50 (66%)			44/50 (88%)	43/50 (86%)		
Overall Incidence	Total	63/100 (63%)	Mean 63%	SD 4.24%	Total	87/100 (87%)	Mean 87%	SD 1.41%	
#All Organs: Malignant Tumors		10/50 (20%)	13/50 (26%)			7/50 (14%)	10/50 (20%)		
Overall Incidence	Total	23/100 (23%)	Mean 23%	SD 4.24%	Total	17/100 (17%)	Mean 17%	SD 4.24%	
#All Organs: Malignant and Benign Tumo Overall Incidence	ors Total	33/50 (66%) 72/100 (72%)	39/50 (78%) Mean 72%	SD 8.49%	Total	46/50 (92%) 91/100 (91%)	45/50 (90%) Mean 91%	SD 1.41%	
#All Organs: Hemangioma Overall Incidence	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	Total	0/50 (0%) 1/100 (1%)	1/50 (2%) Mean 1%	SD 1.41%	
#All Organs: Hemangiosarcoma		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/50 (0%)		
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%	
#All Organs: Hemangiosarcoma or Hema	angioma	0/50 (0%)	0/50 (0%)			0/50 (0%)	1/50 (2%)		
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	1/100 (1%)	Mean 1%	SD 1.41%	

Version: Nov2024 Contract/Lab: All Laborator Species: RATS Strain: Harlan Sprague-Daw Length of Study: CHRONIC	vley		Toxicol Tumor Incider Route: PER Vel	Page: 151 Report Date: 11/07/2024				
			Male				Female	
#All Organs: Histiocytic Sarcoma		4/50 (09()	0/50 (0%/)			0/50 (00/)	0/50 (00/)	
Overall Incidence	Total	1/50 (2%) 1/100 (1%)	0/50 (0%) Mean 1%	SD 1.41%	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%
#All Organs: Leukemia: Granulocytic								
Overall Incidence	Total	1/50 (2%) 1/100 (1%)	Mean 1%	SD 1.41%	Total	0/100 (0%)	0/50 (0%) Mean 0%	SD 0%
#All Organs:		ononuclear, or Undifferen 0/50 (0%)				0/50 (0%)	1/50 (2%)	
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	1/100 (1%)	Mean 1%	SD 1.41%
#All Organs:	listiocytic, Lym	phocytic, Mixed, NOS, La 0/50 (0%)				0/50 (0%)	1/50 (2%)	
Overall Incidence	Total	1/100 (1%)	Mean 1%	SD 1.41%	Total	1/100 (1%)	Mean 1%	SD 1.41%
#All Organs: Malignant Schwannoma								
Overall Incidence	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	Total	1/50 (2%) 2/100 (2%)	1/50 (2%) Mean 2%	SD 0%
#All Organs: Mesothelioma: Benign, I								
Overall Incidence	Total	2/50 (4%) 3/100 (3%)	1/50 (2%) Mean 3%	SD 1.41%	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC			Page: 152 Report Da	te: 11/07/2024				
			Male		Female			
#All Organs: Mesothelioma: Malignant								
		2/50 (4%)	1/50 (2%)	25 <i>i i i i i</i>		0/50 (0%)	0/50 (0%)	25 <i>aut</i>
Overall Incidence	Total	3/100 (3%)	Mean 3%	SD 1.41%	Total	0/100 (0%)	Mean 0%	SD 0%
*Adrenal Cortex: Adenoma								
		0/50 (0%)	0/50 (0%)			2/50 (4%)	3/50 (6%)	
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	5/100 (5%)	Mean 5%	SD 1.41%
*Adrenal Cortex: Carcinoma								
		0/50 (0%)	1/50 (2%)			0/50 (0%)	0/50 (0%)	
Overall Incidence	Total	1/100 (1%)	Mean 1%	SD 1.41%	Total	0/100 (0%)	Mean 0%	SD 0%
*Adrenal Cortex: Carcinoma or Adenoma								
		0/50 (0%)	1/50 (2%)			2/50 (4%)	3/50 (6%)	
Overall Incidence	Total	1/100 (1%)	Mean 1%	SD 1.41%	Total	5/100 (5%)	Mean 5%	SD 1.41%
*Adrenal Medulla: Ganglioneuroma								
-		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/50 (0%)	
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%
*Adrenal Medulla: Pheochromocytoma Benign								
		14/50 (28%)	4/50 (8%)			3/50 (6%)	3/50 (6%)	
Overall Incidence	Total	18/100 (18%)	Mean 18%	SD 14.14%	Total	6/100 (6%)	Mean 6%	SD 0%

*: Denominator is number of animals with tissues examined microscopically #: Denominator is number of animals necropsied

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC			Tumor Incider Route: PER	logy Data Manageme Ince for Selected Contro INATAL AND POSTN hicle: METHYLCELLU		Page: 153 Report Date: 11/07/2024			
			Male			Female			
*Adrenal Medulla: Pheochromocytoma Comp	lex	0/50 (0%)	0/50 (0%)			0/50 (0%)	0/50 (0%)		
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%	
*Adrenal Medulla: Pheochromocytoma Maligr	nant	0/50 (0%)	1/50 (2%)			0/50 (0%)	0/50 (0%)		
Overall Incidence	Total	1/100 (1%)	Mean 1%	SD 1.41%	Total	0/100 (0%)	Mean 0%	SD 0%	
*Adrenal Medulla: Pheochromocytoma: Beniç	gn, Complex	14/50 (28%)	5/50 (10%)			3/50 (6%)	3/50 (6%)	00.0%	
Overall Incidence	Total	19/100 (19%)	Mean 19%	SD 12.73%	Total	6/100 (6%)	Mean 6%	SD 0%	
#Bone: Hemangiosarcoma		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/50 (0%)		
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%	
#Bone: Osteosarcoma		0/50 (0%)	1/50 (2%)			0/50 (0%)	0/50 (0%)		
Overall Incidence	Total	1/100 (1%)	Mean 1%	SD 1.41%	Total	0/100 (0%)	Mean 0%	SD 0%	
#Bone: Osteosarcoma or Osteoma		0/50 (0%)	1/50 (2%)			0/50 (0%)	0/50 (0%)		
Overall Incidence	Total	1/100 (1%)	Mean 1%	SD 1.41%	Total	0/100 (0%)	Mean 0%	SD 0%	

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC			Toxicol Tumor Incider Route: PER Vel	Page: 154 Report Dat	e: 11/07/2024					
			Male			Female				
*Brain: Astrocytoma		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/50 (0%)			
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%		
*Brain: Glioma		0/50 (0%)	0/50 (00%)			0/50 (00/.)	0/50 (09()			
Overall Incidence	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%		
*Brain: Glioma Malignant		1/50 (2%)	0/50 (0%)			0/50 (0%)	0/50 (0%)			
Overall Incidence	Total	1/100 (1%)	Mean 1%	SD 1.41%	Total	0/100 (0%)	Mean 0%	SD 0%		
*Brain: Granular Cell Tumor Benigr	n	3/50 (6%)	0/50 (0%)			0/50 (0%)	0/50 (0%)			
Overall Incidence	Total	3/100 (3%)	Mean 3%	SD 4.24%	Total	0/100 (0%)	Mean 0%	SD 0%		
*Brain: Granular Cell Tumor Malign						0/50 (0%)	0/50 (0%)			
Overall Incidence	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%		
*Brain: Meningioma Benign		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/50 (0%)			
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%		

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC	Il Laboratories Tumor Incidence for Selected Control Animal Groups Route: PERINATAL AND POSTNATAL GAVAGE Vehicle: METHYLCELLULOSE Vehicle: METHYLCELLULOSE						Page: 155 Report Date: 11/07/2024			
			Male				Female			
*Brain: Meningioma Malignant		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/50 (0%)			
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%		
*Brain: Meningioma: Benign, Maligi		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/50 (0%)			
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%		
*Brain: Oligodendroglioma Maligna		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/50 (0%)			
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%		
*Brain: Oligodendroglioma, Glioma		toma 1/50 (2%)	0/50 (0%)			0/50 (0%)	0/50 (0%)			
Overall Incidence	Total	1/100 (1%)	Mean 1%	SD 1.41%	Total	0/100 (0%)	Mean 0%	SD 0%		
*Brain: Schwannoma Malignant		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/50 (0%)			
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%		
*Clitoral/Preputial Gland: Adenocarcinoma		0/50 (0%)	0/50 (0%)			0/49 (0%)	0/48 (0%)			
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/97 (0%)	Mean 0%	SD 0%		

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC			Toxicol Tumor Incider Route: PER Vel	Page: 156 Report Dat	e: 11/07/2024			
			Male				Female	
*Clitoral/Preputial Gland: Adenoma		0/50 (0%)	0/50 (00//)			0/40 (0%)	0/40 (00())	
Overall Incidence	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	Total	0/49 (0%) 0/97 (0%)	0/48 (0%) Mean 0%	SD 0%
*Clitoral/Preputial Gland: Adenoma or Adenocarcinon	na	0/50 (0%)	0/50 (0%)			0/49 (0%)	0/48 (0%)	
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/97 (0%)	Mean 0%	SD 0%
*Clitoral/Preputial Gland: Squamous Cell Carcinoma		0/50 (0%)	0/50 (0%)			1/49 (2%)	1/48 (2%)	
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	2/97 (2.06%)	Mean 2.06%	SD 0.03%
*Clitoral/Preputial Gland: Squamous Cell Papilloma		0/50 (0%)	1/50 (2%)			0/49 (0%)	0/48 (0%)	
Overall Incidence	Total	1/100 (1%)	Mean 1%	SD 1.41%	Total	0/97 (0%)	Mean 0%	SD 0%
*Epididymis: Sarcoma		0/50 (0%)	0/50 (0%)					
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%				
#Eye: Leiomyoma		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/50 (0%)	
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC			Toxicole Tumor Inciden Route: PERI Veh	Page: 157 Report Date: 11/07/2024				
			Male			Female		
#Harderian Gland: Schwannoma Malignant		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/50 (0%)	
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%
*Heart: Schwannoma Malignant								
O	Tatal	0/50 (0%)	0/50 (0%)	OD 00/	T . (.)	1/50 (2%)	0/50 (0%)	
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	1/100 (1%)	Mean 1%	SD 1.41%
#Intestine Large: Cecum: Leiomyosarcoma								
Overall Incidence	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%
		()				()		
#Intestine Large: Cecum: Liposarcoma								
Overall Incidence	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%
#Intestine Large: Colon/Rectur Granular Cell Tumor Benign								
Overall Insidence	Tatal	0/50 (0%)	0/50 (0%)	CD 00/	Tatal	0/50 (0%)	0/50 (0%)	CD 00/
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%
#Intestine Large: Colon/Rectu Leiomyoma	m:							
Overall Incidence	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%
		. ,				()		

#: Denominator is number of animals necropsied

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC			Toxicol Tumor Incider Route: PER Vel	Page: 158 Report Date: 11/07/2024					
			Male			Female			
#Intestine Small: Any Site: Adenocarcinoma									
Overall Incidence	Total	0/50 (0%) 1/100 (1%)	1/50 (2%) Mean 1%	SD 1.41%	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	
#Intestine Small: Any Site: Adenoma or Adenocarcino									
	nu	0/50 (0%)	1/50 (2%)			0/50 (0%)	0/50 (0%)		
Overall Incidence	Total	1/100 (1%)	Mean 1%	SD 1.41%	Total	0/100 (0%)	Mean 0%	SD 0%	
#Intestine Small: Any Site: Leiomyosarcoma									
2		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/50 (0%)		
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%	
#Intestine Small: Any Site: Leiomyosarcoma or Leiomy									
		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/50 (0%)		
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%	
#Intestine Small: Jejunum: Adenocarcinoma									
		0/50 (0%)	1/50 (2%)			0/50 (0%)	0/50 (0%)		
Overall Incidence	Total	1/100 (1%)	Mean 1%	SD 1.41%	Total	0/100 (0%)	Mean 0%	SD 0%	
#Intestine Small: Jejunum: Leiomyoma									
		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/50 (0%)		
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%	

*: Denominator is number of animals with tissues examined microscopically

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC			Toxico Tumor Incider Route: PER Vel	Page: 159 Report Date: 11/07/2024				
					Female			
#Intestine Small: Jejunum: Leiomyosarcoma							-/ /)	
Overall Incidence	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%
*Islets, Pancreatic: Adenoma								
		4/50 (8%)	2/50 (4%)			1/50 (2%)	2/50 (4%)	
Overall Incidence	Total	6/100 (6%)	Mean 6%	SD 2.83%	Total	3/100 (3%)	Mean 3%	SD 1.41%
*Islets, Pancreatic: Carcinoma								
		0/50 (0%)	3/50 (6%)			0/50 (0%)	0/50 (0%)	
Overall Incidence	Total	3/100 (3%)	Mean 3%	SD 4.24%	Total	0/100 (0%)	Mean 0%	SD 0%
*Islets, Pancreatic: Carcinoma or Adenoma								
0	Tatal	4/50 (8%)	5/50 (10%)		T . (.)	1/50 (2%)	2/50 (4%)	
Overall Incidence	Total	9/100 (9%)	Mean 9%	SD 1.41%	Total	3/100 (3%)	Mean 3%	SD 1.41%
*Kidney: Pelvis and Urotheliu Papilloma	m:							
		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/50 (0%)	
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%
*Kidney: Renal Tubule: Adenoma								
A H H H	-	0/50 (0%)	0/50 (0%)	OD 00/	-	0/50 (0%)	0/50 (0%)	OD 997
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%

#: Denominator is number of animals necropsied

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC			Tumor Incider Route: PER	logy Data Manageme nce for Selected Contr INATAL AND POSTN hicle: METHYLCELLU	Page: 160 Report Date: 11/07/2024			
			Male			Female		
*Kidney: Renal Tubule: Carcinoma		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/50 (0%)	
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%
*Kidney: Renal Tubule: Carcinoma or Adenoma		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/50 (0%)	
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%
*Kidney: Renal Tubule: Hemangioma		0/50 /00/)				0/50 /00/	4/50 (00/.)	
Overall Incidence	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	Total	0/50 (0%) 1/100 (1%)	1/50 (2%) Mean 1%	SD 1.41%
*Kidney: Renal Tubule: Lipoma		1/50 (2%)	0/50 (0%)			0/50 (0%)	0/50 (0%)	
Overall Incidence	Total	1/100 (1%)	Mean 1%	SD 1.41%	Total	0/100 (0%)	Mean 0%	SD 0%
*Kidney: Renal Tubule: Liposarcoma		0/50 /0%/	0/50 (00%)			0/50 (00()	0/50 (00()	
Overall Incidence	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%
*Kidney: Renal Tubule: Oncocytoma Benign		1/50 (2%)	0/50 (0%)			0/50 (0%)	0/50 (0%)	
Overall Incidence	Total	1/100 (1%)	Mean 1%	SD 1.41%	Total	0/100 (0%)	Mean 0%	SD 0%

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC			Toxicole Tumor Inciden Route: PERI Veh	Page: 161 Report Date: 11/07/2024				
			Male			Female		
*Kidney: Renal Tubule: Polyp Adenomatous		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/50 (0%)	
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%
#Lacrimal Gland: Carcinoma		0/50 /00/)					0/50 (00/)	
Overall Incidence	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%
*Liver: Cholangioma Overall Incidence	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%
'Liver: Hemangioma Overall Incidence	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%
*Liver: Hepatocellular Adenoma								
Overall Incidence	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	Total	2/50 (4%) 4/100 (4%)	2/50 (4%) Mean 4%	SD 0%
*Liver: Hepatocellular Carcinoma		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/50 (0%)	
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%

*: Denominator is number of animals with tissues examined microscopically #: Denominator is number of animals necropsied

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC			Tumor Incider Route: PER	logy Data Manageme nce for Selected Contro INATAL AND POSTN hicle: METHYLCELLU		Page: 162 Report Date: 11/07/2024		
			Male					
*Liver: Hepatocellular Carcinoma	or Hepatobla	astoma 0/50 (0%)	0/50 (0%)			0/50 (0%)	0/50 (0%)	
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%
*Liver: Hepatocellular Carcinoma		Ilular Adenoma 0/50 (0%)	0/50 (0%)			2/50 (4%)	2/50 (4%)	
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	4/100 (4%)	Mean 4%	SD 0%
*Liver: Hepatocellular Carcinoma Overall Incidence	, Hepatocellu Total	lar Adenoma, or Hepatobl 0/50 (0%) 0/100 (0%)	astoma 0/50 (0%) Mean 0%	SD 0%	Total	2/50 (4%) 4/100 (4%)	2/50 (4%) Mean 4%	SD 0%
*Lung: Alveolar/Bronchiolar Ader		0/50 (0%)	1/50 (2%)			0/50 (0%)	0/50 (0%)	
Overall Incidence	Total	1/100 (1%)	Mean 1%	SD 1.41%	Total	0/100 (0%)	Mean 0%	SD 0%
*Lung: Alveolar/Bronchiolar Carc	inoma	0/50 (0%)	0/50 (0%)			0/50 (0%)	0/50 (0%)	
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%
*Lung: Alveolar/Bronchiolar Carc						0/50 (0%)	0/50 (0%)	
Overall Incidence	Total	1/100 (1%)	Mean 1%	SD 1.41%	Total	0/100 (0%)	Mean 0%	SD 0%
*. Denominator is number of anima								

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC			Toxicol Tumor Incider Route: PER Vel	Page: 163 Report Date: 11/07/2024					
			Male			Female			
#Lymph Node, Mesenteric: Hemangiosarcoma									
Overall Incidence	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	
#Mammary Gland: Adenocarcinoma									
Overall Incidence	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	Total	3/50 (6%) 5/100 (5%)	2/50 (4%) Mean 5%	SD 1.41%	
#Mammary Gland: Adenolipoma									
Overall Incidence	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	
#Mammary Gland: Adenoma									
Overall Incidence	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	Total	1/50 (2%) 2/100 (2%)	1/50 (2%) Mean 2%	SD 0%	
#Mammary Gland: Adenoma or Adenocarcinon									
Overall Incidence	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	Total	4/50 (8%) 7/100 (7%)	3/50 (6%) Mean 7%	SD 1.41%	
#Mammary Gland: Fibroadenoma									
Overall Incidence	Total	3/50 (6%) 3/100 (3%)	0/50 (0%) Mean 3%	SD 4.24%	Total	29/50 (58%) 57/100 (57%)	28/50 (56%) Mean 57%	SD 1.41%	

*: Denominator is number of animals with tissues examined microscopically #: Denominator is number of animals necropsied

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC		Tumor Incider Route: PER	nce for Selected Contr INATAL AND POSTN	Page: 164 Report Date: 11/07/2024			
		Male					
Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%
Total	3/50 (6%) 3/100 (3%)	0/50 (0%) Mean 3%	SD 4.24%	Total	29/50 (58%) 57/100 (57%)	28/50 (56%) Mean 57%	SD 1.41%
enocarcino	ma, or Adenoma 3/50 (6%)	0/50 (0%)			30/50 (60%)	29/50 (58%)	
	()				()		SD 1.41%
Total	0/50 (0%)	0/50 (0%)		Tatal	0/50 (0%)	0/50 (0%)	
	()				()		SD 0%
	0/50 (0%)	1/50 (2%)			0/50 (0%)	0/50 (0%)	
Total	1/100 (1%)	Mean 1%	SD 1.41%	Total	0/100 (0%)	Mean 0%	SD 0%
	va:				0/50 (0%/)	0/50 (0%)	
Total	0/50 (0%) 1/100 (1%)	1/50 (2%) Mean 1%	SD 1.41%	Total	0/50 (0%)	0/50 (0%) Mean 0%	SD 0%
	Total Adenoma Total Ienocarcino Total Total Total Total	0/50 (0%) Total 0/100 (0%) Adenoma 3/50 (6%) Total 3/100 (3%) Jenocarcinoma, or Adenoma 3/50 (6%) Total 3/100 (3%) Jotal 3/100 (3%) Total 3/100 (3%) Total 0/50 (0%) Total 0/100 (0%) Total 1/100 (1%) nx, or Gingiva: 0/50 (0%)	Tumor Incider Route: PER Male Male 0/50 (0%) 0/50 (0%) Total 0/100 (0%) Mean 0% Adenoma 3/50 (6%) 0/50 (0%) Total 3/100 (3%) Mean 3% lenocarcinoma, or Adenoma 3/50 (6%) 0/50 (0%) Total 3/100 (3%) Mean 3% lenocarcinoma, or Adenoma 3/50 (6%) 0/50 (0%) Total 3/100 (3%) Mean 3% Cotal 0/50 (0%) 0/50 (0%) Total 0/100 (0%) Mean 0% Total 0/50 (0%) 1/50 (2%) Total 1/100 (1%) Mean 1% mx, or Gingiva: 0/50 (0%) 1/50 (2%)	Tumor Incidence for Selected Contra Route: PERINATAL AND POSTN. Wehicle: METHYLCELLU Male 0/50 (0%) 0/50 (0%) Total 0/100 (0%) Mean 0% SD 0% Adenoma 3/50 (6%) 0/50 (0%) Total 3/100 3% SD 4.24% Ienocarcinoma, or Adenoma 3/50 (6%) 0/50 (0%) Total 3/100 3% SD 4.24% Ienocarcinoma, or Adenoma 3/50 (6%) 0/50 (0%) Total 3/100 3% SD 4.24% Ional 3/100 (3%) Mean 3% SD 4.24% Ional 0/50 (0%) Mean 3% SD 9% Ional 0/50 (0%) Mean 3% SD 9% Ional 0/50 (0%) Mean 1% SD 1.41% Ional 0/50	Male 0/50 (0%) 0/50 (0%) Total 0/100 (0%) Mean 0% SD 0% Adenoma 3/50 (6%) 0/50 (0%) Total 3/100 (3%) Mean 3% SD 4.24% Total 3/50 (6%) 0/50 (0%) 0/50 (0%) Total 3/100 (3%) Mean 3% SD 4.24% Total 0/100 (0%) Mean 0% SD 0% Total 0/100 (0%) Mean 0% SD 1.41% Total 1/100 (1%) Mean 1% SD 1.41% Total 1/100 (1%) Mean 1% SD 1.41% <td>Tumor Incidence for Selected Control Animal Groups Route: PERINATAL AND POSTNATAL GAVAGE Vehicle: METHYLCELLULOSE Male </td> <td>Male Female 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) Mean 0% SD 0% Total 0/100 (0%) Mean 0% Mean 0% SD 0% Total 0/100 (0%) Mean 0% <td< td=""></td<></td>	Tumor Incidence for Selected Control Animal Groups Route: PERINATAL AND POSTNATAL GAVAGE Vehicle: METHYLCELLULOSE Male	Male Female 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) Mean 0% SD 0% Total 0/100 (0%) Mean 0% Mean 0% SD 0% Total 0/100 (0%) Mean 0% Mean 0% <td< td=""></td<>

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC			Toxico Tumor Incider Route: PER Ve	Page: 165 Report Date: 11/07/2024				
			Male			Female		
#Oral Mucosa, Tongue, Phary Squamous Cell Carcinoma Overall Incidence	Papilloma S				Tatal	0/50 (0%)	0/50 (0%)	SD 0%
	Total	1/100 (1%)		5D 1.41%		0/100 (0%)	Mean 0%	50 0%
*Ovary: Adenocarcinoma, Cystade	noma, or Cys	tadenocarcinoma				0/50 (0%)	0/50 (0%)	
Overall Incidence					Total	0/100 (0%)	Mean 0%	SD 0%
^t Ovary: Adenoma						-/	- /	
Overall Incidence					Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%
Ovary: Cystadenoma						0/50 (00/)	0/50 (00/)	
Overall Incidence					Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%
Ovary: Cystadenoma or Cystaden	ocarcinoma							
Overall Incidence					Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%
*Ovary: Granulosa-Theca Tumor Bo	enign							
Overall Incidence					Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%
*: Denominator is number of animal		xamined microscopically				·····		

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC	Toxicology Data Managemen Tumor Incidence for Selected Control Route: PERINATAL AND POSTNA Vehicle: METHYLCELLUL	Page: 166 Report Date: 11/07/2024					
	Male		Female				
*Ovary: Granulosa-Theca Tumor Malignant							
Overall Incidence		Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%		
'Ovary: Granulosa Cell Tumor Benign							
Overall Incidence		Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%		
Ovary: Granulosa Cell Tumor Malignant							
Overall Incidence		Total	0/50 (0%) 1/100 (1%)	1/50 (2%) Mean 1%	SD 1.41%		
Ovary: Granulosa Cell Tumor, Luteoma, Thecoma, or Sertoli Cell T	umor (Benign, Malignant, NOS)		0/50 (00/.)	1/50 (2%)			
Overall Incidence		Total	0/50 (0%) 1/100 (1%)	1/50 (2%) Mean 1%	SD 1.41%		
Ovary: Granulosa Cell Tumor: Benign, Malignant, NOS							
Overall Incidence		Total	0/50 (0%) 1/100 (1%)	1/50 (2%) Mean 1%	SD 1.41%		
Ovary: Luteoma							
Dverall Incidence		Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%		

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC			Tumor Incider Route: PER	logy Data Manageme nce for Selected Contr INATAL AND POSTN hicle: METHYLCELLU		Page: 167 Report Date: 11/07/2024		
			Male		Female			
*Ovary: Schwannoma Malignant								
Overall Incidence					Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%
*Ovary: Sertoli Cell Tumor Benign								
Overall Incidence					Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%
*Ovary: Thecoma Benign								
Overall Incidence					Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%
*Pancreas: Adenocarcinoma						- ()	- / / /	
Overall Incidence	Total	1/50 (2%) 1/100 (1%)	0/50 (0%) Mean 1%	SD 1.41%	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%
*Pancreas: Adenoma								
Overall Incidence	Total	6/50 (12%) 14/100 (14%)	8/50 (16%) Mean 14%	SD 2.83%	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%
*Pancreas: Adenoma or Adenocarcino	ma					- / /		
Overall Incidence	Total	7/50 (14%) 15/100 (15%)	8/50 (16%) Mean 15%	SD 1.41%	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC			Toxicol Tumor Inciden Route: PERI Veh	Page: 168 Report Date: 11/07/2024				
			Male					
*Parathyroid Gland: Adenoma		0/49 (0%)	1/49 (2%)			0/46 (0%)	0/48 (0%)	
Overall Incidence	Total	1/98 (1.02%)	Mean 1.02%	SD 1.44%	Total	0/94 (0%)	Mean 0%	SD 0%
#Peripheral Nerve: Paraganglioma		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/50 (0%)	
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%
#Peripheral Nerve: Schwannoma Malignant		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/50 (0%)	
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%
#Pharynx: Squamous Cell Carcinoma		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/50 (0%)	
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%
*Pituitary Gland: Pars Distalis o Adenoma								
Overall Incidence	Total	12/50 (24%) 22/100 (22%)	10/50 (20%) Mean 22%	SD 2.83%	Total	20/50 (40%) 41/100 (41%)	21/50 (42%) Mean 41%	SD 1.41%
*Pituitary Gland: Pars Distalis o Carcinoma		cified Site:						
Overall Incidence	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%

Version: Nov2024 Contract/Lab: All Laborator Species: RATS Strain: Harlan Sprague-Dav Length of Study: CHRONI	wley		Tumor Incider Route: PER	logy Data Manageme nce for Selected Contro INATAL AND POSTN hicle: METHYLCELLU	ol Animal Groups ATAL GAVAGE		1/50 (2%) Mean 1% SD 1.41%			
			Male				Female /50 (40%) 21/50 (42%) 00 (41%) Mean 41% SD 1.41% /50 (0%) 0/50 (0%) 00 (0%) Mean 0% SD 0% /50 (0%) 1/50 (2%) 00 (1%) Mean 1% SD 1.41% /50 (0%) 1/50 (2%) 00 (1%) Mean 1% SD 1.41% /50 (0%) 0/50 (0%) /50 (0%) 0/50 (0%)			
*Pituitary Gland: Pars Dist Carcinoma or Adenoma	•									
Overall Incidence	Total	12/50 (24%) 22/100 (22%)	10/50 (20%) Mean 22%	SD 2.83%	Total	20/50 (40%) 41/100 (41%)	· · ·	SD 1.41%		
*Pituitary Gland: Pars Dist Schwannoma Malignant	talis or Unspeci	ified Site:				0/50 (0%)	0/50 (00/.)			
Overall Incidence	Total	0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%			
*Pituitary Gland: Pars Inte Adenoma										
Overall Incidence	Total	0/50 (0%) 1/100 (1%)	1/50 (2%) Mean 1%	SD 1.41%	Total	1/100 (1%)	Mean 1%			
*Pituitary Gland: Pars Inte Carcinoma or Adenoma	ermedia:	0/50 (0%)	1/50 (2%)							
Overall Incidence	Total	1/100 (1%)	Mean 1%	SD 1.41%	Total	1/100 (1%)	Mean 1%			
*Pituitary Gland: Pars Ner Schwannoma Malignant	vosa:									
Overall Incidence	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	Total	0/50 (0%) 0/100 (0%)	()	SD 0%		
*Prostate: Adenoma		0/50 (0%)	0/50 (0%)							
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%						
*: Denominator is number of ani	imals with tissues e	examined microscopically			•••••					

Version: Nov2024 Contract/Lab: All Laboratori Species: RATS Strain: Harlan Sprague-Daw Length of Study: CHRONIC	vley	Toxicology Data Management System Tumor Incidence for Selected Control Animal Groups Route: PERINATAL AND POSTNATAL GAVAGE Vehicle: METHYLCELLULOSE				Page: 170 Report Date: 11/07/2024		
			Male				Female	
*Prostate: Adenoma or Adenocarci Overall Incidence	noma Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%				
*Salivary Glands: Schwannoma Malignant								
Overall Incidence	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%
#Seminal Vesicle: Hemangiosarcoma		0/50 (0%)						
Overall Incidence	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%				
#Skeletal Muscle: Fibrosarcoma								
Overall Incidence	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%
#Skeletal Muscle: Hemangioma								
Overall Incidence	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%
#Skeletal Muscle: Hemangiosarcoma								
Overall Incidence	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC			Tumor Inciden Route: PERI	logy Data Managemer nce for Selected Contro RINATAL AND POSTNA hicle: METHYLCELLUI	ol Animal Groups ATAL GAVAGE	Page: 171 Report Date: 11/07/2024			
			Male				Female		
#Skeletal Muscle: Liposarcoma		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/50 (0%)		
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	
#Skeletal Muscle: Sarcoma							(201)		
Overall Incidence	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	
#Skin: Basal Cell Adenoma									
Overall Incidence	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	Total	0/50 (0%) 1/100 (1%)	1/50 (2%) Mean 1%	SD 1.41%	
#Skin: Basal Cell Carcinoma		0/50 (0%)	1/50 (2%)			0/50 (0%)	2/50 (4%)		
Overall Incidence	Total	1/100 (1%)	Mean 1%	SD 1.41%	Total	2/100 (2%)	Mean 2%	SD 2.83%	
#Skin: Basal or Squamous Cell Caro Adenoma, Papilloma, Sq Pap Carcinoma, Sebaceous Gland	rcinoma, Bas pilloma, Kera nd Adenoma	asosquamous Tumor (Mali ratoacanthoma, Trichoepit a, or Sebaceous Gland Ad 1/50 (2%)	lignant or Benign), Ba ithelioma, Adenoma, denocarcinoma 5/50 (10%)	asal Cell ,		0/50 (0%)	3/50 (6%)		
Overall Incidence	Total	6/100 (6%)	Mean 6%	SD 5.66%	Total	3/100 (3%)	Mean 3%	SD 4.24%	
#Skin: Basal or Squamous Cell Card Adenocarcinoma	cinoma, Ba	sosquamous Tumor (Mal	ignant), or Sebaceou	is Gland					
		0/50 (0%)	1/50 (2%)			0/50 (0%) 2/100 (2%)	2/50 (4%) Mean 2%	SD 2.83%	
Overall Incidence	Total	1/100 (1%)	Mean 1%	SD 1.41%	Total				

Version: Nov2024				ogy Data Manageme	•		•	Page: 172 Report Date: 11/07/2024 Female 1/50 (2%) Mean 1% SD 1.41%			
Contract/Lab: All Laborator	ies			nce for Selected Control	•		Report Da	Report Date: 11/07/2024 Female 1/50 (2%) Mean 1% SD 1.41% 0/50 (0%) Mean 0% SD 0% 0/50 (0%) Mean 0% SD 0% 0/50 (0%) Mean 0% SD 0% 0/50 (0%) 0/50 (0%)			
Species: RATS				INATAL AND POSTN							
Strain: Harlan Sprague-Dav			Vel	nicle: METHYLCELLU	LOSE						
ength of Study: CHRONIC											
			Male				Female				
#Skin: Basosquamous Tumor (Benign), Basal Cell Adenoma, Adenoma, Papilloma, Sq Papilloma, Keratoacanthoma, Trichoepithelioma, or Sebaceous Gland Adenoma											
		1/50 (2%)	4/50 (8%)			0/50 (0%)	1/50 (2%)				
Overall Incidence	Total	5/100 (5%)	Mean 5%	SD 4.24%	Total	1/100 (1%)					
≇Skin: Fibroma											
		4/50 (8%)	2/50 (4%)			0/50 (0%)	()				
Overall Incidence	Total	6/100 (6%)	Mean 6%	SD 2.83%	Total	0/100 (0%)					
≮Skin: Fibroma or Myxoma											
		4/50 (8%)	2/50 (4%)	65 6 6667		0/50 (0%)	()	05.00/			
Overall Incidence	Total	6/100 (6%)	Mean 6%	SD 2.83%	Total	0/100 (0%)					
#Skin: Fibroma Fibrosaraama	Saraama Muy	oma, Myxosarcoma, or Pl	oomornhia Eibrocorr	ama a							
FIDIOIIIa, FIDIOSalcollia,		6/50 (12%)	3/50 (6%)	Jonna		0/50 (0%)	0/50 (0%)				
Overall Incidence	Total	9/100 (9%)	Mean 9%	SD 4.24%	Total	0/100 (0%)	Mean 0%	SD 0%			
#Skin:											
Fibroma, Fibrosarcoma, Hemangiopericytoma	Sarcoma, Myxo	oma, Myxosarcoma, Pleor	morphic Fibrosarcor	na, or							
		6/50 (12%)	3/50 (6%)			0/50 (0%)	0/50 (0%)				
Overall Incidence	Total	9/100 (9%)	Mean 9%	SD 4.24%	Total	0/100 (0%)	Mean 0%	SD 0%			
Skin: Fibrosarcoma							0/50 / (55/)				
		1/50 (2%)	1/50 (2%)	0D		0/50 (0%)	0/50 (0%)	05.00/			
Overall Incidence	Total	2/100 (2%)	Mean 2%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%			

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC			Tumor Incider Route: PER	logy Data Manageme nce for Selected Contr INATAL AND POSTN hicle: METHYLCELLU	ol Animal Groups ATAL GAVAGE		Page: 173 Report Date: 11/07/2024 Female 0/50 (0%) Mean 0% SD 0% 0/50 (0%) Mean 0% SD 0% 0/50 (0%) Mean 0% SD 0%			
			Male				Female			
#Skin: Fibrosarcoma, Sarcoma, My Overall Incidence	/xosarcoma Total	a, or Pleomorphic Fibrosa 2/50 (4%) 3/100 (3%)	r coma 1/50 (2%) Mean 3%	SD 1.41%	Total	0/50 (0%) 0/100 (0%)	()	SD 0%		
						, ,				
Hemangioma										
Overall Incidence	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	Total	0/50 (0%) 0/100 (0%)	()	SD 0%		
#Skin: Hemangiopericytoma Overall Incidence	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	Total	0/50 (0%) 0/100 (0%)	Mean 0%			
#Skin: Keratoacanthoma		1/50 (2%)	2/50 (4%)			0/50 (0%)	0/50 (0%)			
Overall Incidence	Total	3/100 (3%)	Mean 3%	SD 1.41%	Total	0/100 (0%)	Mean 0%	SD 0%		
#Skin: Lipoma		2/50 (4%)	0/50 (0%)			1/50 (2%)	1/50 (2%)			
Overall Incidence	Total	2/100 (2%)	Mean 2%	SD 2.83%	Total	2/100 (2%)	Mean 2%	SD 0%		
#Skin: Liposarcoma		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/50 (0%)			
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%		

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC		Toxicology Data Management System Tumor Incidence for Selected Control Animal Groups Route: PERINATAL AND POSTNATAL GAVAGE Vehicle: METHYLCELLULOSE				Page: 174 Report Date: 11/07/2024		
			Male				Female	
#Skin: Neurofibrosarcoma or Schw	annoma (m	alignant or NOS) 0/50 (0%)	0/50 (0%)			0/50 (0%)	0/50 (0%)	
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%
#Skin: Neurofibrosarcoma, Neurofi	broma, or S	Schwannoma (benign, ma 0/50 (0%)				0/50 (0%)	0/50 (0%)	
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%
#Skin: Osteosarcoma Overall Incidence	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%
#Skin: Papilloma		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/50 (0%)	
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%
#Skin: Pilomatrixoma		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/50 (0%)	
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%
#Skin: Pleomorphic Fibrosarcoma		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/50 (0%)	
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%

Contract/Lab: All Laborato Species: RATS Strain: Harlan Sprague-Dav Length of Study: CHRON	wley	Toxicology Data Management System Tumor Incidence for Selected Control Animal Groups Route: PERINATAL AND POSTNATAL GAVAGE Vehicle: METHYLCELLULOSE						Page: 175 Report Date: 11/07/2024			
			Male				Female				
#Skin: Sarcoma		4/50 (0%)	0/50 (00/)			0/50 (00/.)	0/50 (00/)				
Overall Incidence	Total	1/50 (2%) 1/100 (1%)	0/50 (0%) Mean 1%	SD 1.41%	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%			
#Skin: Schwannoma Malignant						0/50 /00/)	0/50 (00/)				
Overall Incidence	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%			
#Skin: Squamous Cell Carcino	ma	0/50 (0%)	0/50 (0%)			0/50 (0%)	0/50 (0%)				
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%			
#Skin: Squamous Cell Carcino or Carcinoma	ma, Basal Cell C	Carcinoma, Basosquamou 0/50 (0%)	us Tumor (malignant 1/50 (2%)			0/50 (0%)	2/50 (4%)	25.0000			
#Skin: Squamous Cell Carcino or Carcinoma Overall Incidence	ma, Basal Cell C Total	Carcinoma, Basosquamou 0/50 (0%) 1/100 (1%)	u s Tumor (malignant 1/50 (2%) Mean 1%	SD 1.41%	Total	0/50 (0%) 2/100 (2%)	2/50 (4%) Mean 2%	SD 2.83%			
	ma, Basal Cell C Total	Carcinoma, Basosquamou 0/50 (0%) 1/100 (1%)	u s Tumor (malignant 1/50 (2%) Mean 1%	SD 1.41%	Total	0/50 (0%) 2/100 (2%)	Mean 2%	SD 2.83%			
 #Skin: Squamous Cell Carcino or Carcinoma Overall Incidence #Skin: Squamous Cell Papillon Overall Incidence 	ma, Basal Cell C Total na Total	Carcinoma, Basosquamou 0/50 (0%) 1/100 (1%) 0/50 (0%) 2/100 (2%)	us Tumor (malignant 1/50 (2%) Mean 1% 2/50 (4%) Mean 2%	SD 1.41% SD 2.83%	Total Total	0/50 (0%) 2/100 (2%) 0/50 (0%) 0/100 (0%)	Mean 2% 0/50 (0%) Mean 0%	SD 0%			
#Skin: Squamous Cell Carcino or Carcinoma Overall Incidence #Skin:	ma, Basal Cell C Total na Total	Carcinoma, Basosquamou 0/50 (0%) 1/100 (1%) 0/50 (0%) 2/100 (2%)	us Tumor (malignant 1/50 (2%) Mean 1% 2/50 (4%) Mean 2%	SD 1.41% SD 2.83%	Total Total	0/50 (0%) 2/100 (2%) 0/50 (0%) 0/100 (0%)	Mean 2% 0/50 (0%) Mean 0%	SD 0%			

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC			Tumor Incider Route: PER	logy Data Manageme nce for Selected Contr INATAL AND POSTN hicle: METHYLCELLU	ol Animal Groups ATAL GAVAGE		Page: 176 Report Date: 11/07/2024 Female 0/50 (0%) Mean 0% SD 0% 0/50 (0%) Mean 0% SD 0%			
			Male				Female			
#Skin: Squamous Cell Papilloma, I Overall Incidence	Papilloma, o Total	or Keratoacanthoma 1/50 (2%) 5/100 (5%)	4/50 (8%) Mean 5%	SD 4.24%	Total	0/50 (0%) 0/100 (0%)	· · ·	SD 0%		
						()				
#Skin: Squamous Cell Papilloma, I	Papilloma, S	quamous Cell Carcinoma 1/50 (2%)	or Keratoacanthom 4/50 (8%)	а		0/50 (0%)	0/50 (0%)			
Overall Incidence	Total	5/100 (5%)	Mean 5%	SD 4.24%	Total	0/100 (0%)	Mean 0%	SD 0%		
#Skin: Trichoepithelioma		0/50 (0%)	0/50 (0%)	05 ov		0/50 (0%)	0/50 (0%)			
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%		
#Skin: Sebaceous Gland: Adenoma		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/50 (0%)			
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%		
*Spleen: Hemangiosarcoma		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/50 (0%)			
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%		
#Stomach, Forestomach: Papilloma		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/50 /0%/)			
Overall Incidence	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%		

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC			Tumor Incider Route: PER	ogy Data Manageme ice for Selected Contr INATAL AND POSTN hicle: METHYLCELLU	ol Animal Groups ATAL GAVAGE		0/50 (0%) 0/50 (0%)				
			Male			Pups SE Female 0/50 (0%) 0/50 (0%) 1 0/100 (0%) 0/100 (0%) 0/100 (0%) Image: mathematical mathmatical					
#Stomach, Forestomach: Sarcoma											
Overall Incidence	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%				
#Stomach, Forestomach: Squamous Cell Carcinoma (
Overall Incidence	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	Total	()	()	SD 0%			
#Stomach, Forestomach: Squamous Cell Papilloma		0/50 (0%)	0/50 (0%)								
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	()	()	SD 0%			
#Stomach, Glandular: Sarcoma		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/50 (0%)				
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	()	()	SD 0%			
*Testis: Adenoma		1/50 (2%)	0/50 (0%)								
Overall Incidence	Total	1/100 (1%)	Mean 1%	SD 1.41%							
*Thymus: Schwannoma Malignant		0/46 (0%)	0/48 (0%)			0/49 (0%)	0/50 (0%)				
Overall Incidence	Total	0/94 (0%)	Mean 0%	SD 0%	Total	0/99 (0%)	Mean 0%	SD 0%			

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC			Toxicology Data Management System Tumor Incidence for Selected Control Animal Groups Route: PERINATAL AND POSTNATAL GAVAGE Vehicle: METHYLCELLULOSE					Page: 178 Report Date: 11/07/2024 Female				
			Male		Cted Control Animal Groups Report Date: ID POSTNATAL GAVAGE Female Female 0/49 (0%) 0/50 (0%) % Total 0/99 (0%) Mean 0% % Total 0/49 (0%) 0/50 (0%) % Total 0/99 (0%) Mean 0% % Total 0/99 (0%) Mean 0%							
*Thymus: Thymoma Benign		0/40 (00/)	0/40 (0%)			0/40 (0%)	0/50 (0%)					
Overall Incidence	Total	0/46 (0%) 0/94 (0%)	0/48 (0%) Mean 0%	SD 0%		0/99 (0%)	Mean 0%	SD 0%				
*Thymus: Thymoma Malignant												
Overall Incidence	Total	0/46 (0%) 0/94 (0%)	0/48 (0%) Mean 0%	SD 0%	Total	()	()	SD 0%				
*Thymus: Thymoma: Benign, Maligna Overall Incidence	Total	0/46 (0%) 0/94 (0%)	0/48 (0%) Mean 0%	SD 0%		0/99 (0%)	Mean 0%	SD 0%				
Thyroid Gland: C-Cell: Adenoma												
Overall Incidence	Total	11/50 (22%) 19/100 (19%)	8/50 (16%) Mean 19%	SD 4.24%		25/100 (25%)	Mean 25%	SD 9.9%				
*Thyroid Gland: C-Cell: Carcinoma												
Overall Incidence	Total	1/50 (2%) 1/100 (1%)	0/50 (0%) Mean 1%	SD 1.41%	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%				
*Thyroid Gland: C-Cell: Carcinoma or Adenoma												
Overall Incidence	Total	11/50 (22%) 19/100 (19%)	8/50 (16%) Mean 19%	SD 4.24%	Total	9/50 (18%) 25/100 (25%)	16/50 (32%) Mean 25%	SD 9.9%				

*: Denominator is number of animals with tissues examined microscopically

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC	,		Tumor Inciden Route: PERI	logy Data Managemen nce for Selected Contro RINATAL AND POSTNA hicle: METHYLCELLU	rol Animal Groups IATAL GAVAGE		Page: 179 Report Date	te: 11/07/2024
			Male				Female	
*Thyroid Gland: Follicular Cel Adenoma	l:	0/50 (0%)	2/50 (4%)			0/50 (0%)	0/50 (0%)	
Overall Incidence	Total	2/100 (2%)	Mean 2%	SD 2.83%	Total	0/100 (0%)	Mean 0%	SD 0%
*Thyroid Gland: Follicular Cel Carcinoma								
Overall Incidence	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%
*Thyroid Gland: Follicular Cel Carcinoma or Adenoma								
Overall Incidence	Total	0/50 (0%) 2/100 (2%)	2/50 (4%) Mean 2%	SD 2.83%	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%
#Tissue NOS: Schwannoma Malignant		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/50 (0%)	
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%
#Tongue: Fibrosarcoma								
Overall Incidence	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%
#Tongue: Papilloma							2/50 /00/)	
Overall Incidence	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC			Tumor Inciden Route: PERI	ogy Data Managemo ce for Selected Cont NATAL AND POSTN iicle: METHYLCELLI	rol Animal Groups IATAL GAVAGE		Page: 180 Report Date: 11/07/2024				
			Male				Female				
#Tongue: Squamous Cell Carcinoma		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/50 (0%)				
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%			
#Tongue: Squamous Cell Carcinoma o	or Papillom	a Squamous 0/50 (0%)	0/50 (0%)			0/50 (0%)	0/50 (0%)				
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%			
#Tooth: Odontoma		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/50 (0%)				
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%			
*Urinary Bladder: Leiomyosarcoma		0/50 (0%)	0/50 (0%)			0/50 (0%)	0/49 (0%)				
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%	Total	0/99 (0%)	Mean 0%	SD 0%			
*Uterus: Adenocarcinoma											
Overall Incidence					Total	2/50 (4%) 4/100 (4%)	2/50 (4%) Mean 4%	SD 0%			
*Uterus: Adenocarcinoma or Adenon	na					0/50 (40/)					
Overall Incidence					Total	2/50 (4%) 6/100 (6%)	4/50 (8%) Mean 6%	SD 2.83%			
*: Denominator is number of animals	with tissues e	examined microscopically				·····					

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC	Toxicology Data Managemen Tumor Incidence for Selected Control Route: PERINATAL AND POSTNA Vehicle: METHYLCELLUL	Animal Groups TAL GAVAGE		Page: 181 Report Da	te: 11/07/2024
	Male			Female	
*Uterus: Adenoma			0/50 (0%)	2/50 (4%)	
Overall Incidence		Total	2/100 (2%)	Mean 2%	SD 2.83%
*Uterus: Adenoma, Adenocarcinoma, Sq Cell Carcinoma, or	Sq Cell Papilloma		4/50 (8%)	4/50 (8%)	
Overall Incidence		Total	8/100 (8%)	Mean 8%	SD 0%
*Uterus: Deciduoma Benign			0/50 (00/)		
Overall Incidence		Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%
*Uterus: Granular Cell Tumor Benign			0/50 (0%)	0/50 (00/.)	
Overall Incidence		Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%
*Uterus: Hemangioma					
Overall Incidence		Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%
*Uterus: Polyp Stromal					
Overall Incidence		Total	9/50 (18%) 11/100 (11%)	2/50 (4%) Mean 11%	SD 9.9%
*: Denominator is number of animals with tissues examined micro	oscopically				

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC	Toxicology Data Management System Tumor Incidence for Selected Control Animal Groups Route: PERINATAL AND POSTNATAL GAVAGE Vehicle: METHYLCELLULOSE	Tumor Incidence for Selected Control Animal Groups Route: PERINATAL AND POSTNATAL GAVAGE				
	Male		Female			
*Uterus: Sarcoma		0/50 (0%)	0/50 (0%)			
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%		
*Uterus: Sarcoma Stromal		- / /	- / //			
Overall Incidence	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%		
*Uterus: Sarcoma Stromal or Polyp Stromal		0/50 (40%/)	0/50 (484)			
Overall Incidence	Total	9/50 (18%) 11/100 (11%)	2/50 (4%) Mean 11%	SD 9.9%		
*Uterus: Schwannoma Malignant		0/50 (0%)	0/50 (0%)			
Overall Incidence	Total	0/100 (0%)	Mean 0%	SD 0%		
*Uterus: Sq Cell Carcinoma or Papilloma Squamous		2/50 (4%)	0/50 (0%)			
Overall Incidence	Total	2/50 (4%) 2/100 (2%)	0/50 (0%) Mean 2%	SD 2.83%		
*Uterus: Squamous Cell Carcinoma		1/50 (2%)	0/50 (0%)			
Overall Incidence	Total	1/100 (1%)	Mean 1%	SD 1.41%		
*: Denominator is number of animals with tissues examined micros	scopically					

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC			Toxicol Tumor Incider Route: PER Vel	Page: 183 Report Date: 11/07/2024				
			Male				Female	
*Uterus: Squamous Cell Papilloma								
Overall Incidence					Total	1/50 (2%) 1/100 (1%)	0/50 (0%) Mean 1%	SD 1.41%
¥Vagina: Granular Cell Tumor Benig	n							
Overall Incidence					Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%
#Vagina: Polyp								
Overall Incidence					Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%
¢Vagina: Sarcoma								
Overall Incidence					Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%
¢Vagina: Schwannoma Malignant								
Overall Incidence					Total	0/50 (0%) 1/100 (1%)	1/50 (2%) Mean 1%	SD 1.41%
≇Zymbal's Gland: Adenoma								
Overall Incidence	Total	1/50 (2%) 1/100 (1%)	0/50 (0%) Mean 1%	SD 1.41%	Total	0/50 (0%) 0/100 (0%)	0/50 (0%) Mean 0%	SD 0%

Version: Nov2024 Contract/Lab: All Laborate Species: RATS Strain: Harlan Sprague-Da Length of Study: CHRON	awley		Toxicol Tumor Incider Route: PER Vel	Page: 184 Report Date: 11/07/2024				
			Male				Female	
#Zymbal's Gland: Adenoma, Adenocarci	noma, Sq Cell Ca	rcinoma, or Sq Cell Papil 2/50 (4%)	loma 1/50 (2%)			0/50 (0%)	0/50 (0%)	
Overall Incidence	Total	3/100 (3%)	Mean 3%	SD 1.41%	Total	0/100 (0%)	Mean 0%	SD 0%
#Zymbal's Gland: Carcinoma								
Overall Incidence	Total	1/50 (2%)	1/50 (2%)	SD 0%	Total	0/50 (0%)	0/50 (0%)	SD 09/
Overall Incidence	Total	2/100 (2%)	Mean 2%	SD 0%	Total	0/100 (0%)	Mean 0%	SD 0%

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC

Toxicology Data Management System Tumor Incidence for Selected Control Animal Groups Route: Whole Body Exposure Vehicle: AIR

	Study Summary										
Laboratory Name	Study Number	Study Start Date	Length of Study in Days	Number of Animals Total and (#/Cage)	Number Surviving and (Mean Life Span)	Maximum Mean Weekly Body Weight	Chemical				
					Male						
I. I. T. Research Institute	052010556	09/16/12	730	90(1)	25(642)	658.1	Radiofrequency Radiation				
					Female						
I. I. T. Research Institute	052010556	09/16/12	737	90(1)	48(659)	462.4	Radiofrequency Radiation				

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC			Toxico Tumor Incider Re	Page: 186 Report Date	:: 11/07/2024			
			Male		Female			
#All Organs: Benign Tumors Overall Incidence	Total	49/90 (54%) 49/90 (54.44%)	Mean 54.44%	SD 0%	Total	82/90 (91%) 82/90 (91.11%)	Mean 91.11%	SD 0%
#All Organs: Malignant Tumors		24/90 (27%)				37/90 (41%)		
Overall Incidence	Total	24/90 (26.67%)	Mean 26.67%	SD 0%	Total	37/90 (41.11%)	Mean 41.11%	SD 0%
#All Organs: Malignant and Benign Tumc Overall Incidence	rs Total	57/90 (63%) 57/90 (63.33%)	Mean 63.33%	SD 0%	Total	89/90 (99%) 89/90 (98.89%)	Mean 98.89%	SD 0%
#All Organs: Hemangioma		0/90 (0%)				0/90 (0%)		
Overall Incidence	Total	0/90 (0%)	Mean 0%	SD 0%	Total	0/90 (0%)	Mean 0%	SD 0%
#All Organs: Hemangiosarcoma		3/90 (3%)				3/90 (3%)		
Overall Incidence	Total	3/90 (3.33%)	Mean 3.33%	SD 0%	Total	3/90 (3.33%)	Mean 3.33%	SD 0%
#All Organs: Hemangiosarcoma or Hema	ngioma	3/90 (3%)				3/90 (3%)		
Overall Incidence	Total	3/90 (3.33%)	Mean 3.33%	SD 0%	Total	3/90 (3.33%)	Mean 3.33%	SD 0%

0/90 I 0/90 (0%)	(0%)				Female	
al 0/90 (0%)	()					
	. ,			0/90 (0%)		
	Mean 0%	SD 0%	Total	0/90 (0%)	Mean 0%	SD 0%
0/00						
al 0/90 (0%)	(078) Mean 0%	SD 0%	Total	0/90 (0%)	Mean 0%	SD 0%
		SD 0%	Total	0/90 (0%) 0/90 (0%)	Mean 0%	SD 0%
, Lymphocytic, Mixed,	NOS, Large Granular, or					
	()	SD 0%	Total	5/90 (5.56%)	Mean 5.56%	SD 0%
3/00	(30/.)			4/90 (4%)		
al 3/90 (3.33%)	Mean 3.33%	SD 0%	Total	4/90 (4.44%)	Mean 4.44%	SD 0%
NOS						
	()	SD 0%	Total	0/90 (0%)	Mean 0%	SD 0%
	I 0/90 (0%) ic, Mononuclear, or Ul 0/90 I 0/90 (0%) Lymphocytic, Mixed, 2/90 I 2/90 (2.22%) 3/90 I 3/90 (3.33%) NOS 2/90 I 2/90 (2.22%)	II 0/90 (0%) Mean 0% ic, Mononuclear, or Undifferentiated 0/90 (0%) II 0/90 (0%) Mean 0% II 0/90 (0%) Mean 0% Lymphocytic, Mixed, NOS, Large Granular, or 2/90 (2%) II 2/90 (2.22%) Mean 2.22% NOS 2/90 (2%) II 3/90 (3.33%) Mean 3.33%	I 0/90 (0%) Mean 0% SD 0% ic, Mononuclear, or Undifferentiated 0/90 (0%) Mean 0% SD 0% il 0/90 (0%) Mean 0% SD 0% il 0/90 (0%) Mean 0% SD 0% il 0/90 (2%) Mean 2.22% SD 0% il 2/90 (2.22%) Mean 3.33% SD 0% NOS 2/90 (2.22%) Mean 2.22% SD 0%	II 0/90 (0%) Mean 0% SD 0% Total ic, Mononuclear, or Undifferentiated 0/90 (0%) Mean 0% SD 0% Total il 2/90 (2%) Mean 2.22% SD 0% Total il 3/90 (3%) Mean 3.33% SD 0% Total NOS 2/90 (2%) Mean 2.22% SD 0% Total	I $0/90 (0\%)$ Mean 0% SD 0% Total $0/90 (0\%)$ ic, Mononuclear, or Undifferentiated $0/90 (0\%)$ $0/90 (0\%)$ $0/90 (0\%)$ i $0/90 (0\%)$ Mean 0% SD 0% Total $0/90 (0\%)$ i. $0/90 (0\%)$ Mean 0% SD 0% Total $0/90 (0\%)$ i. $0/90 (0\%)$ Mean 2.22% SD 0% Total $5/90 (6\%)$ j. $2/90 (2.22\%)$ Mean 2.22% SD 0% Total $5/90 (4.44\%)$ i. $3/90 (3.33\%)$ Mean 3.33% SD 0% Total $4/90 (4.44\%)$ NOS $2/90 (2.22\%)$ Mean 2.22% SD 0% Total $0/90 (0\%)$ i. $2/90 (2.22\%)$ Mean 2.22% SD 0% Total $0/90 (0\%)$	I 0/90 (0%) Mean 0% SD 0% Total 0/90 (0%) Mean 0% ic, Mononuclear, or Undifferentiated 0/90 (0%) 0/90 (0%) 0/90 (0%) 0/90 (0%) Mean 0% i. 0/90 (0%) Mean 0% SD 0% Total 0/90 (0%) Mean 0% i. 0/90 (0%) Mean 0% SD 0% Total 0/90 (0%) Mean 0% i. 0/90 (0%) Mean 0% SD 0% Total 0/90 (0%) Mean 0% i. 2/90 (2%) Mean 2.22% SD 0% Total 5/90 (5.56%) Mean 5.56% i. 3/90 (3%) Mean 3.33% SD 0% Total 4/90 (4.44%) Mean 4.44% NOS 2/90 (2%) Mean 2.22% SD 0% 0/90 (0%) Mean 0% i. 2/90 (2%) Mean 2.22% SD 0% Total 0/90 (0%) Mean 0%

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC			Toxico Tumor Incider Ro	Page: 188 Report Date: 11/07/2024				
			Male	Female				
#All Organs: Mesothelioma: Malignant		2/90 (2%)				0/90 (0%)		
Overall Incidence	Total	2/90 (2.22%)	Mean 2.22%	SD 0%	Total	0/90 (0%)	Mean 0%	SD 0%
*Adrenal Cortex: Adenoma		1/90 (1%)				1/90 (1%)		
Overall Incidence	Total	1/90 (1.11%)	Mean 1.11%	SD 0%	Total	1/90 (1.11%)	Mean 1.11%	SD 0%
Adrenal Cortex: Carcinoma								
Overall Incidence	Total	0/90 (0%) 0/90 (0%)	Mean 0%	SD 0%	Total	1/90 (1%) 1/90 (1.11%)	Mean 1.11%	SD 0%
Adrenal Cortex: Carcinoma or Adenoma		1/90 (1%)				2/90 (2%)		
Overall Incidence	Total	1/90 (1.11%)	Mean 1.11%	SD 0%	Total	2/90 (2.22%)	Mean 2.22%	SD 0%
Adrenal Medulla: Ganglioneuroma								
Overall Incidence	Total	0/88 (0%) 0/88 (0%)	Mean 0%	SD 0%	Total	0/86 (0%) 0/86 (0%)	Mean 0%	SD 0%
Adrenal Medulla: Pheochromocytoma Benign		10/88 (11%)				1/86 (1%)		
Overall Incidence	Total	10/88 (11.36%)	Mean 11.36%	SD 0%	Total	1/86 (1.16%)	Mean 1.16%	SD 0%

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC			Toxico Tumor Incide Re	Page: 189 Report Date	ə: 11/07/2024									
			Male		Female									
*Adrenal Medulla: Pheochromocytoma Comple	Pheochromocytoma Complex 1/88 (1%) 0/86 (0%)													
Overall Incidence	Total	1/88 (1.14%)	Mean 1.14%	SD 0%	Total	0/86 (0%)	Mean 0%	SD 0%						
*Adrenal Medulla: Pheochromocytoma Malign		1/88 (1%)				0/86 (0%)								
Overall Incidence	Total	1/88 (1.14%)	Mean 1.14%	SD 0%	Total	0/86 (0%)	Mean 0%	SD 0%						
*Adrenal Medulla: Pheochromocytoma: Benig Overall Incidence			Mean 12.5%	SD 0%	Total	1/86 (1%) 1/86 (1.16%)	Mean 1.16%	SD 0%						
#Bone: Hemangiosarcoma Overall Incidence	Total	. ,	Mean 0%	SD 0%	Total		Mean 0%	SD 0%						
#Bone: Osteosarcoma		0/90 (0%)			lotai	0/90 (0%)								
Overall Incidence	Total	0/90 (0%)	Mean 0%	SD 0%	Total	0/90 (0%)	Mean 0%	SD 0%						
#Bone: Osteosarcoma or Osteoma		0/90 (0%)				0/90 (0%)								
Overall Incidence	Total	0/90 (0%)	Mean 0%	SD 0%	Total	0/90 (0%)	Mean 0%	SD 0%						

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC			Toxicology Data Management System Tumor Incidence for Selected Control Animal Groups Route: Whole Body Exposure Vehicle: AIR					Page: 190 Report Date: 11/07/2024		
			Male		Female					
*Brain: Astrocytoma	T - (-1	0/90 (0%)	M 00/	05.9%	T .(.)	0/90 (0%)	M 00/	25.0%		
Overall Incidence	Total	0/90 (0%)	Mean 0%	SD 0%	Total	0/90 (0%)	Mean 0%	SD 0%		
*Brain: Glioma		0/90 (0%)				0/90 (0%)				
Overall Incidence	Total	0/90 (0%)	Mean 0%	SD 0%	Total	0/90 (0%)	Mean 0%	SD 0%		
*Brain: Glioma Malignant Overall Incidence	Total	0/90 (0%) 0/90 (0%)	Mean 0%	SD 0%	Total	0/90 (0%) 0/90 (0%)	Mean 0%	SD 0%		
*Brain: Granular Cell Tumor Benign		1/90 (1%)				1/90 (1%)				
Overall Incidence	Total	1/90 (1.11%)	Mean 1.11%	SD 0%	Total	1/90 (1.11%)	Mean 1.11%	SD 0%		
*Brain: Granular Cell Tumor Maligna		0/90 (0%)				0/90 (0%)				
Overall Incidence	Total	0/90 (0%)	Mean 0%	SD 0%	Total	0/90 (0%)	Mean 0%	SD 0%		
*Brain: Meningioma Benign		0/90 (0%)				0/90 (0%)				
Overall Incidence	Total	0/90 (0%)	Mean 0%	SD 0%	Total	0/90 (0%)	Mean 0%	SD 0%		

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC			Toxic Tumor Incid I	Page: 191 Report Dat	e: 11/07/2024			
			Male		Female			
*Brain: Meningioma Malignant		0/90 (09	<i>2</i> ()			0/90 (0%)		
Overall Incidence	Total	0/90 (0%)	Mean 0%	SD 0%	Total	0/90 (0%)	Mean 0%	SD 0%
*Brain: Meningioma: Benign, Maligr								
Overall Incidence	Total	0/90 (09 0/90 (0%)	%) Mean 0%	SD 0%	Total	0/90 (0%) 0/90 (0%)	Mean 0%	SD 0%
*Brain: Oligodendroglioma Maligna		0/90 (09	,			0/90 (0%)		05 av
Overall Incidence	Total	0/90 (0%)	Mean 0%	SD 0%	Total	0/90 (0%)	Mean 0%	SD 0%
Brain: Oligodendroglioma, Glioma,	or Astrocy	toma 0/90 (09	%)			0/90 (0%)		
Overall Incidence	Total	0/90 (0%)	, Mean 0%	SD 0%	Total	0/90 (0%)	Mean 0%	SD 0%
*Brain: Schwannoma Malignant		0/90 (09				0/90 (0%)		
Overall Incidence	Total	0/90 (0%)	Mean 0%	SD 0%	Total	0/90 (0%)	Mean 0%	SD 0%
*Clitoral/Preputial Gland: Adenocarcinoma		0/88 (09				0/87 (0%)		
Overall Incidence	Total	0/88 (0%)	Mean 0%	SD 0%	Total	0/87 (0%)	Mean 0%	SD 0%

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC			Toxica Tumor Incide F		Page: 192 Report Date: 11/07/2024					
			Male		Female					
*Clitoral/Preputial Gland: Adenoma		0/88 (0%)					0/87 (0%)			
Overall Incidence	Total	0/88 (0%)	Mean 0%	SD 0%	Total	0/87 (0%)	Mean 0%	SD 0%		
*Clitoral/Preputial Gland: Adenoma or Adenocarcinon		0/88 (0%)				0/87 (0%)				
Overall Incidence	Total	0/88 (0%)	Mean 0%	SD 0%	Total	0/87 (0%)	Mean 0%	SD 0%		
*Clitoral/Preputial Gland: Squamous Cell Carcinoma Overall Incidence	Total	0/88 (0%) 0/88 (0%)	Mean 0%	SD 0%	Total	0/87 (0%) 0/87 (0%)	Mean 0%	SD 0%		
*Clitoral/Preputial Gland: Squamous Cell Papilloma Overall Incidence	Total	0/88 (0%) 0/88 (0%)	Mean 0%	SD 0%	Total	0/87 (0%) 0/87 (0%)	Mean 0%	SD 0%		
*Epididymis: Sarcoma Overall Incidence	Total	0/90 (0%) 0/90 (0%)	Mean 0%	SD 0%						
		. ,								
#Eye: Leiomyoma		0/90 (0%)				0/90 (0%)				
Overall Incidence	Total	0/90 (0%)	Mean 0%	SD 0%	Total	0/90 (0%)	Mean 0%	SD 0%		

Male Female #Harderian Gland: Schwannoma Malignant 0/90 (0%) 0/90 (0%) 0/90 (0%) Mean 0% 0/90 (0%) SD 0% 0/90 (0%) Total 0/90 (0%) 0/90 (0%) Mean 0% *Heart: Schwannoma Malignant 0/90 (0%) 0/90 (0%) Mean 0% SD 0% Total 0/90 (0%) 0/90 (0%) Mean 0% Overall Incidence Total 0/90 (0%) Mean 0% SD 0% Total 0/90 (0%) Mean 0% #Intestine Large: Cecum: Leiomyosarcoma 0/90 (0%) Mean 0% SD 0% Total 0/90 (0%) Mean 0% Wintestine Large: Cecum: Liposarcoma 0/90 (0%) Mean 0% SD 0% Total 0/90 (0%) Mean 0% Overall Incidence Total 0/90 (0%) Mean 0% SD 0% Total 0/90 (0%) Mean 0% Watestine Large: Cecum: Liposarcoma 0/90 (0%) Mean 0% SD 0% Total 0/90 (0%) Mean 0% Overall Incidence Total 0/90 (0%) Mean 0% SD 0% Total 0/90 (0%) Mean 0%	t e: 11/07/2024
Schwannoma Malignant O'90 (0%) Mean 0% SD 0% Total 0/90 (0%) Mean 0% *Heart: Schwannoma Malignant 0/90 (0%) Mean 0% SD 0% Total 0/90 0%) Mean 0% *Heart: Schwannoma Malignant 0/90 (0%) Mean 0% SD 0% Total 0/90 0%) Overall Incidence Total 0/90 (0%) Mean 0% SD 0% Total 0/90 0%) #Intestine Large: Cecum: U U Mean 0% SD 0% Total 0/90 0%) Mean 0% Overall Incidence Total 0/90 0(%) Mean 0% SD 0% Total 0/90 Mean 0% Overall Incidence Total 0/90 0(%) Mean 0% SD 0% Total 0/90 Mean 0% #Intestine Large: Cecum: U 0/90 0(%) Mean 0% SD 0% Total 0/90 Mean 0% 0/90 0/90 0(%)	
*Heart: 0/90 (0%) 0/90 (0%) 0/90 (0%) Overall Incidence Total 0/90 (0%) Mean 0% SD 0% Total 0/90 (0%) Mean 0% #Intestine Large: Cecum:	
Schwannoma Malignant 0/90 (0%) Mean 0% SD 0% Total 0/90 (0%) Mean 0% Overall Incidence Total 0/90 (0%) Mean 0% SD 0% Total 0/90 (0%) Mean 0% #Intestine Large: Cecum: Leiomyosarcoma 0/90 (0%) Mean 0% SD 0% Total 0/90 0%) Mean 0% Overall Incidence Total 0/90 (0%) Mean 0% SD 0% Total 0/90 0%) Mean 0% #Intestine Large: Cecum: Liposarcoma 0/90 (0%) Mean 0% SD 0% Total 0/90 0%) Mean 0% Overall Incidence Total 0/90 (0%) Mean 0% SD 0% Total 0/90 0%) Mean 0% Mean 0% SD 0% Total 0/90 0%) Mean 0% Mean 0% SD 0% Total 0/90 Mean 0% #Intestine Large: Colon/Rectum: U U U U U U U <	SD 0%
#Intestine Large: Cecum: Leiomyosarcoma 0/90 (0%) 0/90 (0%) 0/90 (0%) Overall Incidence Total 0/90 (0%) Mean 0% SD 0% Total 0/90 (0%) Mean 0% #Intestine Large: Cecum: Liposarcoma 0/90 (0%) Mean 0% SD 0% Total 0/90 (0%) Mean 0% Overall Incidence Total 0/90 (0%) Mean 0% SD 0% Total 0/90 (0%) Overall Incidence Total 0/90 (0%) Mean 0% SD 0% Total 0/90 (0%) #Intestine Large: Colon/Rectum: U U U U U U	
#Intestine Large: Cecum: Leiomyosarcoma 0/90 (0%) 0/90 (0%) 0/90 (0%) Overall Incidence Total 0/90 (0%) Mean 0% SD 0% Total 0/90 (0%) Mean 0% #Intestine Large: Cecum: Liposarcoma 0/90 (0%) Mean 0% SD 0% Total 0/90 (0%) Mean 0% Overall Incidence Total 0/90 (0%) Mean 0% SD 0% Total 0/90 (0%) Mean 0% #Intestine Large: Colon/Rectum: 10/90 (0%) Mean 0% SD 0% Total 0/90 (0%) Mean 0%	SD 0%
#Intestine Large: Cecum: Liposarcoma 0/90 (0%) 0/90 (0%) Overall Incidence Total 0/90 (0%) Mean 0% SD 0% Total 0/90 (0%) Mean 0% #Intestine Large: Colon/Rectum: Image: Colon/Rec	SD 0%
#Intestine Large: Colon/Rectum:	SD 0%
	SD 0%
Granular Cell Tumor Benign 0/90 (0%) 1/90 (1%)	
Overall Incidence Total 0/90 (0%) Mean 0% SD 0% Total 1/90 (1.11%) Mean 1.11%	SD 0%
#Intestine Large: Colon/Rectum: Leiomyoma 0/90 (0%) 0/90 (0%)	
Overall Incidence Total 0/90 (0%) Mean 0% SD 0% Total 0/90 (0%) Mean 0%	SD 0%

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC			Tumor Incider	logy Data Manageme nce for Selected Contr oute: Whole Body Exp Vehicle: AIR	ol Animal Groups		Page: 194 Report Date	e: 11/07/2024
			Male				Female	
#Intestine Small: Any Site: Adenocarcinoma								
		2/90 (2%)				0/90 (0%)		
Overall Incidence	Total	2/90 (2.22%)	Mean 2.22%	SD 0%	Total	0/90 (0%)	Mean 0%	SD 0%
#Intestine Small: Any Site: Adenoma or Adenocarcinon		2/90 (2%)				0/90 (0%)		
Overall Incidence	Total	2/90 (2.22%)	Mean 2.22%	SD 0%	Total	0/90 (0%)	Mean 0%	SD 0%
#Intestine Small: Any Site: Leiomyosarcoma								
Overall Incidence	Total	0/90 (0%) 0/90 (0%)	Mean 0%	SD 0%	Total	1/90 (1%) 1/90 (1.11%)	Mean 1.11%	SD 0%
#Intestine Small: Any Site: Leiomyosarcoma or Leiomy		0/90 (0%)				1/90 (1%)		
Overall Incidence	Total	0/90 (0%)	Mean 0%	SD 0%	Total	1/90 (1.11%)	Mean 1.11%	SD 0%
#Intestine Small: Jejunum: Adenocarcinoma								
Overall Incidence	Total	2/90 (2%) 2/90 (2.22%)	Mean 2.22%	SD 0%	Total	0/90 (0%) 0/90 (0%)	Mean 0%	SD 0%
#Intestine Small: Jejunum: Leiomyoma		. ,				0/90 (0%)		
Overall Incidence	Total	0/90 (0%)	Mean 0%	SD 0%	Total	0/90 (0%)	Mean 0%	SD 0%

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC			Tumor Incider	logy Data Manageme nce for Selected Contr oute: Whole Body Exp Vehicle: AIR	ol Animal Groups		Page: 195 Report Date	e: 11/07/2024
			Male		Female			
#Intestine Small: Jejunum: Leiomyosarcoma								
Overall Incidence	Total	0/90 (0%) 0/90 (0%)	Mean 0%	SD 0%	Total	1/90 (1%) 1/90 (1.11%)	Mean 1.11%	SD 0%
*Islets, Pancreatic: Adenoma						_/ /		
Overall Incidence	Total	5/90 (6%) 5/90 (5.56%)	Mean 5.56%	SD 0%	Total	5/90 (6%) 5/90 (5.56%)	Mean 5.56%	SD 0%
*Islets, Pancreatic: Carcinoma		8/90 (9%)				2/90 (2%)		
Overall Incidence	Total	8/90 (8.89%)	Mean 8.89%	SD 0%	Total	2/90 (2.22%)	Mean 2.22%	SD 0%
*Islets, Pancreatic: Carcinoma or Adenoma		13/90 (14%)				7/90 (8%)		
Overall Incidence	Total	13/90 (14.44%)	Mean 14.44%	SD 0%	Total	7/90 (7.78%)	Mean 7.78%	SD 0%
*Kidney: Pelvis and Urotheliur Papilloma		0/90 (0%)				0/90 (0%)		
Overall Incidence	Total	0/90 (0%)	Mean 0%	SD 0%	Total	0/90 (0%)	Mean 0%	SD 0%
*Kidney: Renal Tubule: Adenoma		3/90 (3%)				1/90 (1%)		
Overall Incidence	Total	3/90 (3.33%)	Mean 3.33%	SD 0%	Total	1/90 (1.11%)	Mean 1.11%	SD 0%

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC			Tumor Incider	logy Data Manageme nce for Selected Contr oute: Whole Body Exp Vehicle: AIR	ol Animal Groups		Page: 196 Report Date	e: 11/07/2024
			Male				Female	
*Kidney: Renal Tubule: Carcinoma Overall Incidence	Total	1/90 (1%) 1/90 (1.11%)	Mean 1.11%	SD 0%	Total	1/90 (1%) 1/90 (1.11%)	Mean 1.11%	SD 0%
		(/				1/90 (1.11%)		JU U%
*Kidney: Renal Tubule: Carcinoma or Adenoma		3/90 (3%)				2/90 (2%)		
Overall Incidence	Total	3/90 (3.33%)	Mean 3.33%	SD 0%	Total	2/90 (2.22%)	Mean 2.22%	SD 0%
*Kidney: Renal Tubule: Hemangioma Overall Incidence	Total	0/90 (0%) 0/90 (0%)	Mean 0%	SD 0%	Total	0/90 (0%) 0/90 (0%)	Mean 0%	SD 0%
		, ,				. ,		
*Kidney: Renal Tubule: Lipoma		1/90 (1%)				0/90 (0%)		
Overall Incidence	Total	1/90 (1.11%)	Mean 1.11%	SD 0%	Total	0/90 (0%)	Mean 0%	SD 0%
*Kidney: Renal Tubule: Liposarcoma		0/90 (0%)				0/90 (0%)		
Overall Incidence	Total	0/90 (0%)	Mean 0%	SD 0%	Total	0/90 (0%)	Mean 0%	SD 0%
*Kidney: Renal Tubule: Oncocytoma Benign		1/90 (1%)				0/90 (0%)		
Overall Incidence	Total	1/90 (1.11%)	Mean 1.11%	SD 0%	Total	0/90 (0%)	Mean 0%	SD 0%

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC			Tumor Incide	ology Data Manageme ence for Selected Contr Route: Whole Body Exp Vehicle: AIR	ol Animal Groups		Page: 197 Report Date	e: 11/07/2024	
			Male			Female			
*Kidney: Renal Tubule: Polyp Adenomatous		0/90 (0%)				0/90 (0%)			
Overall Incidence	Total	0/90 (0%)	Mean 0%	SD 0%	Total	0/90 (0%)	Mean 0%	SD 0%	
#Lacrimal Gland: Carcinoma		0/90 (0%)				0/90 (0%)			
Overall Incidence	Total	0/90 (0%)	Mean 0%	SD 0%	Total	0/90 (0%)	Mean 0%	SD 0%	
*Liver: Cholangioma Overall Incidence	Total	0/90 (0%) 0/90 (0%)	Mean 0%	SD 0%	Total	0/90 (0%) 0/90 (0%)	Mean 0%	SD 0%	
*Liver: Hemangioma	T 1	0/90 (0%)	M 0%	05.0%	T 1	0/90 (0%)	M 00/	05.0%	
Overall Incidence	Total	0/90 (0%)	Mean 0%	SD 0%	Total	0/90 (0%)	Mean 0%	SD 0%	
*Liver: Hepatocellular Adenoma		0/90 (0%)				7/90 (8%)			
Overall Incidence	Total	0/90 (0%)	Mean 0%	SD 0%	Total	7/90 (7.78%)	Mean 7.78%	SD 0%	
*Liver: Hepatocellular Carcinoma		0/90 (0%)				0/90 (0%)			
Overall Incidence	Total	0/90 (0%)	Mean 0%	SD 0%	Total	0/90 (0%)	Mean 0%	SD 0%	

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC			Tumor Incide	logy Data Manageme nce for Selected Contr oute: Whole Body Exp Vehicle: AIR	ol Animal Groups		Page: 198 Report Date	e: 11/07/2024
			Male				Female	
*Liver: Hepatocellular Carcinoma o	or Hepatobla	astoma 0/90 (0%)				0/90 (0%)		
Overall Incidence	Total	0/90 (0%)	Mean 0%	SD 0%	Total	0/90 (0%)	Mean 0%	SD 0%
'Liver: Hepatocellular Carcinoma o		Ilular Adenoma 0/90 (0%)				7/90 (8%)		
Overall Incidence	Total	0/90 (0%)	Mean 0%	SD 0%	Total	7/90 (7.78%)	Mean 7.78%	SD 0%
'Liver: Hepatocellular Carcinoma, I Dverall Incidence	Hepatocellu Total	llar Adenoma, or Hepatol 0/90 (0%) 0/90 (0%)	b lastoma Mean 0%	SD 0%	Total	7/90 (8%) 7/90 (7.78%)	Mean 7.78%	SD 0%
Lung: Alveolar/Bronchiolar Adeno		4/00 (49/)						
Overall Incidence	Total	1/90 (1%) 1/90 (1.11%)	Mean 1.11%	SD 0%	Total	0/90 (0%) 0/90 (0%)	Mean 0%	SD 0%
Lung: Alveolar/Bronchiolar Carcin	noma	0/90 (0%)				0/90 (0%)		
Overall Incidence	Total	0/90 (0%)	Mean 0%	SD 0%	Total	0/90 (0%)	Mean 0%	SD 0%
Lung: Alveolar/Bronchiolar Carcin						0/90 (0%)		
Overall Incidence	Total	1/90 (1.11%)	Mean 1.11%	SD 0%	Total	0/90 (0%)	Mean 0%	SD 0%
*: Denominator is number of animals	s with tissues e	examined microscopically						

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC			Tumor Incide	nce for Selected Contr oute: Whole Body Exp Vehicle: AIR	ol Animal Groups		Page: 199 Report Date	e: 11/07/2024
			Male				Female	
#Lymph Node, Mesenteric: Hemangiosarcoma		0/90 (0%)				0/90 (0%)		
Overall Incidence	Total	0/90 (0%)	Mean 0%	SD 0%	Total	0/90 (0%)	Mean 0%	SD 0%
#Mammary Gland: Adenocarcinoma		0/90 (0%)				10/90 (11%)		
Overall Incidence	Total	0/90 (0%)	Mean 0%	SD 0%	Total	10/90 (11.11%)	Mean 11.11%	SD 0%
#Mammary Gland: Adenolipoma Overall Incidence		0/90 (0%)		SD 0%		0/90 (0%)	Moon 00/	SD 0%
	Total	0/90 (0%)	Mean 0%		Total	0/90 (0%)	Mean 0%	SD 0%
#Mammary Gland: Adenoma		0/90 (0%)				8/90 (9%)		
Overall Incidence	Total	0/90 (0%)	Mean 0%	SD 0%	Total	8/90 (8.89%)	Mean 8.89%	SD 0%
#Mammary Gland: Adenoma or Adenocarcinon		0/90 (0%)				16/90 (18%)		
Overall Incidence	Total	0/90 (0%)	Mean 0%	SD 0%	Total	16/90 (17.78%)	Mean 17.78%	SD 0%
#Mammary Gland: Fibroadenoma		2/90 (2%)				63/90 (70%)		
Overall Incidence	Total	2/90 (2.22%)	Mean 2.22%	SD 0%	Total	63/90 (70%)	Mean 70%	SD 0%

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC			Tumor Incide	logy Data Manageme nce for Selected Contr oute: Whole Body Exp Vehicle: AIR	ol Animal Groups		Page: 200 Report Date	e: 11/07/2024
			Male				Female	
#Mammary Gland: Fibroma		0/00 (0%)				0/00 (00/)		
Overall Incidence	Total	0/90 (0%) 0/90 (0%)	Mean 0%	SD 0%	Total	0/90 (0%) 0/90 (0%)	Mean 0%	SD 0%
#Mammary Gland: Fibroma, Fibroadenoma or /		2/90 (2%)				64/90 (71%)		
Overall Incidence	Total	2/90 (2.22%)	Mean 2.22%	SD 0%	Total	64/90 (71.11%)	Mean 71.11%	SD 0%
#Mammary Gland: Fibroma, Fibroadenoma, Ad Overall Incidence			Mean 2.22%	SD 0%	Total	66/90 (73%) 66/90 (73.33%)	Mean 73.33%	SD 0%
#Nerve Trigeminal: Schwannoma Malignant		0/90 (0%)				0/90 (0%)		
Overall Incidence	Total	0/90 (0%)	Mean 0%	SD 0%	Total	0/90 (0%)	Mean 0%	SD 0%
#Oral Mucosa: Squamous Cell Carcinoma		0/90 (0%)				1/90 (1%)		
Overall Incidence	Total	0/90 (0%)	Mean 0%	SD 0%	Total	1/90 (1.11%)	Mean 1.11%	SD 0%
#Oral Mucosa, Tongue, Phary Squamous Cell Carcinoma						2/90 (2%)		
Overall Incidence	Total	0/90 (0%)	Mean 0%	SD 0%	Total	2/90 (2.22%)	Mean 2.22%	SD 0%

Version: Nov2024 Contract/Lab: All Laborator Species: RATS Strain: Harlan Sprague-Day Length of Study: CHRONI	wley		Tumor Incide	ology Data Manageme ence for Selected Contr coute: Whole Body Exp Vehicle: AIR	ol Animal Groups		Page: 201 Report Date	e: 11/07/2024
			Male				Female	
#Oral Mucosa, Tongue, Ph Squamous Cell Carcino		quamous, or Papilloma				0/00 (00/)		
Overall Incidence	Total	0/90 (0%) 0/90 (0%)	Mean 0%	SD 0%	Total	2/90 (2%) 2/90 (2.22%)	Mean 2.22%	SD 0%
*Ovary: Adenocarcinoma, Cysta		·····						
Overall Incidence					Total	1/90 (1%) 1/90 (1.11%)	Mean 1.11%	SD 0%
*Ovary: Adenoma								
Overall Incidence					Total	0/90 (0%) 0/90 (0%)	Mean 0%	SD 0%
*Ovary: Cystadenoma						4/00 (40())		
Overall Incidence					Total	1/90 (1%) 1/90 (1.11%)	Mean 1.11%	SD 0%
*Ovary: Cystadenoma or Cystad	lenocarcinoma							
Overall Incidence					Total	1/90 (1%) 1/90 (1.11%)	Mean 1.11%	SD 0%
[*] Ovary: Granulosa-Theca Tumo	r Benian							
						0/90 (0%)		
Overall Incidence					Total	0/90 (0%)	Mean 0%	SD 0%
*: Denominator is number of ani #: Denominator is number of an		xamined microscopically						

Version: Nov2024 Contract/Lab: All Laboratories 7 Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC	Toxicology Data Management System Tumor Incidence for Selected Control Animal Groups Route: Whole Body Exposure Vehicle: AIR	Page: 202 Report Dat	e: 11/07/2024			
	Male		Female			
*Ovary:						
Granulosa-Theca Tumor Malignant		0/00 (00/)				
Overall Incidence	Total	0/90 (0%) 0/90 (0%)	Mean 0%	SD 0%		
*Ovary: Cranulass Coll Tumer Benian						
Granulosa Cell Tumor Benign		1/90 (1%)				
Overall Incidence	Total	1/90 (1.11%)	Mean 1.11%	SD 0%		
'Ovary:						
Granulosa Cell Tumor Malignant						
Overall Incidence	Total	2/90 (2%) 2/90 (2.22%)	Mean 2.22%	SD 0%		
	TULAI	2/90 (2.22/0)	Wiedi1 2.2270			
*Ovary:						
Granulosa Cell Tumor, Luteoma, Thecoma, or Sertoli Cell Tumor (Benign	n, Malignant, NOS)					
		4/90 (4%)		OD 00/		
Overall Incidence	Total	4/90 (4.44%)	Mean 4.44%	SD 0%		
*Ovary:						
Granulosa Cell Tumor: Benign, Malignant, NOS						
		3/90 (3%)				
Overall Incidence	Total	3/90 (3.33%)	Mean 3.33%	SD 0%		
Ovary:						
Luteoma						
		0/90 (0%)				
Dverall Incidence	Total	0/90 (0%)	Mean 0%	SD 0%		
: Denominator is number of animals with tissues examined microscopically						
Denominator is number of animals necronsied						

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC	,		Tumor Incide	logy Data Management ince for Selected Cont oute: Whole Body Exp Vehicle: AIR	ol Animal Groups		Page: 203 Report Date	e: 11/07/2024
			Male				Female	
*Ovary: Schwannoma Malignant								
Overall Incidence					Total	0/90 (0%) 0/90 (0%)	Mean 0%	SD 0%
*Ovary: Sertoli Cell Tumor Benign						1/90 (1%)		
Overall Incidence					Total	1/90 (1.11%)	Mean 1.11%	SD 0%
*Ovary: Thecoma Benign								
Overall Incidence					Total	0/90 (0%) 0/90 (0%)	Mean 0%	SD 0%
*Pancreas: Adenocarcinoma		1/90 (1%)				0/90 (0%)		
Overall Incidence	Total	1/90 (1.11%)	Mean 1.11%	SD 0%	Total	0/90 (0%)	Mean 0%	SD 0%
*Pancreas: Adenoma								
Overall Incidence	Total	18/90 (20%) 18/90 (20%)	Mean 20%	SD 0%	Total	0/90 (0%) 0/90 (0%)	Mean 0%	SD 0%
*Pancreas: Adenoma or Adenocarcino	ma	18/90 (20%)				0/90 (0%)		
Overall Incidence	Total	18/90 (20%)	Mean 20%	SD 0%	Total	0/90 (0%)	Mean 0%	SD 0%

				Vehicle: AIR	oosure			
			Male				Female	
*Parathyroid Gland: Adenoma		1/83 (1%)				0/87 (0%)		
Overall Incidence To	otal	1/83 (1.2%)	Mean 1.2%	SD 0%	Total	0/87 (0%)	Mean 0%	SD 0%
#Peripheral Nerve: Paraganglioma		0/90 (0%)				0/90 (0%)		
	otal	0/90 (0%)	Mean 0%	SD 0%	Total	0/90 (0%)	Mean 0%	SD 0%
#Peripheral Nerve: Schwannoma Malignant Overall Incidence To	otal	0/90 (0%) 0/90 (0%)	Mean 0%	SD 0%	Total	0/90 (0%) 0/90 (0%)	Mean 0%	SD 0%
#Pharynx: Squamous Cell Carcinoma	otal	0/90 (0%)	Mean 0%			0/90 (0%)	Mean 0%	SD 0%
		0/90 (0%)				0/90 (0%)	Mean 0%	50 0%
*Pituitary Gland: Pars Distalis or U Adenoma	Unspecif					40/00 (40%)		
Overall Incidence To	otal	17/89 (19%) 17/89 (19.1%)	Mean 19.1%	SD 0%	Total	43/90 (48%) 43/90 (47.78%)	Mean 47.78%	SD 0%
*Pituitary Gland: Pars Distalis or U Carcinoma						1/90 (1%)		
Overall Incidence To	otal	0/89 (0%)	Mean 0%	SD 0%	Total	1/90 (1.11%)	Mean 1.11%	SD 0%

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC	/		Toxico Tumor Incide Ro		Page: 205 Report Date: 11/07/2024			
			Male				Female 5) Mean 48.89% SD 0% 5) Mean 0% SD 0%	
*Pituitary Gland: Pars Distali Carcinoma or Adenoma	s or Unspec	ified Site: 17/89 (19%)				44/90 (49%)		
Overall Incidence	Total	17/89 (19.1%)	Mean 19.1%	SD 0%	Total	44/90 (48.89%)		
*Pituitary Gland: Pars Distalis Schwannoma Malignant						0/90 (0%)		
Overall Incidence	Total	0/89 (0%)	Mean 0%	SD 0%	Total	0/90 (0%)	Mean 0%	SD 0%
*Pituitary Gland: Pars Intermo Adenoma		0/89 (0%)				0/90 (0%)		
Overall Incidence	Total	0/89 (0%)	Mean 0%	SD 0%	Total	0/90 (0%)	Mean 0%	SD 0%
Pituitary Gland: Pars Interm Carcinoma or Adenoma		0/89 (0%)				0/90 (0%)		
Overall Incidence	Total	0/89 (0%)	Mean 0%	SD 0%	Total	0/90 (0%)	Mean 0%	SD 0%
*Pituitary Gland: Pars Nervos Schwannoma Malignant						0/00 (0%)		
Overall Incidence	Total	0/89 (0%) 0/89 (0%)	Mean 0%	SD 0%	Total	0/90 (0%) 0/90 (0%)	Mean 0%	SD 0%
*Prostate: Adenoma								
Overall Incidence	Total	2/90 (2%) 2/90 (2.22%)	Mean 2.22%	SD 0%				

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC	ey Vehicle: AIR							Page: 206 Report Date: 11/07/2024		
			Male				Female			
*Prostate: Adenoma or Adenocarcinon		2/90 (2%)	Maga 0.00%							
Overall Incidence	Total	2/90 (2.22%)	Mean 2.22%	SD 0%						
*Salivary Glands: Schwannoma Malignant	Tatal	0/90 (0%)	Maaa 00/		Tatal	0/90 (0%)	Maara 00/			
Overall Incidence	Total	0/90 (0%)	Mean 0%	SD 0%	Total	0/90 (0%)	Mean 0%	SD 0%		
#Seminal Vesicle: Hemangiosarcoma Overall Incidence	Total	0/90 (0%) 0/90 (0%)	Mean 0%	SD 0%						
#Skeletal Muscle: Fibrosarcoma		0/90 (0%)				0/90 (0%)				
Overall Incidence	Total	0/90 (0%)	Mean 0%	SD 0%	Total	0/90 (0%)	Mean 0%	SD 0%		
#Skeletal Muscle: Hemangioma		0/90 (0%)				0/90 (0%)				
Overall Incidence	Total	0/90 (0%)	Mean 0%	SD 0%	Total	0/90 (0%)	Mean 0%	SD 0%		
#Skeletal Muscle: Hemangiosarcoma		0/90 (0%)				0/90 (0%)				
Overall Incidence	Total	0/90 (0%)	Mean 0%	SD 0%	Total	0/90 (0%)	Mean 0%	SD 0%		

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC			Tumor Incide	logy Data Manageme nce for Selected Contr oute: Whole Body Exp Vehicle: AIR	ol Animal Groups		Page: 207 Report Dat	ate: 11/07/2024 SD 0% SD 0%			
			Male				Female	Female Mean 0% SD 0% Mean 0% SD 0%			
#Skeletal Muscle: Liposarcoma		0/90 (0%)			bected Control Animal Groups Report Date: 11/07/2 e Body Exposure icle: AIR Female Female 0% Total 0/90 (0%) 0% Total 0/90 (0%)						
Overall Incidence	Total	0/90 (0%)	Mean 0%	SD 0%	Total	()	Mean 0%	SD 0%			
/Skeletal Muscle: Sarcoma		0/00 /000/				a/aa /22/)					
Overall Incidence	Total	0/90 (0%) 0/90 (0%)	Mean 0%	SD 0%		0/90 (0%)					
Skin: Basal Cell Adenoma		1/90 (1%)									
Overall Incidence	Total	1/90 (1.11%)	Mean 1.11%	SD 0%		0/90 (0%)					
Skin: Basal Cell Carcinoma		0/90 (0%)									
Overall Incidence	Total	0/90 (0%)	Mean 0%	SD 0%		0/90 (0%)					
έSkin: Basal or Squamous Cell Carα Adenoma, Papilloma, Sq Pap Carcinoma, Sebaceous Glan	cinoma, Ba billoma, Ker	sosquamous Tumor (Ma ratoacanthoma, Trichoe	alignant or Benign), E pithelioma, Adenoma	asal Cell							
Overall Incidence	Total	9/90 (10%)	Mean 10%	SD 0%							
Skin: Basal or Squamous Cell Caro Adenocarcinoma		sosquamous Tumor (Ma									
Overall Incidence	Total	0/90 (0%) 0/90 (0%)	Mean 0%	SD 0%	Total	0/90 (0%)	Mean 0%	SD 0%			

/ersion: Nov2024 Contract/Lab: All Laboratorie Species: RATS Strain: Harlan Sprague-Dawle Length of Study: CHRONIC	-		Page: 208 Report Date: 11/07/2024								
			Male				Female				
#Skin: Basosquamous Tumor (Benign), Basal Cell Adenoma, Adenoma, Papilloma, Sq Papilloma, Keratoacanthoma, Trichoepithelioma, or Sebaceous Gland Adenoma 9/90 (10%) 0/90 (0%)											
Overall Incidence	Total	9/90 (10%)	Mean 10%	SD 0%	Total	0/90 (0%)	Mean 0%	SD 0%			
∜Skin: Fibroma											
Overall Incidence	Total	2/90 (2.22%)	Mean 2.22%	SD 0%	Total	2/90 (2%) 2/90 (2.22%)	Mean 2.22%	SD 0%			
Skin: Fibroma or Myxoma						0/00 /00/)					
Overall Incidence	Total	2/90 (2%) 2/90 (2.22%)	Mean 2.22%	SD 0%	Total	2/90 (2%) 2/90 (2.22%)	Mean 2.22%	SD 0%			
Skin: Fibroma, Fibrosarcoma, S		oma, Myxosarcoma, or F 5/90 (6%)		coma		5/90 (6%)					
Overall Incidence	Total	5/90 (5.56%)	Mean 5.56%	SD 0%	Total	5/90 (5.56%)	Mean 5.56%	SD 0%			
Skin: Fibroma, Fibrosarcoma, S Hemangiopericytoma											
Overall Incidence	Total	5/90 (6%) 5/90 (5.56%)	Mean 5.56%	SD 0%	Total	5/90 (6%) 5/90 (5.56%)	Mean 5.56%	SD 0%			
Skin: Fibrosarcoma											
		1/30 (1%)									

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC			Page: 209 Report Date: 11/07/2024							
			Male				Female			
#Skin: Fibrosarcoma, Sarcoma, Myxosarcoma, or Pleomorphic Fibrosarcoma 3/90 (3%) 3/90 (3%)										
Overall Incidence	Total	3/90 (3.33%)	Mean 3.33%	SD 0%	Total	3/90 (3.33%)	Mean 3.33%	SD 0%		
#Skin: Hemangioma		0/90 (0%)				0/90 (0%)				
Overall Incidence	Total	0/90 (0%)	Mean 0%	SD 0%	Total	0/90 (0%)	Mean 0%	SD 0%		
#Skin: Hemangiopericytoma Overall Incidence	Total	0/90 (0%) 0/90 (0%)	Mean 0%	SD 0%	Total	0/90 (0%) 0/90 (0%)	Mean 0%	SD 0%		
έSkin: Keratoacanthoma		5/90 (6%)				0/90 (0%)				
Overall Incidence	Total	5/90 (5.56%)	Mean 5.56%	SD 0%	Total	0/90 (0%)	Mean 0%	SD 0%		
έSkin: Lipoma		2/90 (2%)				0/90 (0%)				
Overall Incidence	Total	2/90 (2.22%)	Mean 2.22%	SD 0%	Total	0/90 (0%)	Mean 0%	SD 0%		
≭Skin: Liposarcoma		0/90 (0%)				0/90 (0%)				
Overall Incidence	Total	0/90 (0%)	Mean 0%	SD 0%	Total	0/90 (0%)	Mean 0%	SD 0%		

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC			Toxica Tumor Incide F	Page: 210 Report Date: 11/07/2024				
			Male				Female	
#Skin: Neurofibrosarcoma or Schw	annoma (m	alignant or NOS) 0/90 (0%)				0/90 (0%)		
Overall Incidence	Total	0/90 (0%)	Mean 0%	SD 0%	Total	0/90 (0%)	Mean 0%	SD 0%
#Skin: Neurofibrosarcoma, Neurof						0/90 (0%)		
Overall Incidence	Total	0/90 (0%)	Mean 0%	SD 0%	Total	0/90 (0%)	Mean 0%	SD 0%
#Skin: Osteosarcoma Overall Incidence	Total	0/90 (0%) 0/90 (0%)	Mean 0%	SD 0%	Total	0/90 (0%) 0/90 (0%)	Mean 0%	SD 0%
έSkin: Papilloma		0/90 (0%)				0/90 (0%)		
Overall Incidence	Total	0/90 (0%)	Mean 0%	SD 0%	Total	0/90 (0%)	Mean 0%	SD 0%
#Skin: Pilomatrixoma		0/90 (0%)				0/90 (0%)		
Overall Incidence	Total	0/90 (0%)	Mean 0%	SD 0%	Total	0/90 (0%)	Mean 0%	SD 0%
#Skin: Pleomorphic Fibrosarcoma		0/90 (0%)				1/90 (1%)		
Overall Incidence	Total	0/90 (0%)	Mean 0%	SD 0%	Total	1/90 (1.11%)	Mean 1.11%	SD 0%

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC			Tumor Incide	logy Data Manageme nce for Selected Contr oute: Whole Body Exp Vehicle: AIR	ol Animal Groups		Page: 211 Report Date: 11/07/2024 Female Mean 2.22% SD 0%				
			Male				Female				
#Skin: Sarcoma		2/90 (2%)				2/90 (2%)					
Overall Incidence	Total	2/90 (2.22%)	Mean 2.22%	SD 0%	Total	2/90 (2.22%)	Mean 2.22%	SD 0%			
#Skin: Schwannoma Malignant						0/00 /00/)					
Overall Incidence	Total	0/90 (0%) 0/90 (0%)	Mean 0%	SD 0%	Total	0/90 (0%) 0/90 (0%)	Mean 0%	SD 0%			
#Skin: Squamous Cell Carcinoma		0/90 (0%)				0/90 (0%)					
Overall Incidence	Total	0/90 (0%)	Mean 0%	SD 0%	Total	0/90 (0%)	Mean 0%	SD 0%			
#Skin: Squamous Cell Carcinoma, I or Carcinoma	Basal Cell	Carcinoma, Basosquamo 0/90 (0%)	ous Tumor (malignan	t or NOS),		0/90 (0%)					
Overall Incidence	Total	0/90 (0%)	Mean 0%	SD 0%	Total	0/90 (0%)	Mean 0%	SD 0%			
#Skin: Squamous Cell Papilloma		2/90 (2%)				0/90 (0%)					
Overall Incidence	Total	2/90 (2.22%)	Mean 2.22%	SD 0%	Total	0/90 (0%)	Mean 0%	SD 0%			
#Skin: Squamous Cell Papilloma or		l									
Overall Incidence	Total	2/90 (2%) 2/90 (2.22%)	Mean 2.22%	SD 0%	Total	0/90 (0%) 0/90 (0%)	Mean 0%	SD 0%			
*: Denominator is number of animals		examined microscopically									

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC			Tumor Incider	logy Data Manageme nce for Selected Contr oute: Whole Body Exp Vehicle: AIR	ol Animal Groups		e: 11/07/2024				
			Male				Mean 0% SD 0%) Mean 0% SD 0%) Mean 0% SD 0%				
#Skin: Squamous Cell Papilloma, F	apilloma, c	r Keratoacanthoma 7/90 (8%)				0/90 (0%)					
Overall Incidence	Total	7/90 (7.78%)	Mean 7.78%	SD 0%	Total	0/90 (0%)					
#Skin: Squamous Cell Papilloma, F		quamous Cell Carcinom 7/90 (8%)				0/90 (0%)					
Overall Incidence	Total	7/90 (7.78%)	Mean 7.78%	SD 0%	Total	0/90 (0%)	Mean 0%	SD 0%			
#Skin: Trichoepithelioma Overall Incidence	Total	0/90 (0%) 0/90 (0%)	Mean 0%	SD 0%	Total	0/90 (0%) 0/90 (0%)	Mean 0%	SD 0%			
#Skin: Sebaceous Gland: Adenoma		1/90 (1%)				0/90 (0%)					
Overall Incidence	Total	1/90 (1.11%)	Mean 1.11%	SD 0%	Total	0/90 (0%)	Mean 0%	SD 0%			
'Spleen: Hemangiosarcoma		3/90 (3%)				1/90 (1%)					
Overall Incidence	Total	3/90 (3.33%)	Mean 3.33%	SD 0%	Total	1/90 (1.11%)	Mean 1.11%	SD 0%			
#Stomach, Forestomach: Papilloma		0/90 (0%)				0/90 (0%)					
Overall Incidence	Total	0/90 (0%)	Mean 0%	SD 0%	Total	0/90 (0%)	Mean 0%	SD 0%			

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC			Tumor Incide	logy Data Manageme nce for Selected Contr pute: Whole Body Exp Vehicle: AIR	ol Animal Groups		Page: 213 Report Date: 11/07/202				
			Male				Female				
#Stomach, Forestomach: Sarcoma		0/00 (0%)				4/00 (48())					
Overall Incidence	Total	0/90 (0%) 0/90 (0%)	Mean 0%	SD 0%	Total	1/90 (1%) 1/90 (1.11%)	Mean 1.11%	SD 0%			
#Stomach, Forestomach: Squamous Cell Carcinoma c		a Squamous 1/90 (1%)				0/90 (0%)					
Overall Incidence	Total	1/90 (1.11%)	Mean 1.11%	SD 0%	Total	0/90 (0%)	Mean 0%	SD 0%			
#Stomach, Forestomach: Squamous Cell Papilloma Overall Incidence	Total	1/90 (1%) 1/90 (1.11%)	Mean 1.11%	SD 0%	Total	0/90 (0%) 0/90 (0%)	Mean 0%	SD 0%			
#Stomach, Glandular: Sarcoma Overall Incidence				SD 0%	Total	0/90 (0%) 0/90 (0%)	Mean 0%	SD 0%			
Testis: Adenoma		2/90 (2%)									
Overall Incidence	Total	2/90 (2.22%)	Mean 2.22%	SD 0%							
*Thymus: Schwannoma Malignant		0/88 (0%)				0/87 (0%)					
Overall Incidence	Total	0/88 (0%)	Mean 0%	SD 0%	Total	0/87 (0%)	Mean 0%	SD 0%			

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC			Page: 214 Report Date: 11/07/2024					
			Male				Female	
*Thymus: Thymoma Benign Overall Incidence	Total	0/88 (0%) 0/88 (0%)	Mean 0%	SD 0%	Total	1/87 (1%) 1/87 (1.15%)	Mean 1.15%	SD 0%
		0,00 (0,0)				()		
*Thymus: Thymoma Malignant		0/88 (0%)				1/87 (1%)		
Overall Incidence	Total	0/88 (0%)	Mean 0%	SD 0%	Total	1/87 (1.15%)	Mean 1.15%	SD 0%
*Thymus: Thymoma: Benign, Malignar Overall Incidence		0/88 (0%) 0/88 (0%)	Mean 0%	SD 0%	Total	2/87 (2%) 2/87 (2.3%)	Mean 2.3%	SD 0%
*Thyroid Gland: C-Cell: Adenoma		8/89 (9%)				6/90 (7%)		
Overall Incidence	Total	8/89 (8.99%)	Mean 8.99%	SD 0%	Total	6/90 (6.67%)	Mean 6.67%	SD 0%
*Thyroid Gland: C-Cell: Carcinoma		2/89 (2%)				0/90 (0%)		
Overall Incidence	Total	2/89 (2.25%)	Mean 2.25%	SD 0%	Total	0/90 (0%)	Mean 0%	SD 0%
*Thyroid Gland: C-Cell: Carcinoma or Adenoma		10/89 (11%)				6/90 (7%)		
Overall Incidence	Total	10/89 (11.24%)	Mean 11.24%	SD 0%	Total	6/90 (6.67%)	Mean 6.67%	SD 0%

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC			Page: 215 Report Date: 11/07/2024					
			Male				Female	
Thyroid Gland: Follicular Cel Adenoma	l:							
Additionia		0/89 (0%)				0/90 (0%)		
Overall Incidence	Total	0/89 (0%)	Mean 0%	SD 0%	Total	0/90 (0%)	Mean 0%	SD 0%
Thyroid Gland: Follicular Cel Carcinoma								
		0/89 (0%)				1/90 (1%)		
Overall Incidence	Total	0/89 (0%)	Mean 0%	SD 0%	Total	1/90 (1.11%)	Mean 1.11%	SD 0%
Thyroid Gland: Follicular Cel Carcinoma or Adenoma								
		0/89 (0%)				1/90 (1%)		
Overall Incidence	Total	0/89 (0%)	Mean 0%	SD 0%	Total	1/90 (1.11%)	Mean 1.11%	SD 0%
≭Tissue NOS: Schwannoma Malignant		1/90 (1%)				1/90 (1%)		
Overall Incidence	Total	1/90 (1.11%)	Mean 1.11%	SD 0%	Total	1/90 (1.11%)	Mean 1.11%	SD 0%
≭Tongue: Fibrosarcoma								
		0/90 (0%)				0/90 (0%)		
Overall Incidence	Total	0/90 (0%)	Mean 0%	SD 0%	Total	0/90 (0%)	Mean 0%	SD 0%
≮Tongue: Papilloma		0/90 (0%)				0/90 (0%)		
Overall Incidence	Total	0/90 (0%)	Mean 0%	SD 0%	Total	0/90 (0%)	Mean 0%	SD 0%

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC			Toxicology Data Management System Tumor Incidence for Selected Control Animal Groups Route: Whole Body Exposure Vehicle: AIR				Page: 216 Report Date: 11/07/2024 Female Mean 1.11% SD 0%				
			Male 0/90 (0%) 0/90 (0%) Mean 0% SD 0% Total 1/90 (1%) 1/90 (1.11%) quamous 0/90 (0%) Mean 0% SD 0% Total 1/90 (1.11%) 0/90 (0%) Mean 0% SD 0% Total 1/90 (1.11%) 0/90 (0%) Mean 0% SD 0% Total 1/90 (1.11%)				Female				
#Tongue: Squamous Cell Carcinoma	Totol	()	Magn 09/	SD 0%	Total	()	Moon 4 110/	SD 0%			
Overall Incidence	Total	()		SD 0%	I Otai	1/90 (1.11%)	Mean 1.11%	SD 0%			
#Tongue: Squamous Cell Carcinoma c	or Papilloma					1/90 (1%)					
Overall Incidence	Total	0/90 (0%)		SD 0%	Total	()	Mean 1.11%	SD 0%			
#Tooth: Odontoma						0/90 (0%)					
Overall Incidence	Total	()				()	Mean 0%	SD 0%			
*Urinary Bladder: Leiomyosarcoma		0/89 (0%)				1/88 (1%)					
Overall Incidence	Total	()	Mean 0%	SD 0%	Total	()	Mean 1.14%	SD 0%			
*Uterus: Adenocarcinoma											
Overall Incidence											
*Uterus: Adenocarcinoma or Adenon	na										
Overall Incidence											
*: Denominator is number of animals											

Version: Nov2024	Toxicology Data Management System	Page: 217
Contract/Lab: All Laboratories	Tumor Incidence for Selected Control Animal Groups	Report Date: 11/07/2024
Species: RATS	Route: Whole Body Exposure	
Strain: Harlan Sprague-Dawley	Vehicle: AIR	
Length of Study: CHRONIC		
	Male	Female
*Uterus:		
Adenoma		
Overall Incidence		
*Uterus: Adenoma, Adenocarcinoma, Sq Cell Carcinoma, c	or Sq Cell Papilloma	
Overall Incidence		
*Uterus: Deciduoma Benign		
Overall Incidence		
*Uterus: Granular Cell Tumor Benign		
Overall Incidence		
*Uterus: Hemangioma		
Overall Incidence		
*Uterus: Polyp Stromal		
Overall Incidence		
* Denominator is number of animals with tissues examined mic	roooninglu	

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC	Toxicology Data Management System Tumor Incidence for Selected Control Animal Groups Route: Whole Body Exposure Vehicle: AIR	Page: 218 Report Date: 11/07/2024
	Male	Female
*Uterus: Sarcoma		
Overall Incidence		
*Uterus: Sarcoma Stromal		
Overall Incidence		
*Uterus: Sarcoma Stromal or Polyp Stromal		
Overall Incidence		
*Uterus: Schwannoma Malignant		
Overall Incidence		
*Uterus: Sq Cell Carcinoma or Papilloma Squamous		
Overall Incidence		
*Uterus: Squamous Cell Carcinoma		
Overall Incidence		
* Dependent is number of opingle with tigging evening might		,

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC			Toxicology Data Management System Tumor Incidence for Selected Control Animal Groups Route: Whole Body Exposure Vehicle: AIR			Page: 219 Report Date: 11/07/2024		
			Male				Female	
*Uterus: Squamous Cell Papilloma								
Overall Incidence								
#Vagina: Granular Cell Tumor Benign						0/90 (0%)		
Overall Incidence					Total	0/90 (0%)	Mean 0%	SD 0%
#Vagina: Polyp								
Overall Incidence					Total	0/90 (0%) 0/90 (0%)	Mean 0%	SD 0%
#Vagina: Sarcoma						0/90 (0%)		
Overall Incidence					Total	0/90 (0%) 0/90 (0%)	Mean 0%	SD 0%
#Vagina: Schwannoma Malignant								
Overall Incidence					Total	1/90 (1%) 1/90 (1.11%)	Mean 1.11%	SD 0%
#Zymbal's Gland: Adenoma								
Overall Incidence	Total	0/90 (0%) 0/90 (0%)	Mean 0%	SD 0%	Total	0/90 (0%) 0/90 (0%)	Mean 0%	SD 0%

*: Denominator is number of animals with tissues examined microscopically #: Denominator is number of animals necropsied

Version: Nov2024 Contract/Lab: All Laboratories Species: RATS Strain: Harlan Sprague-Dawley Length of Study: CHRONIC			Toxicology Data Management System Tumor Incidence for Selected Control Animal Groups Route: Whole Body Exposure Vehicle: AIR				Page: 220 Report Date: 11/07/2024		
			Male				Female		
#Zymbal's Gland: Adenoma, Adenocarcinc	oma, Sq Cell Ca	rcinoma, or Sq Cell Pap 0/90 (0%)	pilloma			0/90 (0%)			
-	oma, Sq Cell Car Total	· · ·	pilloma Mean 0%	SD 0%	Total	0/90 (0%) 0/90 (0%)	Mean 0%	SD 0%	
Adenoma, Adenocarcino	•	0/90 (0%)		SD 0%	Total	()	Mean 0%	SD 0%	
Adenoma, Adenocarcino Overall Incidence #Zymbal's Gland:	•	0/90 (0%)		SD 0%	Total	()	Mean 0%	SD 0%	